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Abstract 
 
The overarching aim of this thesis is to study the mechanisms by which giant congenital 
nevi form and to study if such mechanisms are targetable. Virtually nothing is known about 
genes conferring susceptibility to the development of giant congenital nevi, largely 
untreatable lesions which increase the risk of patients for development of neurocutaneous 
melanocytoma and malignant melanoma. To discover such genes, we utilized a nevus-
prone transgenic mouse model together with the Collaborative Cross (CC), a genetic 
resource for discovery of genes for complex diseases. It not only allows gene discovery, 
but also a systems genetics approach that enabled us to determine how the gene 
functions in vivo to modify the nevogenesis.  
We also show that the identity of somatic oncogenic mutation (e.g. in NRAS) does not 
always define the histopathological subtype of nevus, as is generally thought. In sum, we 
have performed an unbiased genetic screen and discovered a novel gene (Cdon), a 
dependence receptor of sonic hedgehog (Shh) as the modifier gene for nevus 
exacerbation. We then used three different mouse models to validate it as the causal gene 
and determine its mechanism of action. We also show that Shh pathway components are 
active in the epidermis adjacent to human congenital nevi (Chapter 2 and 3). In summary 
this is the first time a gene has been successfully mapped and functionally validated using 
CC. In Chapter 4 we discuss the result from an unbiased genetic screen to map the 
modifier gene for development of sub-cutaneous (hypodermis) metastasis using 45 CC 
strains. Gja1 which encodes a gap junction subunit connexion 43 (Cx43) is the best 
candidate. Our gene expression and protein expression studies suggest that Gja1 could 
be a strong candidate for further study of sub-cutaneous metastasis.  
 
In Chapter 5 we went on to study the gene expression of normal skin, melanocytoma and 
malignant melanoma samples from our NRAS-Cdk4 mouse model to study the 
transformation and progression of melanocytic lesions. Dusp6 a negative regulator of 
MAPK pathway was highly upregulated with transformation and progression. Our protein 
expression study validated this result on murine and human nevi versus malignant 
melanoma samples.  
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1.1 Skin 
Diverse cell types, including keratinocytes, melanocytes, and immune cells, form a 
complex tissue called skin as a protective barrier in mammals. The epidermis is the 
outermost layer of skin. It contains different stem cell populations located in a complex 
structure called hair follicle. Hair follicles have multiple tasks including hair generation, 
anchoring of sensory neurons, arrector pili muscles, and blood vessels (Figure 1.1). The 
majority of skin stem cells and their niches are located in hair follicles, making it an 
interesting model for studying the interaction between different stem cell populations and 
their niches.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 ǀ The skin structure. Skin is composed of epidermis, dermis and hypodermis 
(fat layer). Hair follicles are composed of three areas, infundibulum, junctional zone, and 
bulge. Melanocyte stem cells reside in the bulge area (from Hsu 2014).  
 
 
Hsu 2014
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Also, disruption of such interactions has huge influence in development of hair 
follicle related cancers e.g. basal cell carcinoma. Dermis and hypodermis make up the 
middle and inner layer of skin. Melanocytes reside in the epidermis and hair follicle in 
human. During neoplastic hyperproliferation, melanocytes could invade the dermis or 
hypodermis and occupy one or multiple layers of skin.  
Murine skin has a higher density of hair follicles while human skin has longer inter-
follicular epidermis. Also, human skin is composed of thicker epidermis and dermis while 
the presence of rete ridges is only seen in human epidermis. Murine epidermis can also be 
differentiated from human epidermis due to presence of Vγ5+ dendritic T cells which are 
absent in human epidermis (Pasparakis 2014). 
 
Sonic hedgehog signaling in skin homeostasis 
The sonic hedgehog (SHH) pathway is a critical factor in the regulation of skin 
homeostasis. SHH signaling is mediated through five membrane bound receptors; CDON, 
BOC, GAS1, PTCH1 and SMO (Mehlen 2014). SMO is a positive regulators of SHH while 
PTCH1 and CDON (Delloye-Bourgeois 2013) negatively regulates the pathway via 
inhibition of SMO. Activation of SMO in keratinocytes results in the upregulation of 
transcription factors such as GLI1 and secretion of factors such as ET-1, TGFB2, WIF1 
and Sema3E (Youssef 2012). This activation also has an impact on the hair follicle stem 
cell niche which is evident by upregulation of stemness markers such as SOX9, FOXC1 
and TCF3 (Youssef 2012).  
 Upregulation of the SHH pathway is a critical feature of the development of basal 
cell carcinoma (BCC). The American Cancer society estimates that in 2012, 5.4 million 
cases of non-melanoma skin cancers (NMSCs) were diagnosed in 3.3 million people, of 
which approximately 8 in 10 cases would have been BCC. Pigmentation of BCCs is 
dependent on ethnic background since 50-80% of Asian BCCs are pigmented but only 3% 
of Caucasians develops pigmented BCC (Moore 2012, Chow 2011). Asians develop BCC 
later in life and develop fewer BCCs over their lifetime than Caucasians, despite similar 
estimated lifetime daily sun exposure (Moore 2012).  
Grachtchouk et al. studied the role of GLI2 overexpression in keratinocytes using albino 
and pigmented K5-Gli2 transgenic mice. K5 promoter is active in keratinocytes of the 
epidermal basal layer and outer root sheath of hair follicles. By three months of age, K5–
22 
 
Gli2 trangenics developed multiple skin tumours. Tumours on the albino founder exhibited 
features characteristic of human BCCs. Many tumours on the agouti and black founders 
resembled human pigmented BCC (Grachtchouk 2000). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 ǀ Proposed model of Shh signaling pathway regulation. Cdon acts as 
decoy receptor for Shh. In the presence of high level of Shh ligand, Cdon and Ptch1 bind 
to Shh and Smo is activated which in turn signals the transcription of Shh target genes 
(from Bosnac 2009). 
 
Further studies using constitutive Shh transgenic mouse model under control of human 
keratin 1 (HK1) promoter emphasized the governing role of Shh on proliferation of 
melanocytes. The HK1-Shh transgenic mice did not develop BCC at all but showed 
extensive dermal hyperplasia of pigmented melanocytes. Similar results were reported by 
Grachtchouk et al., who used truncated keratin 5 (∆K5) promoter to assess the potential 
role of the human M2SMO mutant in BCC development in adult transgenic mice. ΔK5-
M2SMO mice developed pigmented nevi and showed signs of hair loss but did not develop 
BCC.   
Bosnac2009
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Interestingly, most of the aforementioned models develop inguinal lesions which 
nonetheless express a similar profile of marker proteins as that of human BCC. The 
competition between keratinocytes and melanocytes over secretory cues released by 
transgenic keratinocytes could play a vital role in development of melanocytic nevus over 
BCC. Another explanation would be that the secreted cues are simply not adequate for 
development of BCC but sufficient for more sensitive and sympathetic melanocytes to 
undergo hyperplasia. 
In 2012, Eberl et al. studied the effect of Shh activation in the context of SMO activation 
using K5creER;SmoM2;EGFR+/+ mice which resulted in development of pigmented BCC. 
This phenotype was most prominent in the ears. Loss of EGFR due to tamoxifen induction 
inhibited the development of BCC and nevogenesis in dermis (Ebrel 2012). Convergence 
of nevogenesis and BCC development under control of EGFR is very interesting which 
ushers in new targeted therapy possibilities. 
In mammals, the stem cell niche within hair follicles is home to epithelial hair follicle 
stem cells and melanocyte stem cells, which sustain cyclical bouts of hair regeneration 
and pigmentation (Blanpain 2009, Cotsarelis 2006, Tumbar 2004, and Nishimura 2002). 
Dissecting the inter-stem-cell crosstalk governing this intricate coordination has been 
difficult, because mutations affecting one lineage often affect the other. The perturbation of 
hair follicle structure as a result of melanocyte proliferation or as an independent factor 
could be the determining factor in nevogenesis.  
 
1.2 The melanocyte lineage in development 
The neural tube is the origin of neural crest, from which melanocytes are derived. Neural 
crest cells are derived from the dorsal part of neural tube and go through epithelial to 
mesenchymal transition (EMT) and become migratory. 
These cells migrate to different parts of the embryo and generate a multitude of 
specialized structures and tissues (Mayor and Theveneau, 2013). Melanocytes, glia, and 
neurons are derived from the neural crest in the trunk. Cells that leave neural crest early 
and follow a ventral migration through the anterior scleretome differentiate into glia and 
neurons. Cells that leave neural crest later and follow the dorsolateral path between the 
ectoderm and through the early dermis differentiate into melanocytes (Erickson and Goins, 
1995, Henion and Weston, 1997). Fate determination process is very complex and needs 
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more study. Other studies suggest a dual neural crest origin of melanocytes 
encompassing; 1) early differentiation from NC (dorsolateral migration). 2) late 
differentiation from melanoblast or Schwann cell progenitors (Henion and Weston, 1997, 
Dupin et al., 2003). Melanoblasts then migrate large distances in order to populate the 
epidermis and early hair follicles. There is a huge increase in melanoblast populations in 
mouse skin between mouse embryonice day 10.5 (E10.5) and E15.5 from <100 to around 
20,000 (Luciani 2011).  
 
 
 
 
 
 
Figure 1.3 ǀ An overview of melanocyte development (from Mort 2015). 
 
The migration from dermis to epidermis and colonisation of the epidermis by 
melanoblasts is complete by E15.5 in mice (Mann 1962). Melanoblasts then colonise the 
developing hair follicle (E15.5 onward) and start to produce pigment by E16.5 (Hirobe 
1984). The appearance of white patches in mouse mutants and humans is the result of 
unsuccessful proliferation or migration of melanoblasts (Lamoreux et al., 2010, Fleischman 
et al., 1991). 
Another interesting aspect of melanocyte migration is changes in the expression of 
cell adhesion molecules since pre-migratory neural crest populations express N-cadherin 
which is down regulated during migration (due to EMT changes induced by up-regulation 
of Snail) (Nieto et al., 1994; Jiang et al., 1998). Melanoblast that reach dermis by E11.5 do 
not express E-cadherin and P-cadherin but majority of melanoblast that migrate from 
dermis to epidermis show 200 fold upregulation of cadherins and become E-cadherinHigh 
and P-cadherinLow ((Nishimura et al., 1999). Melanoblasts are sensitive to keratinocyte 
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cadherin expression as they localize in the hair follicles which is concomitant with switch 
from E-cadherinhigh/P-cadherinlow to E-cadherin-/P-cadherinhigh phenotype (Nishimura et al., 
1999).  
The switch in cadherin expression of melanoblasts in the presence of keratinocytes 
suggests a non-cell autonomous effect on melanoblasts migration.  
 
1.3 Melanocyte growth in culture 
Melanocytes generally can only be propagated in culture via the inclusion in the growth 
media containing cholera toxin and phorbol ester. However co-culture with keratinocytes is 
also successful (Scott and Haake, 1991). In mouse 2D serum free culture of epidermal cell 
suspensions from neonatal mice keratinocytes proliferate first and melanoblast and 
melanocytes divide in the periphery. Keratinocytes are the first cells to die after 8-9 days 
which lead to melanoblast or melanocyte pure cultures after 14 days (Hirobe 1992a). In 
neonatal mice, keratinocytes also have important role in differentiation of melanocytes in 
the presence of agents that increase cAMP production (α-MSH, ACTH, DBcAMP) (Hirobe 
1992c, Hirobe and Abe 2000). The concentration of Ca2+ in human keratinocyte-
melanocyte co-culture has a huge impact on the release of mitogenic secretory cues 
released from keratinocytes. Low Ca2+ medium or undifferentiated keratinocytes co-
cultured with melanocytes have higher impact on the proliferation and melanogenesis of 
the latter while high Ca2+ medium or co-culture of differentiated keratinocytes with 
melanocytes only result in melanogenesis. (Hennings et al., 1980, Valyi-Nagy et al., 1993, 
Abdel-Naser, 1999, Valyi-Nagy et al., 1993). 
1.4 Non-cell autonomous effect of keratinocytes on melanocyte proliferation and 
differentiation  
Melanocyte behaviour, including proliferation, melanogenesis, and dendritogenesis, is 
mainly controlled by keratinocytes in normal or UV induced skin (Archambault  et  al.,  
1995;  Todd et al., 1993, Toyoda et  al.,  1999, Seiberg  et  al.,  2000). Figure 1.4 shows 
multitude of keratinocyte derived cytokines, which in turn stimulate melanocyte 
proliferation by binding to their receptors on melanocyte. 
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Figure 1.4 ǀ Schematic image showing the action of keratinocyte-derived cytokines on the 
proliferation and differentiation of mammalian melanocytes (from Hirobe 2004). 
 
1.5 Keratinocyte cytokines which are melanocyte mitogens 
Endothelins 
Ednothelin-1 (EDN1/ET-1), EDN2 (ET-2), and EDN3 (ET-3) exert their mitogenic effect by 
binding to their receptor on melanoblasts/melanocytes, Endothelin receptor B (EdnrB) 
(Sakurai 1990). Their mitogenic effect in newborn mice melanocytes may be in 
combination with factors that elevate cAMP or in cooperation with bFgf (Hirobe 2001). 
These cytokines increase the number of mitotic melanoblasts/melanocytes and also push 
the cell cycle to S phase and expedite the proliferation of these cells (Hirobe 2004). 
Endothelins also trigger the DNA synthesis in human epidermal melanocyte cultures in 
cooperation with cAMP elevating agents and serum (Imokawa et al., 1992). UV exposure 
increases EDN1 secretion from keratinocytes both in vitro and in vivo. The increases in 
EDN1 secretion will result in down-regulation of E-Cadherin in melanocytes and melanoma 
cells. Blockade of EDN1 receptor (EDNRB) inhibits melanoma progression and metastasis 
(Jamal 2002). 
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Stem cell factor  
Stem cell factor (SCF/Kitl) exerts its mitogenic and melanogenic effects on mouse 
melanoblasts/melanocytes by binding to melanocytes. Kit receptor then activates the 
melanocyte MAPK pathway (Grichnik et al., 1998, Geissler et al., 1988) induces 
transcription of MITF.  
Leukemia inhibitory factor 
Leukemia inhibitory factor (LIF) has mitogenic and melanogenic effects on murine 
epidermal melanocytes in the presence of cAMP elevating agents (Hirobe 2002) by 
expediting G0/G1S and G2M transitions (Hirobe 2004). Mechanistically this is done by 
binding of LIF to its receptor on melanocytes, gp130LIFRa and activation of JAK/STAT 
and MAPK pathways (Coughlin et al., 1988, Auernhammer  and Melmed, 2000). 
 
Hepatocyte growth factor 
Hepatocyte growth factor (HGF) has mitogenic and melanogenic effects on murine 
melanocytes in vitro (Hirobe 2004) in the presence of cAMP elevating agents through 
activation of c-Met receptor of melanocytes. Activated c-Met in melanoblasts and 
melanocytes expedite S phase transition and increases the number of melanoblast and 
melanocytes in the mitotic state (Hirobe 2004a). HGF also stimulates the proliferation of 
non-cutaneous melanocytes (eye, ear, dermal melanocytes) in vivo and has less effect in 
growth of cutaneous melanocytes (Aoki 2009). HGF also stimulates the hyperproliferation 
of human epidermal melanocytes without the need of cAMP elevating agents (Bottaro  et  
al., 1991, Halaban  et  al.,  1993;  Matsumoto  et  al., 1991). 
 
1.6 Melanocytic nevi 
Melanocytic nevi have distinct colors and patterns which allow the physician to draw 
partial conclusions about the localization of pigmented cells within the skin. Black and 
brown colors (due to melanocytes or pigmented parakeratosis) indicate pigmentation in the 
epidermis, while gray and blue (due to melanocytes or pigment-laden melanophages) 
correspond to pigmented cells within the superficial and deep dermis, respectively 
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(Zalaudek 2009) (Figure 1.5a). Nevi can occupy the epidermis or dermis which are 
classified as epidermal or dermal nevi (Fig 1.5b,c). They also could reside in both layers 
hence compound nevi (Fig 1.5d).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 ǀ Color of melanocytic nevi is dependent on location in skin layers. a, if 
they reside in epidermis the color will be black while superficial lesions have a gray color. 
Nevi forming in dermatoepidermal junction look brown. Nevi residing deep in dermis have 
a blue color. Scale bar = 500 μm. b, c, and d, H&E images of epidermal, dermal and 
compound nevi respectively. Red arrows point to location of nevus melanocytes 
(nevocytes) in the epidermis and yellow arrows point to the location of dermal nevi. Scale 
bars = 200 μm. 
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Congenital nevi 
Congenital nevi are classified based on their size and their location in skin (Figure 
1.6a). NRAS and BRAF mutations are the most common oncogenic changes (55% and 
39.3%) in congenital melanocytic nevi (CMN) while BRAF mutation (79%) is the most 
frequent mutation in acquired nevi. Large and medium size CMN tend to have NRAS 
mutations (66%) but smaller CMN have BRAF mutations (79%) (Raeve 2006, Ichii-Nakato 
2006, Bauer 2007, Wu 2007 and Dessars 2009). Ultraviolet radiation (UVR) has no role 
since the mutation occurs in utero. The preference for NRAS mutations has been 
suggested could be explained by the fact that they may favor upregulation of CRAF. CRAF 
shares many functional aspects with BRAF but also has a unique function, the inhibition of 
apoptosis (Dumaz 2006, Wojnowski 2000 and Smalley 2009). Majority of CMNs show 
angiotropism which is defined by clear and recognizable presence of nevus cells in the 
proximity of the external surfaces of vessles or lymphatic channels. These aggregates 
show no sign of internalization to the vessel or lymphatic channel (Barnhill 2010). In 
melanoma, angiotropism is indicative of micrometastasis, often associated with regional 
lymph node metastasis (Day 1981, Day 1982, Harrist 1984), and is considered a poor 
prognosis factor (Wilmott 2012). Since angiotropism is common in CMN and metastatic 
melanoma, this extravascular migration may be an important mechanism in metastasis 
which could be linked to perturbation of developmental processes during embryonic 
development.  
Acquired nevi 
In acquired nevi (mainly epidermal and junctional) BRAF and NRAS mutations 
occur in almost 79% (Pollock 2003, Uribe 2006, Venesio 2008 and Ross 2011) and 4.6%  
(Saldanha 2004, Gill 2004, Poynter 2006 and Venesio 2008) of cases of acquired nevi 
respectively. 65% of dysplastic/atypical nevi carry BRAF mutations (Pollock 2003 and 
Uribe 2006). The origin of the most common BRAFV600E mutation is still obscure (Figure 
1.6b). There is no compelling evidence that UVR directly induces this mutation: 1) 
BRAFV600E occur more frequently in malignant melanomas (MM) from intermittently sun-
exposured skin (Poynter 2006 and Maldonado 2003); 2) BRAFV600E does not occur as a 
result of a UV signature (C>T transition) (Davies 2002); 3) CMNs harboring BRAF 
mutations that occur in utero (Wu 2007), 4) BRAFV600E mutation commonly occurs in 
internal cancer like colorectal carcinoma. 
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Figure 1.6 ǀ Classification of congenital and acquired melanocytic nevi. a, Congenital 
nevi are classified as small, large, giant, Mongolian spots, hairy, agminated, speckled 
lentiginous and café-au-lait macules. b, Acquired nevi are classified as agminated, blue, 
Spitz, Reed, Halo, acral and Unna. 
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1.7 Dermoscopic patterns of melanocytic nevi 
The presence of uniform and regularly distributed globular, reticular, starburst,  blue, and 
complex patterns (Kreusch 1990, Yadav 1993, Soyer 2000, Ferrara 2005, Schärer 2007, 
Arevalo 2008, Zalaudek 2009, Shiga 2012) identify a given lesion as a melanocytic nevus 
(ie, per definition absence of melanoma-specific patterns) (Argenziano 2003). Each pattern 
corresponds to a specific underlying histopathologic correlate (Figure 1.7). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 ǀ Dermascopic pattern of nevi. Pigmentation patterns of melanocytic nevi 
give them specific dermascopic patterns. Blue nevi are uniform structureless lesions with 
blue color, reticluar nevi are meshwork of brown lines, globular nevi show aggregated oval 
structures, complex nevi are composed of two different patterns and starburst nevi show 
radial lines around the periphery of lesion. 
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1.8 Skin type related nevus pattern 
Individuals with skin type I exhibit a predominant nevus type characterized by light brown 
color and central hypopigmentation. In contrast, nevi in patients with skin type IV tend to 
be dark brown with a central hyperpigmentation (so-called black or hypermelanotic nevi). 
Nevi of skin types II and III are prone to be light to dark brown with multifocal pigmentation 
(Figure 1.8) (Giorgi 2006, Zalaudek 2007). 
 
 
 
 
 
 
 
Figure 1.8 ǀ Skin type dictates the color of nevi. People with lighter skin pigmentation 
have hypopigmented nevi while people with darker skin colors have hyperpigmented nevi. 
 
 
1.9 Nevogenesis 
Nevogenesis is a multifaceted process involving complex interplay of environmental 
and genetic factors. Although the nature of this process is not well understood. Activation 
of certain molecular pathways is crucial to drive nevogenesis (Ross 2011). The life cycle of 
benign melanocytic lesions can consist of four stages: initiation, promotion, senescence, 
and occasionally involution. In general, initiation is the result of a mutation in nevus 
progenitor cell that permits future growth. Activation and proliferation of mutated cell 
begins the promotion phase, which may involve a change in the relationship between the 
nevocyte and its local environmental that favors proliferation. After a period of growth, nevi 
stop proliferating through the activation of senescence pathways. Senescence keeps nevi 
stable for an extended period of time and, occasionally, the cycle comes to end with 
involution (Ross 2011).  
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Although some models of nevogenesis (Robinson 1998, Hui 2001, Grichnik 2008) 
propose the single cell origin of the melanocytic lesion, the location of the putative 
progenitor cell is still unclear. This would depend upon the location of the nevi (i.e. 
epidermal, dermal, or junctional), hence the progenitor cell could arise from epidermis, 
dermis, or both. It is possible that an immature melanocytic stem cell serves as the 
progenitor. UV light exposure and other mutagenic processes could cause such secondary 
changes. These genetic alterations would result in abnormal proliferation of the progenitor 
cell in response to normal environmental signals which activate this cell to produce 
melanocytes.  
Another model for nevogenesis predicts that the nevus derives from a diﬀerentiated 
melanocyte that drives the nevogenesis. The oncogenic mutation enables the cell to 
regain proliferative capacity, dedifferentiate, and develop invasive properties which allows 
the cell to migrate into greater depths of the dermis (Ross 2011). It is more difficult to 
explain the second model with the clinical behavior of nevi since the initial nevogenic 
mutation induces nevus growth immediately.  
Nnevocytes are senescent, hence express several markers of senescence, namely, 
tumor p16INK4a (p16), macroH2A, 53BP1, and senescence-associated β-galactosidase 
(SAβ-gal) (Michaloglou 2005, Gray-Schopfer 2006 and Suram 2012). Inactivation of tumor 
suppressor genes e.g. PTEN and CDKN2A (p16), induction of embryonic epithelial-
mesenchymal transition (EMT), and activation of Wnt signaling are just some of 
mechanisms thought to contribute to nevus to melanoma progression via enabling escape 
from senescence (Dankort 2009, Vredeveld 2012, Delmas 2007 and Dhomen 2009). 
The location, differentiation state and gene expression profile of the cell of origin for 
benign moles remains to be discovered. Further comprehensive research is necessary to 
fully understand nevogenesis, and in particular, why a small proportion of nevi progress to 
melanoma (Figure 1.9).  
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Figure 1.9 ǀ Schema of melanoma progression from a nevus (from Vultur and Herlyn 
2013). 
 
1.10 Nevi as a risk factor for melanoma  
The survival rates for metastatic melanoma are directly proportional to the thickness 
of the primary melanoma.  Surgical excision of primary melanomas of <1 mm thickness 
results in a 5 year survival rate of >90%, whereas for excision of lesions of >4 mm average 
5 year survival is 40% (Balch 2001). Thus the case for early detection of suspicious nevi 
for prevention of melanoma is very strong. The morphology and type of premalignant nevi 
are indicator of melanoma risk. However, total body surface nevus count is very important, 
with individuals harbouring >100 nevi having a 7-fold elevated risk of developing 
melanoma (Chang 2009).  
Nevi are melanoma precursor lesions, and 35-50% melanomas arise from pre-
existing moles (Skender-Kalnenas 1995), although the overall risk of any individual nevus 
developing into a melanoma is small, estimated at ~1/30,000 nevi (Tsao 2003). Thus, 
although nevi represent a reservoir of premalignant cells, the transformation rate is 
extremely low, making surveillance a time consuming task.  
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This situation is exacerbated in dysplastic nevus syndrome (DNS) (Figure 1.10). 
DNS is classified differently by different groups but generally refers to people with >50, 2 
mm melanocytic lesions, at least one with atypical features, and one or more close relative 
with melanoma (Duffy 2012). The presence of one dysplastic nevus is associated with a 2 
fold increased risk of developing melanoma, and 10 or more nevi with 12-fold increased 
risk (Tucker 1997).  
There is a significant inherited component to nevogenesis, with members of melanoma-
prone families often having large numbers of atypical nevi (Olsen, 2010), and persons with 
2 or more family members with melanoma having a >85-fold increased risk (Friedman 
2009). The presence of morphological atypia increases the risk of melanoma >4 fold 
(Arumi-Uria 2003).  
 
 
 
 
 
 
 
Figure 1.10 ǀ Clinical image of a patient with high mole count who is at high risk of 
developing melanoma. Extensive scarring from previous excision of suspicious nevi is 
evident (UQ Dermatology Research Centre).  
 
Nevi are very common premalignant lesions in high mole count individuals who are 
at high risk of developing melanoma in whom they may more frequently develop into 
melanoma. Clinically, these high risk patients tend to have large numbers of suspicious 
lesions surgically excised often unnecessarily with the associated cost and morbidity 
(Figure 1.10). Thus, there is a clear clinical need in the assessment of DNS patients, to 
develop rapid, non-invasive methods to accurately assess the transformation potential of 
36 
 
individual nevi, providing the treating clinician with a readout that can be readily applied to 
determining the treatment of each nevus. This is done by morphological features, but they 
are often not very predictive. Hence there are no clear molecular markers to distinguish 
dysplastic and non-dysplastic nevi. BRAF and CDKN2A and TP53 mutations are reported 
in DN, and clinical and histopathological markers are suggested to classify these lesions, 
but there is still a deal of debate as to what constitutes a dysplastic nevus (Friedman 2009, 
Duffy 2012).  
Knowing the particular molecular changes occurring during the transition of nevus 
to melanoma would greatly enhance our understanding of why some nevi progress. The 
shortcoming of the correlative approaches possible using patient derived samples is that 
when the lesion is excised for analysis the future of that lesion can only be conjectured. 
Any markers identified will be correlated based on statistical associations. While it is not 
ethically possible to continuously sample a suspicious lesion without treating it, this type of 
longitudinal study is possible using an animal model of the disease. For example using a 
mouse model it should be possible to interfere with the expression or function of genes 
identified in patient lesion based studies, to determine whether a particular gene is 
involved in melanomagenesis. This project will use a mouse model of nevus progressing 
to melanoma, which will provide the opportunity to perform a variety of analyses of lesions 
at various stages of nevogenesis and melanomagenesis.   
 
 
 
1.11 Transgenic model used for current research 
The contribution of one or multiple genes to nevogenesis, melanomagenesis, and 
metastasis can be studied using transgenic animal models. Since there are many types 
and subtypes of human nevi, the ideal model of nevus to melanoma progression does not 
exist. An ideal model should show identical: 1) Histopathological features; 2) Progression 
patterns and stages; 3) Driving molecular pathways; 4) Response to treatment; with 
human nevi and melanoma. However human melanomas are so diverse that it is 
impossible to precisely model all of these aspects except for the case of a “generalised” 
human melanoma. Nevertheless, transgenic mouse models are the best mammalian 
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model systems to study nevogenesis and melanomagenesis. They have a similar genome, 
comparable organs and physiology.  
Also, their genome is well described, and a large panel of mutants already exist, the 
introduction of new genetic modifications is quite simple, and environmental and 
therapeutic studies can readily be tested in a whole organism (Gremel 2009). NRAS, 
KRAS, HRAS, BRAF, CDK4, CDKN2A, PTEN, TRP53, CTNNB1 and STK11are just some 
of the genes that have been studied using transgenic mouse models throughout the years 
(Ferguson 2010, Wurm 2012, and Vultur and Herlyn 2013). 
 
Cdk4R24C/R24C::Tyr-NRASQ61K mouse model 
This project will use Cdk4R24C/R24C::Tyr-NRASQ61K (or Cdk4::NRAS) mouse model 
for nevi progressing to melanoma (Ferguson 2010, Wurm et al., 2012).  In these mice 
nevus like-lesions were observed in the papillary dermis, immediately beneath the 
epidermis in a band-like distribution (Figure 1.11). In terms of classical morphology the 
nevi mimic a superficial congenital nevus pattern. This phenotype was observed in both 
UVR-treated and control mice. All nevi show extremely low levels of proliferation by Ki-67 
staining and little or no histological features of malignancy. The groupings of nevus cells 
have been studied by three  
dimensional modelling based on serial sectioning of the skin (Figure 1.12). Over the 
course of about 6 months, very slow growing flat lesions will develop out of these nevi, and 
a small portion of which will develop into a fast growing melanoma.  
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Figure 1.11 ǀ H&E stain of the band like nevus specific to the Cdk4::Tyr-NRAS mice. 
In terms of classical morphology these cells are reminiscent of a superficial congenital 
nevus pattern. 
 
A staging system (Wurm 2012, Figure 1.13) was developed for the murine lesions, 
based on Breslow thickness, a prognostic indicator in human melanoma. The small 
plaques histopathologically mimic human congenital nevi or dysplastic nevi. The dysplastic 
pattern is characterised by melanocytes singly and in nests throughout the superficial 
dermis and focally in the epidermis. In some cases we could histopathologically confirm 
that a melanoma was emanating from one of the nevi. Because we observe multiple nevi 
of different morphologies, and melanoma, in the same animal, it was speculated that this 
mouse model mimics the critical aspects of the familial atypical multiple mole melanoma 
(FAMMM) syndrome (Lynch 1980), or DNS on the FVB strain background. 
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Figure 1.12 ǀ Schematic of nevi in Cdk4::NRAS mouse skin looking from above. This 
was modelled by serial sectioning. We calculate that there are about 350 nevus nests on 
the dorsal surface of each mouse. 
 
Notably, dermal nevi are sometimes seen in these patients (Tucker 2002). Careful 
histopathological assessment of many murine lesions was performed by an experienced 
dermatopathologist (Professor H Peter Soyer), who characterized the nevi and assessed 
how they relate morphologically to human lesions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13 ǀ Staging schema for murine melanoma. Staging is based on  dermascopy 
of MMs and H&E staining (from Wurm 2012). 
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1.12 Natural genetic factors that regulate nevus development and density 
Risk factors for invasive MM are (approximate relative risk is shown in brackets) 
(Gandini 2005a, Gandini 2005b, Mackie 2009): 1) Three or more clinically atypical 
(dysplastic) nevi (12); 2) Previous personal primary invasive melanoma (8.5); 3) Multiple 
banal melanocytic nevi: 100 vs. <15 nevi (6.9); 4) High solar exposure in early childhood 
(4.3); 5) Red hair (2.4). Therefore, genetic factors are arguably more important to 
melanoma risk than sun exposure. Genome Wide Association Studies (GWAS) have 
shown that SNPs within or near many genes (MC1R, ASIP, TYR, SLC45A2, TYRP, 
PLA2G6, ATM, CASP8, MX2, TERT, and NID1) are in linkage disequilibrium with 
melanoma-predisposing variants (Gerstenblith, 2010, Bishop 2009, Barrett 2011, Nan 
2011, Gerstenblith 2010, Kim and Chanock 2012).  
Loci associated with nevus count include CDKN2A/MTAP (Falchi 2009) and IRF4 
(Duffy 2010), with several other genes also having very small effects. The nevus genes 
discovered to date account for less than 10% of the variance in nevus count, surprisingly 
low given that it is highly heritable (70-80%, Law 2013). Many of these genes are of 
unknown function, and where this is known, it has not been functionally determined how 
and where they act during melanoma progression.  
 
1.13 Collaborative Cross 
The Collaborative cross (CC) is a panel of recombinant inbred (RI) mice, derived 
from a genetically diverse set of founder strains and designed specifically for complex trait 
analysis (Figure 1.14).  The genomes of eight genetically diverse founder strains: 1) 
129S1/SvImJ; 2) A/J; 3) C57BL/6J; 4) CAST/EiJ; 5) NOD/LtJ; 6) NZO/HlLtJ; 7) PWK/PhJ; 
and 8) WSB/EiJ are combined (Figure 1.14) to capture ~90% of the known variation 
present in laboratory mice while other RI panels e.g. AXB/BXA and BXD only capture 
~13% of known variations (Churchill 2004).   
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Figure 1.14 ǀ Collaborative cross is a typical eight-way RI strain. The color scheme 
indicates the parental origin of genomic segments.  
The CC is ideal for the discovery of genes for complex diseases (i.e. those where 
many genes are involved) such as cancer. Each of the 100’s of CC strains is inbred, hence 
infinitely available, and the genome sequence is known. Therefore the CC provides not 
only gene mapping power, but also integration, such that any other characteristics of 
nevus susceptible strains (i.e. immune system, or tissue gene expression, in fact any 
variable that can be measured) is available (Figure 1.15). By breeding Cdk4R24C::Tyr-
NRAS males (FVB strain background) with females of many CC strains, it has been noted 
that there is a tremendous variation in the density of dermal nevi in these mice when 
crossed against up to 70 CC strains (Chitsazan 2016). This provides an opportunity to use 
the CC to discover genetic modifiers of nevus density.   
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Figure 1.15 ǀ Multiple, diverse phenotypic assays using collaborative cross (Churchill 
2004). 
 
1.14 Successful precedent for the “transgene modifier of cancer” approach 
Genes which do not predispose to a disease, but which can influence its course or 
severity, are “modifier genes”. They are very difficult to identify, especially in humans 
(Nadeau, 2001). An excellent example of the power of the transgene modifier approach 
comes from the work of Hunter et al. (Lifsted, 1998). To find modifier genes of breast 
cancer metastasis, they crossed a relevant transgenic mouse with each of 27 strains.  
Recombinant inbred mouse lines are generally derived from just two parental strains. 
Despite the smaller size and lower heterogeneity of their panel compared to the CC that 
are using, they discovered a set of interacting genes in a pathway that regulates 
metastasis; they named the pathway “Diaspora”, alleles of which predict survival outcomes 
for patient genotype groups (Crawford, 2008). A similar strategy has been used to identify 
a modulator of breast cancer metastasis in mouse and humans by a non-cell-autonomous 
mechanism (Faraji, 2012). These studies used a small number of closely related common 
inbred strains. Instead, we can use the CC to harness the available genetic repertoire of 
the mouse. The mapping power of the CC has recently been demonstrated using coat 
colour as a known Mendelian trait (Figure 1.16, Ram, 2012).  
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1.15 Forward and reverse genetic study 
Understanding the biological underpinnings of complex diseases such as autoimmunity, 
cancer and infection requires study of appropriate tissues, spatio-temporal progression, 
genetic and gene expression. Next step is studying the observed changes in animal 
models such as mouse. Mouse models are used to phenocopy the human disease to a 
degree. This model also provides an opportunity to study the desired phenotype in human 
by removing many factors that could have huge impact on the result of study e.g. diet, 
stress, exercise, sun exposure etc. Hence mouse models are used to simplify the study by 
removing factors that can’t be removed in human studies.  
Mouse models are currently used for forward and reverse genetic studies which 
complement each others. Forward genetic studies (FGSs) use innate genetic variation 
between different mouse strains with known genotype (e.g. Collaborative Cross mouse 
strains) to conduct unbiased genetic screens. In order to perform such analysis, the 
genetic variation should first be quantitated e.g. nevus density in chapter 2 and 
microsatellite count in chapter 4. The unbiased genetic screen will provide a region that 
can be fine mapped using available recombinations in CC mouse strains. Finally, the 
candidate gene or genes can be studies using reverse genetic studies (RGSs) such as 
Figure 1.16 ǀ Genome wide scan for the mouse albino locus. Figure 
shows mapping the mouse albino locus on murine chromosome 7 (Tyr) using 
64 collaborative cross strains (Ram 2012).  
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development of knock outs, knock ins or transgenic mice for candidate genes or mutations 
(e.g. Cdon+/- mouse in chapter 3).  
Studies using mouse models have provided many seminal contributions to biomedical 
research e.g. Noble prizes in physiology and medicine in 1980, 1984, and 2011 for 
discovery of major histocompatibility complex, development of monoclonal antibody, and 
activation of innate immunity respectively. FGSs also discovered many important genes 
involved in metabolic diseases (Ob and Lepr), circadian rythms (Bmal1, Npas2, Cry1, 
Cry2), and central nervous system (Hnrpul1).  
Cdk4R24C/R24C::Tyr-NRASQ61K (or NRAS-Cdk4) mouse model (Ferguson 2010; Wurm 2012) 
carry the NRASQ61K mutation common in malignant melanoma, and a germline Cdk4R24C 
mutation, mimicking families who carry such mutations or those in the gene encoding its 
binding partner, p16 (Zuo 1996). They develop malignant melanomas characterized by 
downward invasion into the dermis and hypodermis, cellular atypia, and other histological 
signs of malignancy. Because we are using an animal model, we can obtain very accurate 
and precise data on these phenotypes for gene mapping. 
My thesis is comprised of three projects where I use NRAS-Cdk4 mouse model (Ferguson 
2010; Wurm 2012) to conduct following studies: 1) FGS and RGS of nevus exacerbation, 
2) FGS of microsatellite count, and 3) Detecting cell autonomous changes involved in 
melanoma progression and metastasis.  
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Chapter 2 
This chapter is comprised of a publication emanating from my thesis project. This 
publication is the preliminary result of a congenital nevus modifier gene mapping using 
collaborative cross mouse model.  
 
2.1 Publication  
Chitsazan, A., Ferguson, B., Ram, R., Mukhopadhyay, P., Handoko, H.Y., Gabrielli, B., 
Soyer, P.H., Morahan, G., and Walker, G.J. A mutation in the Cdon gene potentiates 
congenital nevus development mediated by NRAS(Q61K). Pigment Cell Melanoma Res 
2016;29(4):459-64 
 
2.3 Contribution  
My contribution to the publication above included;  
 Mouse breeding 
 Acquisition of mouse lesions 
 Design of scoring approach for scoring of nevus density in mouse using H&E 
stained slides 
 Design of immunohistochemical staining protocol to examine CDON and SOX10 
expression 
 Acquisition of patient congenital melanocytic nevi samples from collaborators 
 Processing and immunohistochemical staining of lesion set  
 Analysis of staining patterns of lesion set  
 Preparation  of the manuscript 
 
 
Contribution by others: 
 
 B.F. provided technical support, animal breeding, sample collection.  
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 R.R. provided bioinformatic support and analysed data. 
 P.M. provided bioinformatic support and analysed data.  
 H.Y.H. provided technical support. 
 B.G. contributed to experimental design and supplied pathological specimens.  
 H.P.S. contributed to Pathological diagnosis.  
 G.M. provided the CC mouse strains, and genetic analysis software.  
 G.J.W. designed the project, analysed data and prepared manuscript. 
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Summary 
 
Congenital nevi develop before birth and sometimes cover large areas of the body. They 
are presumed to arise from the acquisition of a gene mutation in an embryonic melanocyte 
that becomes trapped in the dermis during development. Mice bearing the Cdk4 
R24C::Tyr-NRASQ61K transgenes develop congenital nevus-like lesions by post-natal day 
10, from melanocytes escaping the conﬁnes of hair follicles. We interbred these mice with 
the collaborative cross (CC), a resource that enables identiﬁcation of modiﬁer genes for 
complex diseases (those where multiple genes are involved). We examined variation in 
nevus cell density in 66 CC strains and mapped a large-effect quantitative trait locus (QTL) 
controlling nevus cell density to murine chromosome 9. The best candidate for a gene that 
exacerbates congenital nevus development in the context of an NRAS mutation is Cdon, a 
positive regulator of sonic hedgehog (Shh) that is expressed mainly in keratinocytes. 
 
 
Signiﬁcance 
 
Giant congenital nevi can cause a variety of clinical problems and can convert to 
melanoma. They are not easily removed as they can be located deep within the dermis. 
No genome-wide association studies have been performed to help us understand the 
susceptibility to the development of congenital nevi. For the ﬁrst time, we utilized a 
systems genetics approach to deﬁne innate variation that dramatically inﬂuences the 
density of congenital nevi. Understanding genes that control the development of these 
lesions will be a ﬁrst step in the development of new treatments and control measures for 
these lesions.
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Congenital nevi can manifest as small commonplace “birthmarks” anywhere on the body, 
large lesions on the head and neck, or giant lesions covering substantial areas of the torso 
(Krengel et al., 2013). Large congenital nevi are often associated with increased skin 
fragility, dryness and itching, and overheating due to less subcutaneous fat. The risk of 
otherwise extremely rare childhood melanoma is significantly increased for those with 
giant congenital nevi (Krengel et al. 2006). In an early prospective study of large 
congenital nevus patients, Hale et al. (2005) reported pediatric melanoma in 2.3%, while 
Vourc’h-Jourdain et al. (2013) found that 51 of 2578 similar patients developed melanoma 
in fourteen selection-based studies, about a 2% absolute risk. 
 
Congenital nevi develop before or occasionally soon after birth. Located in the superficial 
and sometimes deep dermis and hypodermis, they are thought to arise from an oncogenic 
mutation in an embryonic melanocyte precursor. NRASQ61K mutation is the most common 
somatic mutation, present in ~95% of giant congenital melanocytic nevi (Kinsler et al. 
2013; Charbel et al, 2014). However, there is little information about innate genetic 
differences between individuals, whereby variation in epigenetic or melanocyte-
microenvironment interactions may also be important in nevus development. Many 
transgenic mice carrying melanocyte-specific oncogenic mutations develop dermal 
melanocytic proliferations reminiscent of human congenital or blue nevi (e.g. Dohmen et 
al. 2009; Shakhova et al. 2012; Pawlikowski et al. 2015). The development and size of 
these lesions can be dramatically altered with genetic engineering that results in changes 
in expression of stem cell or hepatocyte growth factor from keratinocytes (Kunisada et al. 
1998, 2000), or increased Wnt signaling within melanocytes (Pawlikowski et al. 2013). 
 
To investigate innate genetic variation that regulates congenital nevus development, we 
used Cdk4R24C/R24C::Tyr-NRASQ61K mice (Ferguson et al., 2010, 2015) in conjunction with a 
cohort of genetically-defined mouse strains, the Collaborative Cross (CC) (Morahan et al. 
2008; Welsh et al. 2012). The CC is derived from eight diverse founder strains and 
captures ~90% of genetic variation present in the species (Churchill et al., 2004, 
Collaborative Cross Consortium 2012), making it ideal for the discovery of genes for 
complex traits (those where many genes are involved). The genome sequence at any 
locus for each strain is easily inferred based upon knowledge of the haplotype blocks 
inherited from the founder(s), for which the genome sequence is known. In a proof of 
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concept, the CC could rapidly map the variants responsible for mouse coat colour (Ram et 
al. 2014).  
 
By breeding Cdk4R24C/R24C::Tyr-NRASQ61K/+ males with females from many CC strains we 
generated progeny heterozygous for both the Cdk4 and NRAS mutations. As we 
previously reported (Chai et al. 2014), at between days 0 and 5 after birth (P0-P5) 
melanocytes are migrating downwards to the hair follicle (unlike in humans, mouse 
interfollicular melanocytes do not normally persist at the epidermal-dermal junction). At 
P10 there are more melanocytes in the epidermis, and by P21 these have developed into 
nests of cells (nevi) within the superficial dermis, around hair follicles (Figure 1A). Hence 
the nevi begin to develop at P10, apparently from melanocytes that break away from the 
hair follicle (Figure 1B). In littermates not carrying NRASQ61K, melanocyte numbers were 
much lower at all timepoints, and between P10 and p42 there was no sign of any 
congregation of melanocytes in the form of nevi (Figure S1).  
 
We collected skin from >3 mice of each cross, and the density of nevus cells in dermis was 
scored between 1 (least dense) and 10 (most dense). Cdk4R24C/R24C::Tyr-NRASQ61K/+ mice 
develop many thousands of nevi over their dorsal surface (Chai et al. 2014). Note that 
nevus density is not a measure of the number of nevi in each mouse skin, instead, an 
arbitrary score for the density of nevus cells right across the skin section analyzed. For 
albino strains we estimated the relative density of nevus cell nuclei across the section. 
Note that this, being a biological variable, can vary greatly across a given section, so an 
estimate has to be made. Figures S2 and S3 show examples of each of the scores (1-10). 
For lightly pigmented low nevus count strains we assessed the number of lightly 
pigmented (brown) dendritic nevus cells. For heavily pigmented strains (i.e. dark 
pigmentation covering a large portion of the dermis), we also try to assess dendritic “nevus 
cells”, but essentially we scored based on the area covered by dense pigmentation as a 
marker for the density score.  
The median score per strain is shown in Figure S4. Normal skin was collected when each 
mouse was sacrificed (generally had developed a melanoma of ~10mm in diameter). We 
determined whether nevus count was dependent upon whether or not a mouse had 
received neonatal UVR. In the 12 strains for which we had data for both spontaneous and 
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neonatal UVR-induced melanoma we compared nevus count between the two groups and 
found no correlation (Figure 1C). Hence nevus cell density (Figure 1D,E) is genetically 
determined. We previously reported the presence of these dermal nevi, and early stage 2 
or 3 melanomas whose location in the superficial dermis suggests that they have 
emanated from these nevi (Wurm et al. 2010). We compared the age of onset of stage 2/3 
melanomas with the nevus cell density score for all mice in our study (Figure 1F), but we 
found a negative correlation (correlation co-efficient = -0.18, p= 0.00048, Spearman Rank 
Correlation test with an in-house R script).  
 
We tested 66 CC strains to discover quantitative trait loci (QTLs) that modify median nevus 
density per strain in Cdk4R24C::Tyr-NRASQ61K mice. The construction of the CC founder 
haplotypes is described in Ram et al. (2014). For mapping we used a logistic regression 
matrix model over the reconstructed haplotypes matrix to produce genome-wide 
distribution of P values (ANOVA chi-squared). We used a false discovery rate of p=0.0001 
to define significant genome wide linkage. We identified a major effect QTL on mouse 
chromosome 9 (-1 -Log10(P) interval=28.2-36.2 megabases (Mb), a region containing 23 
genes) (Figure 2A). We also detected linkage at lower levels of significance to 
chromosome 11 (Figure S5, (-1 -Log10(P) interval=12.3-17.4 Mb, containing 13 genes), 
and chromosome 19 (-1 -Log10(P) interval=38.5-42.8 Mb, containing about 70 genes).  
 
We began to ascertain which genes within the intervals are the best candidates by 
cataloguing DNA variants that vary between susceptible or resistant strains (see Figure 
2B for the coefficients together with the corresponding ANOVA test –log10(P) values). For 
instance, examination of the founder haplotype coefficients through the linked interval 
(Figure 2C) on chromosome 9 shows that the causal variant is derived from the NOD/LtJ 
founder (hereafter termed NOD). Mining the Sanger Mouse Genomes database for NOD-
specific variants revealed just 2 genes (Cdon and Pus3) carrying non-synonymous 
mutations, while 11 had NOD-specific single nucleotide polymorphisms (SNPs) in their 5’ 
or 3’ UTR, or introns (Figure 2D). The other gene in the chromosome 9 interval carrying a 
NOD-specific missense mutation is Pus3 (encoding Pseudouridylate Synthase 3), whose 
protein product is involved in tRNA metabolism but not skin or melanocyte biology. Other 
less likely candidates are listed in Figure 1d. Most of these have no known role in skin or 
melanocyte biology.  
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The interval on chromosome 11 carries 13 genes (Figure S5A,B). Here also the nevus 
“susceptibility” allele is inherited from NOD. On chromosome 11 only one candidate carries 
a NOD-specific missense variant, Cobl (Cordon-Bleu). It encodes a protein that binds actin 
and regulates neuronal behavior (Hou et al., 2015). On chromosome 19 the NOD 
haplotype again carries the causal allele, and of the 70 genes in the 4 Mb interval, only 
one, Tctn3 (Tectonic Family Member 3) carries a NOD-specific missense variant. Neither 
Cobl nor Tctn3 are reported to regulate melanocyte behavior. Many strains that carry the 
susceptibility haplotype on chromosome 9 also carry the susceptibility haplotype on 
chromosomes 11 and 19, (Figure S5C), suggesting some cooperation between the causal 
variants. Susceptibility to common diseases generally involves cooperation between 
multiple low risk genetic variants.  
 
This may be similar for congenital nevus, however the linkage to chromosome 9 is by far 
the strongest hit in the genome, suggesting a large effect locus modifying congenital nevus 
formation is located here. Because our method of scoring nevus cell density is in some 
ways different for albino and pigmented strains, we ran a genome wide linkage analysis on 
albino and pigmented strains separately (Figure S6). Despite the relatively smaller 
samples sizes than with all strains analyzed altogether, the chromosome 9 locus was 
under the most significant peak in both cases.  
 
The best candidate under the Chromosome 9 peak is Cdon, the NOD allele of which 
carries a missense mutation; none of the other founder strains have this change (Figure 
2D). Cdon has five Immunoglobulin (Ig) and three fibronectin type III domains (Sanchez-
Arrones et al. 2012). The CdonP456S mutation is in the Ig domain and could modify the 
glycosylation, phosphorylation and interactions of the mutant protein. Cdon is a neural cell 
adhesion molecule that is an activator of sonic hedgehog (SHH) (Allen et al. 2011). SHH-
GLI signaling is crucial for melanoma progression via cross-talk between the GLI and 
RAS-MEK/AKT pathways. SHH-GLI1 signaling in human hair follicle matrix controls 
normal proliferation of human melanocytes (Stecca et al. 2007). The Functional Networks 
of Tissues in Mouse (http://fntm.princeton.edu) database provides a means to assess 
tissue-specific co-expression and functional interactions between genes. The most 
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significant genes interacting with Cdon were in the hair follicle, particularly Shh (sonic 
hedgehog). We stratified the hair follicle gene network looking for genes interacting with 
Tyrosinase (Tyr) to identify melanocyte-specific networks, and Keratin 14 (Krt14) to identify 
keratinocyte-specific networks. In the Krt14 and Cdon (but not the Tyr) networks, Shh was 
the strongest associated gene, suggesting that the activity of Cdon via Shh may be mostly 
within follicular keratinocytes. Using a commercial anti-CDON antibody we were not able 
to obtain acceptable staining of mouse skin, but in human skin CDON is mostly expressed 
in the follicular inner root sheath (Figure 2E, F). If Cdon deregulation facilitates escape of 
melanocytes from the hair follicle in the nevus-prone mice, it may be via disrupting cell-cell 
adhesion, since in zebrafish Cdon promotes neural crest migration by regulating N-
cadherin localization, and Cdon knockout suppresses melanocyte migration to the ventral 
surface (Powell et al. 2015). Further, transgenic mice overexpressing Shh under a keratin 
gene promoter have hyperpigmented skin due to increased melanocytes near the 
epidermis, and develop discrete pigmented lesions on hind-limbs, made up of masses of 
highly pigmented melanocytes near the basal epidermis (Ellis et al. 2003). This non cell-
autonomous influence of the Shh on pigmented lesion formation has to our knowledge not 
been followed up. 
In a mouse model carrying the human NRASQ61K cDNA, lesions very reminiscent of 
congenital nevi formed at ~post-natal day 10, probably from melanocytes escaping the 
hair follicle. While these mice do not perfectly phenocopy human congenital nevus, they 
are one of the best characterized mouse models of dermal nevi. Mice are the only 
mammals in which we could have take the CC approach. Nevus cell density varied greatly 
with genetic background, with CC progeny in some strains hardly developing the lesions. 
Nevus cell density was not influenced by neonatal UVR exposure. Further, the gene we 
have localized seems to only influence the formation of the nevi, not whether they proceed 
to melanoma. Genetic linkage analysis of nevus density revealed a highly significant locus 
on chromosome 9, with Cdon a strong candidate modifier driving high nevus density. 
Other minor, but significant loci were located on chromosomes 11 and 19. Fine mapping of 
the genomic intervals can now be performed by testing further CC strains with the 
Cdk4R24C::Tyr-NRASQ61K mice and/or using the diversity outbred (DO) system (Churchill et 
al. 2012). DO mice carry many more recombinations than the CC strains, allowing more 
detailed mapping within the intervals.  
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These novel findings may provide the first clues as to how innate genetic variation may 
control the growth and development of congenital nevi.   
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Figure legends 
 
Figure 1. (A) Sox10-stained skin taken from Cdk4R24C/R24C::Tyr-NRASQ61K mice at various 
time-points after birth. Yellow arrows denote nevi. See immunohistochemistry staining 
methods in supplementary methods file. (b). Yellow arrows show Sox10-positive 
melanocytes escaping (left panel), or escaped (right panel), the hair bulb. (C) Average 
nevus score per strains for mice with and without previous exposure to neonatal UVR. Two 
people (AC and GW) independently scored them blind, and a third (BF) agreed on the 
score. Experiments were undertaken with institute animal ethics approval (A98004M). 3-
day-old mice were exposed to a single UVB exposure as described (Ferguson et al., 2010) 
(D) H&E skin sections from albino strains. Upper panel: a strain with very high nevus cell 
density, lower panel, a strain with very low density. (E) A pigmented strain. Upper panel: a 
strain with very high, lower panel, one with very low density. (F) Heat map showing the 
lack of correlation between congenital nevus cell density and neonatal UVR-induced and 
spontaneous melanoma. . Red denotes high nevus cell density and early melanoma age 
of onset, yellow low score and late onset. Black denotes data not yet available. All scale 
bars = 100μM 
 
Figure 2. (A) Genome-wide scan based on nevus cell density score in 66 CC strains. 
Genotyping, construction of CC strain haplotypes, and linkage analysis was performed as 
described in (Ram et al., 2014). Nevus score was treated as a multinomial analysis with 
values ranging from one to ten. The x-axis shows the chromosomal position and the y-axis 
shows the 2log10(P) values; the P-values were derived from the linkage haplotype data. 
(B) Plot of LOD scores along chromosome 9. (C) Founder allele coefficients: plot of the 
calculated log-odds ratio of eight founder alleles over the chromosome where the founders 
are colour-coded. (D) Genes within the -1 -Log10(P) interval. Red asterisk in blue box 
denoted missense mutation, black asterisk in yellow box denotes an intronic, 5’or 3’ UTR 
variant. (D) Table showing genes in the chromosome 9 interval. Columns at right show 
genes carrying variants specific to the NOD haplotype. Candidates carrying missense 
variants are marked in red with a blue box. Genes carrying synonymous, 5 or 3’ UTR, or 
intronic variants, highlighted in yellow. (E) Staining for CDON in the human anagen (E) 
and telogen (F) hair follicle, with positivity (red) in the inner root sheath indicated by yellow 
arrows. There is some much weaker positivity in the suprabasal epidermis (not shown).  
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Supplementary Figure legends. 
 Figure S1. Graph shows spread of nevus scores for 66 CC strains. 
Figure S2. (A) Summary of linkage peak on murine chromosome 11 (see legend to Figure 
2). Founder strain coefficients across chromosome 11 are shown below. (B) Genes within 
the -1 -Log10(P) interval. Red asterisk in blue box denotes missense mutation, black 
asterisk in yellow box denotes an intronic variant. (C) Yellow boxes denote strains that 
carry the NOD founder haplotype. 
Figure S3. (A) Sox10-stained skin taken from Cdk4R24C/+::Tyr-NRASQ61K mice at various 
time-points after birth. (B). (B) Sox10-stained skin taken from Cdk4R24C/+ mice at various 
time-points after birth. See immunohistochemistry staining methods in supplementary 
methods file.  
Figure S4.  Examples of Cdk4R24C/+::Tyr-NRASQ61K mouse skin for each or our arbitrary 
nevus cell density scores 1-10. Nevus cell deposits in the subcutis fat layer were not 
scored.  
Figure S5.  Same images as in Figure S4, except at the original size for ease of closer 
examination of specific sections.  
Figure S6.  Genome-wide scan based on nevus cell density score in (A), 26 albino CC 
strains, and (B), 40 pigmented CC strains.  Red arrows denote the major linkage peak on 
chromosome 9 containing Cdon. The x-axis shows the chromosomal position and the y-
axis shows the 2log10(P) values; the P-values were derived from the linkage haplotype 
data. Panels below contain plot of LOD scores along chromosome 9, and colour coded 
founder allele coefficients. 
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Figure S5. Same images as in Figure S4, except at the original size for ease of closer 
examination of specific sections. 
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Figure S6. Genomewide scan based on nevus cell density score in (A), 26 albino CC 
strains, and (B), 40 pigmented CC strains. Red arrows denote the major linkage peak on 
chromosome 9 containing Cdon. The x-axis shows the chromosomal position and the y-
axis shows the 2log10(P) values; the P-values were derived from the linkage haplotype 
data. Panels below contain plot of LOD scores along chromosome 9, and color-coded 
founder allele coefficients. 
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Chapter 3 
This chapter is comprised of a publication emanating from my thesis project.  
 
2.1 Publication  
Chitsazan, A., Ferguson, B.,Villani, R., Handoko, HY., Mukhopadhyay, P., Gabrielli, B., 
Mooi, WJ., Soyer, HP., Lambie, D., Khosrotehrani, K., Morahan, G., and Walker, GJ. 
Keratinocyte Sonic Hedgehog Up-regulation Drives the Development of Giant Congenital 
Nevi via Paracrine Endothelin-1 Secretion. J Investigative Derma. Accepted for 
publication. 
 
2.3 Contribution  
My contribution to the publication above included;  
 Mouse breeding 
 Acquisition of mouse lesions 
 Design of scoring approach for scoring of nevus density in mouse using H&E 
stained slides 
 Design of 5-Plex immunohistochemical staining protocol  
 Acquisition of patient congenital melanocytic nevi samples from collaborators 
 Processing and immunohistochemical staining of lesion set  
 Analysis of staining patterns of lesion set  
 Drug treatment 
 Gene expression 
 Preparation  of the manuscript 
Contribution by others: 
 B.F. provided technical support, animal breeding, sample collection.  
 R.V. gene expression study of Ptch1 KO mice 
 P.M. provided bioinformatic support and analysed data.  
 H.Y.H. provided technical support. 
 B.G. contributed to experimental design and supplied pathological specimens.  
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 G.J.W. designed the project, analysed data and prepared manuscript. 
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Abstract 
 
Giant congenital nevi are associated with serious clinical complications such as 
neurocutaneous melanosis and melanoma. Virtually nothing is known about why some 
individuals develop these lesions. We previously identified the sonic hedgehog (Shh) 
pathway regulator Cdon as a candidate nevus modifier gene. Here we validate this by 
studying Cdon knockout mice, and go on to establishment the mechanism by which Shh 
exacerbates nevogenesis. Cdon knockout mice develop blue nevi without the need for 
somatic melanocyte oncogenic mutation. In a mouse model carrying melanocyte 
NRASQ61K we found that strain backgrounds that carry genetic variants that cause 
increased keratinocyte Shh pathway activity, as measured by Gli1 and Gli2 expression, 
develop giant congenital nevi. Shh components are also active adjacent to human 
congenital nevi. Mechanistically, this exacerbation of nevogenesis is driven via the release 
of the melanocyte mitogen endothelin-1 from keratinocytes. We then suppressed nevus 
development in mice using Shh and endothelin antagonists. Our work suggests a novel 
aspect of nevus development whereby keratinocyte cytokines such as endothelin-1 can 
exacerbate nevogenesis, and provides potential therapeutic approaches for giant 
congenital nevi. Further, it highlights the notion that germline genetic variation, in addition 
to somatic melanocyte mutation, can strongly influence the histopathological features of 
melanocytic nevi. 
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Introduction 
The presence of multiple nevi is the strongest risk factor for development of melanoma 
(Gandini et al., 2005). Whereas common acquired nevi emanate from the dermo-epithelial 
junction of the skin, many nevi are dermal or have a dermal component. Congenital nevi 
are mostly dermal, and observed at birth or in the very young (Sowa et al., 2008; Price et 
al., 2010). They may be small birthmarks anywhere on the body, large lesions mostly on 
the head and neck, or giant lesions sometimes covering large areas of body. The latter 
have an increased risk for transformation melanoma (Zaal et al., 2004). Some patients 
develop neural melanosis, which carries a poor prognosis, with no effective treatment. One 
way to approach understanding the formation of these lesions is to look for natural gene 
variation that confers susceptibility to their development. But in terms of germline gene 
variation there are no GWAS or genetic association studies conducted on human giant 
congenital nevi patients, nor familial studies that might reveal rare mutations. 
Congenital nevi probably derive from melanocytes that have escaped the 
developmental route from the neural crest to the skin, and become trapped in the dermis, 
where they proliferate. Many transgenic mice carrying melanocyte-specific oncogenic 
mutations develop dermal melanocytic proliferations reminiscent of giant congenital nevi 
(Shakhova et al., 2012; Pawlikowski et al., 2015). Transgenic Cdk4R24C::Tyr-NRASQ61K 
(hereafter termed Cdk4::NRAS) mice begin to develop dermal nevi during the second 
week after birth (Chai et al., 2014; Chitsazan et al., 2016). Since the corresponding 
developmental period in which embryonic melanocytes have mostly migrated to the hair 
bulb is pre-natal in humans, beginning at around 18 weeks (Gleason et al., 2008), and 
examination of aborted foetuses at this stage have indicated the presence of deep dermal 
nevi at this stage (Cramer et al., 2012). one might expect that the mechanisms promoting 
escape of melanocytes from the hair follicle to the dermis should be similar in both 
species. Hence in order to discover genes affecting congenital nevogenesis, we utilised 
the Collaborative Cross (CC) (Morahan et al., 2008; Welsh et al., 2014), a resource of 
characterised mouse strains, in conjunction with the Cdk4:;NRAS model,  to identify a 
quantitative trait locus (QTL) on mouse chromosome 9 (Chitsazan et al., 2016) influencing 
nevocyte density. Examination of the founder haplotype coefficients through the linked 
interval on chromosome 9 showed that the nevus-susceptible strains carried the causal 
variant derived from the NOD/LtJ founder (hereafter termed NOD). One of the best 
candidates in this QTL was Cdon, a sonic hedgehog (Shh) pathway regulator. Shh 
signalling is controlled by dependence receptors Cdon and Ptch1 (Delloye-Bourgeois et 
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al., 2013). Their inactivation by Shh removes the inhibition on smoothened (Smo), a 
positive regulator of Gli transcription factors (Ruizi Altaba et al., 1997; Taipale et al., 2002; 
Ouspenskaia et al., 2016). Deregulation of the SHH pathway drives the formation of the 
keratinocyte-derived skin cancer, basal cell carcinoma (BCC), which are sometimes 
pigmented. Here we define a cell extrinsic role for the Shh-endothelin1 axis in the 
development of giant congenital nevi. 
Results 
Genetic Background Dictates the Histopathology of Melanocytic Hyperplasia 
Cdk4::NRAS mice develop dermal nevi by postnatal day 10, from melanocytes escaping 
the hair follicles (Chitsazan et al., 2016). Cdk4R24C/R24C::Tyr-NRASQ61K/+ males were bred 
with females from many CC strains to generate progeny heterozygous for Cdk4 and NRAS 
transgenes. Dorsal skin was collected from >3 progeny of each CC cross, and the density 
of dermal nevocytes scored from 1 (least dense) to 10 (most dense). The method of 
scoring each strain for nevus cell density in the dermis is described in Chitsazan et al., 
(2016). Here we went on to diagnose lesions at each density level according to 
histopathological criteria for diagnosing human melanocytic hyperplasia. Those with a 
score of 1-4 were best defined as superficial or deep blue nevi (Figure 1a; Figure S1), a 
score of 5-6 as deep penetrating nevi, 7 as epitheloid blue nevus, and 8-10 as 
melanocytoma. The nevus density score was closely related to depth and 
histopathological diagnosis (Figure 1b). In general a particular histopathological parameter 
may be shared by more than one lesion subtype, and we observed a gradation of 
nevocyte density scores closely, but not perfectly, reflecting nevus subtype (Figures 1c). 
Despite all mice carrying a melanocyte NRASQ61K mutation making them susceptible to the 
development of nevi, germ-line genetic variation dramatically alters nevus 
histopathological presentation.  
Validation of a candidate Modifier Gene for Nevus Exacerbation  
Previously we identified Cdon as candidate nevus modifier gene by studying Cdk4::NRAS 
mice crossed onto many CC strain backgrounds (Chitsazan et al., 2016). We used 
heterozygous loss of Cdon, since homozygous loss is embryonic lethal. Cdon+/- mice 
(n=4), and not littermate wild type controls (n=3), developed blue nevi in old age. 
Dermoscopy of the lesions showed a blue hue suggesting nevocyte location in the deep 
dermis (Figure 2a). Dendritic and epithelioid melanocytes were present. Whereas in the 
normal skin of these mice hair follicles were in telogen (the resting phase of the hair cycle), 
surrounding the blue nevi there were more hair follicles and they were in in anagen (the 
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growth phase of the hair cycle) (Figures 2b and Figure S4a and b). Also, these aged 
Cdon+/- mice had fewer hair follicles than controls (Figure S4). The differences in hair 
follicle number and the inappropriate stage of cycle are unsurprising given the pivotal role 
of Shh in hair follicle homeostasis (Sato et al., 1999). Cdon+/- mice develop dermal nevi 
without the need for somatic BRAF or NRAS mutation in melanocytes.  
We then assessed the visual appearance of Cdk4::NRAS mice carrying the 
CdonNOD allele (Figure 2c), versus controls carrying the non-NOD allele (by genotyping the 
CdonP456S mutation). Both cohorts were hyperpigmented, but susceptible mice carrying 
CdonNOD developed leathery thickenings reminiscent of giant congenital nevi. Dermoscopy 
of the tail and dorsal skin of resistant mice showed a scattered blue hue on a white 
background with some small superficial and deep nodules, whereas in the susceptible 
mice carrying CdonNOD both the deeper nevi and nodules were much larger (Figure 2c). 
Histologically, the former were blue nevi, while the latter consisted of strings 
interconnected melanocytomas producing a macroscopic appearance of giant congenital 
nevus. The formation of leathery lesions can be observed in patients with either medium-
sized (Figure 2d) or giant congenital nevi (Figure 2e). The human and murine giant 
congenital nevi lesions showed other similarities including generalised hyperpigmentation, 
some large plaques, and ectopic hair growth (hypertrichosis). lnactivation of the Shh 
pathway in mouse keratinocytes, in conjunction with melanocyte NRASQ61K mutation, 
produced large leathery melanocytic plaques reminiscent of human giant congenital nevi. 
Thus, while we do not know that status of the SHH pathway in such individuals, 
upregulated keratinocyte SHH and EDN1 might be one potential mechanism.  
 
In vivo Activation of Shh Signaling in Cdk4::NRAS Mice with Giant Congenital Nevi  
To confirm activation of the Shh pathway in strains carrying the CdonNOD variant we 
stained the mouse skin for Gli1 and Gli2, markers of Shh activation, using multiplexed 
immunofluorescence (IF) staining with Tyramide-based amplification (Figure 3). We 
stained dorsal skin from Cdk4::NRAS mice with Sox10 (a melanocyte maker) and Gli1 and 
Gli2 antibodies, to examine protein expression in the vicinity of the early nevi (mice at P10 
and P21), and melanocytoma (in adult mice). In CdonNOD strains, at P10 when nevi are 
beginning to form, Gli proteins were mostly in the hair bulb (Figure 3a). In susceptible adult 
mice with follicles in telogen, Gli1 was expressed in a much higher proportion of cells 
within the skin (Figure 3b). In contrast, in the skin of resistant strains there was low levels 
Gli1 expression at P10 and in adults (Figures 3c and 3d). This is likely due to the low (and 
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only scattered) Shh activity in normal skin (except during anagen for which Shh activity is 
essential). Quantitating the proportion of Gli1 positive cells in the skin, we found that both 
in young mice at P10 and P21 (Figure 3e), and in adult animals (Figure 3f) the CdonNOD-
carrying strains contained significantly more Gli-positive keratinocytes.  
In human skin, CDON is expressed mainly in the suprabasal epidermis, and in parts 
of the hair follicle, probably the inner root sheath (Figure S2). In mouse skin also Cdon is 
expressed in the epidermis and the hair follicle, although because of thin hair shaft it is 
more difficult to ascribe staining to a specific layer. We stained four human intradermal 
nevi (Figure 3g and S3a) with congenital features including deep extension into the 
reticular dermis, and peri-appendageal accentuation. CDON was mostly expressed in 
differentiated keratinocytes in upper epidermis, and in the hair follicle. The expression of 
GLI1 in keratinocytes is consistent with a role for activated SHH in exacerbating human 
dermal nevus development. In the mouse this effect largely influences the early stages of 
nevus formation, which occur prenatally in humans. Understanding the temporal 
development (beginning at ~ 10 days of age), and the skin compartment in which they are 
first observed (in the superficial dermis adjacent to hair follicles) in our mouse model, 
provides us with a unique opportunity to better study the mechanisms by which natural 
genetic variation influences congenital nevi formation.  
Linking Keratinocyte Shh Signalling to Development of Dermal Nevi 
LDE225, a potent antagonist of the Shh pathway protein Smo, is an FDA-approved drug 
for topical treatment of BCC. We administered this topically in DMSO to the dorsal skin 
every day from P5 to P10. Skin samples harvested at the end of P10 from drug-treated 
and control groups were stained for Sox10 (Figure 3a). Whereas at P10 small groups of 
melanocytes (early nevi) were beginning to form in the control mice, these were not 
evident in the drug-treated animals. The proportion of Sox10 positive nuclei in the dorsal 
skin of LDE225-treated mice was significantly lower in the superficial dermis than in 
controls (Figure 3i). The drug treatment also suppressed melanocyte numbers in the hair 
bulb suggesting that less melanocytes may be escaping from it (Figure 3i). Thus, drug 
targeting of Shh pathway activity can significantly suppress nevus formation.  
Shh-Edn1 Axis Exacerbates Nevogenesis 
Basal cell carcinomas in humans and mice are sometimes pigmented (Chow et al., 2011; 
Grachtchouk et al., 2003; Moore et al., 2012; Peterson et al., 2015). In mice with 
keratinocyte-specific inactivation of Ptch1 (Peterson et al., 2015), or activation of other Shh 
pathway components e.g. Smo (Grachtchouk et al., 2003), Gli2 (Grachtchouk et al., 2000), 
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and Shh (Ellis et al., 2003), hyperpigmentation is usually evident as pigmented 
melanocytes within or near BCCs. These transgenics were all generated to study BCC 
hence did not properly analyse the hypigmentation. Where hyperpigmented skin was 
reported, and adequate published images available, the lesions appeared to be blue nevi 
(Ellis et al., 2003), which also develop in the Cdon+/- mice.  
 
We set out to ask which genes that influence melanocyte behaviour are over-expressed in 
the skin of these transgenics? We compared gene expression from RNA sequencing of 
Ptch1 knockout epidermis to that of controls. For additional confirmation we used 
published data from another mouse BCC model (Youssef et al., 2012). In this case YFP-
positive keratinocytes were isolated from tamoxifen-treated and control K14-CreER::Rosa-
Smo2 (K14-Smo2) mice, and microarray gene expression analysis performed. In both 
cases Shh target genes are up-regulated in keratinocytes e.g. Gli1, Shh, Ptch1, Hhip 
(Figure 5a). Given that transgenic over-expression of known melanocyte mitogens like 
hepatocyte growth factor (Hgf), endothelin 3 (Edn3), in murine keratinocytes induces 
similar melanocytic dermal lesions to that we see in our model (Aoki et al., 2009), we 
looked for up-regulation of genes encoding secreted cytokines known to be melanocyte 
mitogens; Edn1, Edn2, Edn3, Hgf, Fgf, Pomc (Msh and Acth), and Ngf (Hirobe 2005), 
and Wnt5a and Wnt7b (Figure 4a). Edn1 (endothelin 1) (Zhang et al., 2013; Hyter et al., 
2013; Urtatiz et al., 2016; Chiriboga et al., 2016) was the only such gene statistically 
upregulated in both the Ptch1 and Smo mouse model epidermis. By IF staining of mouse 
dorsal skin we found that Edn1 is expressed in the epidermis and certain cells in the outer 
root sheath and hair bulb (Figure 4b). We quantitated the expression of Edn1 protein in 
susceptible and resistant strains. The number of positive cells per mm2 was significantly 
higher in the susceptible strains (Figure 4c), suggesting that Edn1 secretion is a plausable 
mechanism for exacerbation of nevogenesis.  
To confirm this, we utilized an inhibitor of the Edn1 receptor, Bosentan. Daily treatments of 
Cdk4-NRAS mice (from P5 to P10 intraperitoneally and topically) with Bosentan 
significantly reduced the appearance of developing bands of nevi in the superficial dermis 
(Figures 4f and 5g). 
 
Discussion 
Although NRASQ61K mutation is the major somatic mutation carried in giant 
congenital nevi, virtually nothing else is known about the mechanism of formation of these 
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lesions. Despite the evolutionary differences in the pigmentary system between species 
(mouse melanocytes are usually limited to hair follicles whereas in humans they are also in 
the epidermis), virtually all genes involved in regulating mouse melanocyte behaviour (i.e. 
pigmentation) are relevant in humans (Walker et al., 2011). Given that we have gone to 
great lengths to diagnose the murine nevi precisely according to the histopathological 
criteria used for human nevi, and shown that the pathway we have discovered is active in 
the epidermis adjacent to human congenital nevi, the cell extrinsic mechanism we have 
delineated could be involved in the formation of human nevi. It is not known whether 
germline CDON variants influence the development of human congenital nevi, but our 
findings enable us to postulate that variants in any gene that results in up-regulation of a 
pathway that increases expression of a secreted keratinocyte cytokine that is a 
melanocyte mitogen, could be a candidate.  
A role for paracrine Edn1 driving nevogenesis seems uncontroversial. It is a 
mitogen for human melanocytes in culture (Imokawa et al., 1992) and in human skin 
explants (Takeo et al., 2016), and is involved in wound-induced melanocyte activation 
(Park et al., 2015). Edn1, along with Edn2 and Edn3, are mostly active only in anagen, or 
growth phase of the hair cycle, when they assist either to activate melanocyte stem cells, 
and/or to assist in migration of melanocytes to the hair bulb (Mort 2015). Hence under 
stress such as increased endothlin secretion or the presence of a NRAS or BRAF mutation 
it is unsurprising that melanocytes escape their follicular niches and congregate in the 
dermis as nevi. Edn1 binds to the melanocyte Ednrb receptor and stimulates signalling 
through Gnaq/Gna11 and subsequently the MAPK pathway (Figure 6). GNAQ is 
somatically mutated in ~80% of human blue nevi, suggesting that signalling through it is 
important in dermal nevus development, and mice expressing an activated Gnaq mutant in 
their melanocytes exhibit essentially the same phenotype in terms of dermal melanocytic 
nevi that we observe in our model with activated keratinocyte Shh (Huang et al., 2015). 
Perhaps SHH-EDN1 signalling acts as a rheostat, via melanocyte EDN1-GNAQ-MAPK, in 
exacerbating blue nevi to form very large or giant nevi (Figure 6).  
SHH is normally associated with BCC. PTCH1 is frequently mutated in BCC-prone 
patients, and the SHH pathway is mutated somatically in BCC (Tang et al., 2010; Briscoe 
et al., 2013). Notably, the mouse strains carrying the CdonNOD variant do not develop BCC, 
presumably since the associated keratinocyte Shh up-regulation is relatively subtle. But 
one would expect BCCs to be pigmented, and many are, with melanocytes unusually 
located around the edges or within the lesion. EDN1 is highly expressed adjacent 
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pigmented, but not non-pigmented human BCCs (Lan et al., 2005). Since 80% of Asian, 
but only 3% of Caucasian BCCs show pigmentation (Moore et al., 2012; Chow et al., 
2011), it is likely that modifier alleles that differ between these ethnic backgrounds 
modulate the SHH-EDN1 axis. However murine models with keratinocyte-specific 
deregulation of Shh components e.g. Shh (Ellis et al., 2003), Ptch1 (Peterson et al., 2015), 
Smo (Grachtchouk et al., 2003; Eberl et al., 2012), and Gli2 (Grachtchouk et al., 2000), all 
exhibit melanocyte hyperplasia.  
An important message is the notion that different genes act at different stages of 
tumor progression. We show (Figure 1c) that the strains carrying the CdonNOD allele and 
upregulated keratinocyte Shh components are not necessarily more prone to the 
development of melanoma, although the nevi are much larger. Since the transformation of 
an individual nevus (of which there are >10,000 per mouse on an FVB strain background) 
is extremely low (a 0.04% probability that a nevus will convert to melanoma; Chi et al., 
20012), it must be modified by epigenetic, or other genetic background effects yet been 
elucidated.  
Our strategy using mouse models could be helpful in gaining insights into genetic 
background influences in other rare diseases. Giant congenital nevi are only seen in about 
1/20,000 births, and no genetic studies have been performed on large case-control 
cohorts. But they can be disfiguring, covering significant parts of the body surface, and 
with a high propensity to convert to melanoma. They are not always stable. Satellite 
lesions can form, and neural melanosis sometimes becomes manifest in these patients. 
Studying human lesions post-natally does not tell us how they are formed. In years to 
come germ-line DNA from large enough cohorts may become available for genome wide 
association studies into susceptibility. But not being a common disease it will be difficult to 
attract traditional research funding. To confirm our hypothesis that keratinocyte cytokines 
may feed the formation of giant nevi would entail sensitive gene expression and or 
immunohistochemical studies of representative skin samples from perhaps hundreds of 
patients and ethnic matched controls, again a difficult study to realize.  
Targeting keratinocyte cytokines might provide hope for a drug therapy by which 
giant nevi could be controlled, or even reversed, since they can spontaneously regress 
(Arpaia et al., 2005; Nath et al., 2011; Cusak et al., 2009). Surgical excision is the gold 
standard treatment for most cutaneous tumours. But topical treatments are now available 
for solar keratosis and in situ squamous and basal cell carcinomas (e.g. fluorouracil, 
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imiquimod, Picato gels), lesions previously only removed by excision. The same may 
eventually be true for large/giant nevi. Topical treatment of pigmented BCCs with the SMO 
antagonist LDE225, and Bosentan an inhibitor of Edn signalling, which we used in our 
study to suppress the development of dermal nevi, results in the disappearance of the 
associated melanocytosis.  
 
 
Methods 
Mice and Phenotyping 
Mouse breeding and screening for nevus density modifier gene: By breeding 
Cdk4R24C/R24C::Tyr-NRASQ61K/+ males with females from 70 CC strains. Experiments were 
undertaken with institute animal ethics approval (A98004M). Cdon knockout mice were 
provided by Robert S. Krauss (Icahn School of Medicine at Mount Sinai, NY). 
Collaborative Cross mouse strains were provided by Grant Morahan (Harry Perkins 
Institute of Medical Research, Perth). By breeding Cdk4R24C/R24C::Tyr-NRASQ61K/+ males 
(FVB background) with CC females we generated progeny heterozygous for Cdk4 and 
NRAS (Chitsazan 2016). At P10 small nests of melanocytic cells (nevi) appear within the 
superficial dermis around hair follicles (Chai et al., 2013). Nevi are completely formed by 
P40.  
RNA Sequencing 
Four weeks after tamoxifen injection, epidermal cells of K14-CreER::Ptch1fl/fl and control 
mice were recovered by digestion and flow sorting of EPCAM+ epidermal cells. RNA was 
isolated using RNeasy Kit and libraries generated with Illumina mRNA kit. Sequencing 
was performed using Ilumina HiSeq chemistry, with 50bp single reads. The RNA-
seq samples were mapped to mouse genome MM10 using TopHat2, then mapped reads 
for each gene counted for every sample using HT-Seq. We used EdgeR and DEseq to 
estimate the significance of differential expression between groups. 
Haematoxylin and Eosin Staining Protocol 
Slides from formalin-fixed paraffin-embedded blocks were dewaxed and stained with 
haematoxylin and eosin using Leica autostainer XL. 
Dermoscopy of Mouse Skin 
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After shaving to remove hair, clinical images were acquired with a digital camera (Canon 
PowerShot G10; Canon, Tokyo, Japan). Detailed macroscopic images were acquired with 
the same camera equipped with a dermoscopic attachment (Dermlite©, 3Gen, USA). 
 
Multiplexed Fluorescent Immunohistochemistry with Tyramide Signal Amplification 
Sections from paraffin-embedded lesions were dewaxed and treated with Dako low pH 
antigen retrieval solution at 1000C for 15 minutes. Endogenous peroxidase activity was 
quenched in 3% H2O2, and sections blocked with 5% bovine serum albumin. Primary 
Sox10 (sc-17342), Gli1 (ab151796), Gli2 (AF3635), Cdon (sc-134837) and Edn1 
(ab117757) antibodies were applied, followed by the appropriate secondary antibodies. 
After washing, the signal was amplified using Perkin Elmer Tyramide amplificiation kit 
(FITC, CY3, CY3.5, CY5), slides were washed, counterstained with DAPI, and 
coverslipped using DAKO mounting medium. Slides were scanned using the Vectra 
spectral imaging system (PerkinElmer). Images were scanned at at 4X magnification. 
Multispectral images (MSI) were captured using Phenochart software and scanned from 
420 nm to 720 nm using Vectra 3.1 Automated quantitative pathology imaging system. 
Three MSIs per sample was analysed using InForm analysis software. Positive cells were 
segmented and counted per 20X magnification field. 
LDE225 Treatment 
To generate high nevus count mice we crossed NOD X Cdk4R24C/R24C::Tyr-NRASQ61K 
transgenics. We topically treated the dorsal area with LDE225-DMSO (10 mg/ml, Selleck 
Chemicals) every day from P5 to P10 (with skin harvested at P10). Controls were treated 
with DMSO alone. Skin was harvested from drug treated and control groups (n=21) 
stained for Sox10 and slides digitised with an Aperio AT-Turbo Brightfield slide scanner. 
Sox10 positive nuclei count was determined using the Aperio IHC nuclear algorithm 
V8.001, and nuclear staining stratified into three intensities (1+ to 3+). We scored the 
number of strongly positive nuclei (3+) per 2 mm2 section. 
Bosentan Hydrate Treatment 
To generate nevus-susceptible mice crossed NOD mice with Cdk4R24C/R24C::Tyr-NRASQ61K 
transgenics. Pups were both injected intraperinatally with Bosentan hydrate-DMSO 
(10mM/1mL in DMSO, Selleck Chemicals) every day from P5 to P10 (skin harvested at 
P10). Controls were treated with DMSO. Skin was harvested from drug-treated and control 
groups (n=14). H&E-stained slides were digitized with Aperio AT-Turbo Brightfield slide 
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scanner, and intensity of pigmented cells analysed with Aperio-V9 software. We 
quantitated to intensity of strongly positive cells. 
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Figure legends 
 
Figure 1. Comparison of human and murine melanocytic lesions. (a) The inner ring 
shows representative images of H&E staining of murine melanocytic lesions at each 
nevocyte density score (1-10). The outer circle shows representative images of H&E 
staining of corresponding human melanocytic lesions. (b) Distribution of 70 CC strains 
based on their nevocyte density score and histopathological diagnosis. SBN: Superficial 
blue nevus, DBN: Deep blue nevus, DPN: Deep penetrating nevus, EBN: Epithelioid blue 
nevus and M: Melanocytoma. (c) Heat map of pigmentation in megapixel per 20X field of 
digitized mouse skin from 40 pigmented CC strains bearing Cdk4::NRAS and their relevant 
1-10 nevocyte density score. 
 
Figure 2. Giant congenital nevus is composed of interconnected melanocytomas. (a) 
Lesions in Cdon+/- mice. By dermoscopy blue coloration is due to dermal melanocytes 
(blue nevus). H&E shows dermial dendritic melanocytes (yellow arrow), while the white 
arrow shows dermal epithelioid melanocytes. (b) Normal skin from wild type and Cdon+/- 
mice, showing higher density of hair follicles in wild type. (c) Visual appearance of dorsal 
surface of susceptible Cdk4::NRAS::CdonNOD/+ mouse (right), at 8 months of age, versus a 
resistant Cdk4::NRAS::Cdon+/+ (+/+ = wild type) mouse (left), at 24 months, with 
dermoscopic images of tail and dorsal skin, and H&E staining of dorsal skin. Both mice are 
hyperpigmented, but the animal carrying the Cdon NOD allele exhibits a large thick giant 
congenital nevus-like lesion covering the majority of the dorsal surface. All Scale bars = 
300 μm. (d) Large human congenital nevus. Red box shows large hyperpigmented plaque 
within nevus area. (e) Giant human congenital nevus covering most of the child’s leg.  
 
Figure3. Upregulation of Gli in keratinocytes potentiates nevogenesis. Images of 4-
plex fluorescent immunohistochemistry with Tyramide signal amplification using 
Sox10/Gli1/Gli2 antibodies. Samples are of dorsal skin. (a-d) The magnification of A and 
C, and B and D, are the same. Images show susceptible Cdk4::NRAS::CdonNOD/+ mice 
and resistant Cdk4::NRAS::Cdon+/+ mice at P10 and adulthood. Yellow arrows denote 
melanocytoma. (e and f) Proportion of Gli1-positive cells per mm2 in dorsal skin from 
susceptible and resistant mouse strains at P10 (n=10), P21 (n=10) and adulthood (n=21), 
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quantitated using InForm software. (p-values calculated using two-tailed T test, 
****=p<0.0001). Scale bars = 60 μm. (g) Human congenital nevus expressing Shh pathway 
components. Scale bars = 800 μm. (h) Sox10 staining of dorsal skin from susceptible 
Cdk4::NRAS::CdonNOD/+ mice treated with LDE225 versus (control left panel). Red dotted 
line denotes superficial blue nevus. Blue arrows denote melanocytes located ectopically in, 
and at risk of escape from, the hair bulb. Graphs to the right show Sox10-positive nuclei 
counts in hair follicle bulb (i) at 40X, and the superficial dermis (j), at 20X magnification, of 
LDE225-treated mice (n=11) and controls (n=10). Cells quantitated using the nuclear 
staining algorithm of the AperioTM.  Scale bars = 60 μm. ****=p<0.0001, **=p<0.007. 
 
Figure 4. Mechanism of exacerbation of nevogenesis. (a) Relative gene expression 
(Log fold change) in tamoxifen-induced versus control K14-Ptch1 and K14CREER/Rosa-
SmoM2 epidermis. Differences significant except where marked (n.s=p> 0.05). (b) 
Expression of Edn1 in p10 anagen skin from Cdk4::NRAS mice carrying the CdonNOD 
variant. (c) Quantitative protein expression analysis of Edn1 in susceptible 
Cdk4::NRAS::CdonNOD/+ (n=14 mice) versus a resistant Cdk4::NRAS::Cdon+/+ (+/+ denotes 
wild type at Cdon) (n=7), as measured with InForm software (p=value calculated using the 
two-tailed T test (****= p<0.0001). (d) Edn1 expression in adult wt versus Cdon+/- in 
telogen. (e) Quantitative protein expression analysis of Edn1 in adult wt  (n=3) versus 
Cdon+/- (n=4). (**= p<0.005). (f) Images of H&E staining of dorsal skin from control and 
Bosentan (an endothelin receptor inhibitor)-treated Cdk4::NRAS::CdonNOD/+ mice. Yellow 
arrowheads indicate blue nevi. White asterix denotes hair bulb filled with melanocytes in 
control but not Bosentan-treated mice. Graphs at right show pigmentation level in the 
dermis (g), and hair follicles (h) of control (n=7) and Bosentan-treated 
Cdk4::NRAS::CdonNOD/+ mice. There was significantly more pigmentation in the control 
skin (two-tailed T test, **= p<0.001), ****= p<0.0001). All Scale bar = 60 μm. 
Figure 6. Model of nevus exacerbation. Proposed mechanism of action of the Cdon-
Shh-Edn1 axis, exacerbating nevogenesis. Panel to the left depicts low innate Shh 
signaling activity in Cdk4::NRAS::Cdon+/+ resistant mouse strain (Cdon+/+), where 
NRASQ61K is the sole driver of nevogenesis. This leads to the formation of blue nevi. In 
Cdk4::NRAS::CdonNOD/+ mice with high innate Shh signaling, the Shh-Edn1 axis is 
activated by the CdonNOD variant. Upregulation and secretion of Edn1 from keratinocytes 
activates the Ednrb-Gnaq/Gna11 complex, which in turn augments the effect of NRASQ61K 
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on MAPK, resulting in the formation of melanocytoma (right panel). Targeting of the Cdon-
Shh-Edn1 axis using Shh and endothelin pathway antagonists (LDE225 and Bosentan 
respectively) suppresses nevogenesis. 
Suppl. Figure 1. Histopathological variation of melanocytic lesions with Cdk4::NRAS 
mutation. (a) Images of H&E staining of superficial and deep blue nevus in mouse and 
human. Nevocytes are comprised of pigmented dendritic cells having wedge shape 
architecture. (b) Images of H&E staining of mouse and human deep penetrating nevus. 
These lesions appear in deep dermis, superficial hypodermis, or adjacent to hair follicle 
bulb area. Pigmented balloon cell-like nevocytes sometimes appear in these lesions. Scale 
bars = 100 um. (c) Images of H&E staining of mouse non-bleached and bleached 
epithelioid blue nevus (left) and human epithelioid blue nevus (right). Scale bars = 400 μm. 
(d) Images of H&E staining of mouse non-bleached and bleached murine melanocytoma 
(left) and human melanocytoma (right). These lesions contain 3 cell types: dendritic 
cells, heavily pigmented balloon cells and epithelioid cells. Scale bars = 400 μm.  
 
Supplementary Figure 2. CDON expression in non-lesional human and mouse skin 
IF staining of CDON in normal human (a) and mouse skin (b). CDON expression is mainly 
detected in the upper layer of epidermis and in the hair follicles. Scale bar = 100 μm. 
 
Supplementary Figure 3. SHH activity in human dermal nevus and mouse 
melanocytoma (a) Three-Plex immunofluoresence with tyramide signal amplification 
(3Plex-TSA) of SOX10, CDON and GLI1 in human dermal nevus with congenital features. 
CDON is mainly expressed in keratinocytes of epidermis, hair follicle. CDON expression 
and GLI1 overlap follows similar pattern. Scale bars = 300 μm. (b) 3Plex-TSA of adult 
NOD mouse melanocytoma with Sox10-Cdon-Gli1. Murine lesion shows similar high Shh 
signalling. Scale bars = 100 μm.  
 
Supplementary Figure 4. Alopecia is observed in high Shh signalling strains (a) H&E 
images of dorsal skin from wild type and Cdon heterozygous knockout littermates. Lower 
panels, H&E images of dorsal skin from Cdk4::NRAS+CC progeny mice on nevus-
resistant and susceptible strain backgrounds respectively. Scale bars = 300 μm. (b) 
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Average count per strain of hair follicles per 1.5mm of dorsal skin (WT, n=4, susceptible 
strains, n=8, wt, resistant strains, n=8, Cdon+/-, n= 5). Statistical comparisons performed 
with a T-=test, ***=p<0.001, **=p<0.01, *=p<0.05). 
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Chapter 4 
 
4.1 Introduction 
As described in chapter 2 and 3, by crossing many Collaborative cross (CC) strains with 
Tyr-NRAS::Cdk4 (NRAS-Cdk4) mouse model we observed tremendous diversity in the 
nevus density of superficial and deep dermal nevi. Another interesting diversity between 
CC strained crossed with (NRAS-Cdk4) was the number of melanocytic microsatellites 
(MSs) that appeared in the hypodermis layer of skin. Majority of these MSs appear near 
blood vessels (angiotropic features) (Wilmott 2012) (Figure 4.1a). MSs can sometimes be 
detected in the skin, associated with congenital nevi and melanoma. In congenital nevi and 
melanoma they represent groups of melanocytic cells away from the main lesion, often 
associated with regional lymph node metastasis (Day 1982, Harrist 1984) and are 
considered a poor prognosis factor. Presence of angiotropic MSs in stage III melanoma 
patients results in diminished 5-year survival rates (Barnhill 2002, Lugassy 2004, Van 
2008, Lugassy 2011, Kokta 2013).  
The majority of these patients have positive lymph node biopsies compared to other 
melanoma patients whose melanomas are negative for MS (Lugassy 1997, Lugassy 
2014), supporting the existence of extravascular migratory metastasis (EVMM) or 
intravascular migratory metastasis (IVMM) culminating in lymph node positivity for 
melanoma cells (Figure 4.1b).  It is unclear if MSs are only faithful to one of these two 
possible routes. 
Wilmott et al. (2012) show that factors such as angiotropism, absence of regression, and 
Clark level V invasion, are strongly correlated with the presence of MSs in the skin. Hence, 
angiotropism in a sample predict the possibility of finding MSs and positive sentinel lymph 
node biopsies. Intriguingly, many other neural crest (NC) derived cancers e.g. 
glioblastoma multiforme and diffuse gliomas also exhibit angiotropic features (Lugassy 
2005, Preusser 2007). 
Virtually nothing is known about genes or mechanism conferring susceptibility to the 
development of MSs. To discover such genes, we conducted an unbiased genetic screen 
of MS counts in 45 CC strains. Our genetic analysis of MS count revealed a strong hit on 
murine chromosome 10, to an interval containing 22 candidate genes.  
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Allele segregation from 8 founders of CC strains revealed that the causal allele is inherited 
from NZO/HlLtJ (NZO) founder. Further, by using SNP cataloguing analysis we find 
mapped the region to an interval containing 11 genes. Our gene expression and protein 
expression studies suggest that Gja1 could be a strong candidate for further study of MS 
development. 
 
4.2 Hypothesis 
Germline genetic variation potentiates the development of melanocytic microsatellites in 
the hypodemirs of skin. 
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Figure 4.1 ǀ Microsatellite showing angiotropism. a, The image of H&E staining of 
mouse dorsal skin. A microsatellite with angiotropism (green arrows) appear 420 μm from 
a superficial blue nevus (left).  Scale bar = 100 μm. b, Extravascular migratory metastasis 
(EVMM) model depicted in the diagram. EVMM is schematically depicted in the diagram 
by following steps: 1. tumor cells form an advancing front in the primary site; 2. tumor cells 
migrate near a vessel and cuff themselves to the vessel in order to from a colony 
(angiotropism); 3. tumor cells undergo epithelial mesenchymal transition (EMT)  and obtain 
a pericytic phenotype; 4. pericytic cells migrate along vessels without intravasation; 5. 
formation of secondary colony in lymph nodes or distant site (Lugassy 2014). 
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4.3 Materials and Methods 
Mice and phenotyping 
Experiments were undertaken with institute animal ethics approval (A98004M). 
Collaborative Cross mouse strains were provided by Grant Morahan (Harry Perkins 
Institute of Medical Research, Perth). By breeding Cdk4R24C/R24C::Tyr-NRASQ61K/+ males 
(FVB background) with females from 45 CC strains we generated progeny that are 
heterozygous for both the Cdk4 and NRAS mutations.  
 
Genetic analyses 
We tested 45 CC strains to discover quantitative trait loci (QTLs) that modify the density of 
microsatellite lesions in different mouse strains. The construction of the CC founder 
haplotypes is described in Ram et al. (2014). For mapping we used a logistic regression 
matrix model over the reconstructed haplotypes matrix to produce genome-wide 
distribution of P values (ANOVA chi squared). We used a false discovery rate of p=0.0001 
to define significant genome wide linkage.  
 
Gene expression study of genes differentially expressed during anagen and telogen 
Dorsal skin from 20 CC strains collected during anagen (5 weeks after birth) and telogen 
(8 weeks after birth) in RNAlater™ stabilization solution. All mice were checked for the 
absence of melanocytic lesions with dermoscopy prior to collection of normal dorsal skin. 
 
Assessment of RNA quantity and quality from frozen sections 
The QIAGEN RNeasy® Micro Kit combined with our hands results in very good yield and 
quality of RNA. Quality control by direct analysis using Qsep100 analyzer is possible with 
quite large skin samples (often some 4 mm2 collected area from tissue sections of 8 μm 
thickness) and is limited to concentrations ≥5 ng/μl. Total RNA extracted from nevi and 
melanoma samples, with ribosomal RNA peaks ratio of ≥1.7 (28S:18S) are selected for 
downstream studies. 
cRNA Synthesis 
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We usually use 500 ng of total RNA for cRNA syntehsis using Illumina® TotalPrepTM RNA 
Amplification Kit. The yield and quality check is performed using Nanodrop Lite and 
Qsep100 analyzer respectively.  
 
Analysis of cRNA size 
The size distribution of cRNA is evaluated using Qsep 100 analyzer. The Qsep 100 can 
provide a fast and accurate size. The expected cRNA  profile is  a distribution  of sizes 
from  250  to 5500 nucleotide (nt) with most of the cRNA at 1000 to 1500 nt. 
 
Expression array analysis  
RNA was subjected to one round of amplification/labeling with a MessageAmp kit 
(Ambion), then 1.5 μg labeled cRNA will be hybridized to MouseWG-6 v2.0 Expression 
BeadChips. The laboratory has used these systems extensively; labelling with 100 ng of 
total RNA gives high reproducibility (r2>0.99 across independent experiments). Data was 
extracted using GenomeStudio (Illumina) and imported into GeneSpring (Agilent) for 
normalisation, visualisation, and unsupervised hierarchical clustering. Analysis of variance 
(p-value ≤0.05 using Benjamini and Hochberg correction for multiple testing) was applied 
to identify genes whose expression differs between groups. 
 
Haematoxylin and eosin staining protocol 
Slides from formalin-fixed paraffin-embedded blocks were dewaxed and stained with 
haematoxylin and eosin using Leica autostainer XL. 
 
 
 
Multiplexed fluorescent immunohistochemistry with Tyramide signal amplification 
 
Sections from paraffin-embedded lesions were dewaxed and treated with Dako low pH 
antigen retrieval solution at 1000C for 15 minutes. Endogenous peroxidase activity was 
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quenched in 3% H2O2, and sections blocked with 5% bovine serum albumin. Primary 
Sox10 (sc-17342), and Cx43 (ab11370) antibodies were applied, followed by the 
appropriate secondary antibodies. After washing, the signal was amplified using Perkin 
Elmer Tyramide signal amplification kit (FITC and CY5). Finally slides were washed, 
counterstained with DAPI, and coverslipped using DAKO mounting medium. The entire 
slides were scanned using the Vectra spectral imaging system (PerkinElmer) to accurately 
identify all regions. Images were scanned at 4X magnification. Multispectral images (MSI) 
were captured using Phenochart software and scanned from 420 nm to 720 nm using 
Vectra 3.1 automated quantitative pathology imaging system. Three MSIs per sample was 
analysed using InForm analysis software. Positive cells were segmented and counted per 
20X magnification field. 
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Figure 4.2 ǀ MS usually appear in the vicinity of vessels. a, image of H&E staining of 
human congenital melanocytic nevus with multiple angiotropic MSs (asterisk). MSs invade 
deep into dermis and even hypodermis. b, image of H&E staining of dorsal skin from a 
susceptible NRAS-Cdk4  mouse at postnatal day 10 (P10).  Only susceptible mouse 
strains develop MS by P10 in the hypodermis near the vessels. Blue arrows depict 
vessels. Scale bar = 100 μm.  c, image of H&E staining of dorsal skin from a susceptible 
NRAS-Cdk4  mouse at postnatal day 60 (P60). Note that melanocytes cuff themselves 
around the vessel (V). Scale bar = 300 μm.  
4.4 Results 
 
Histopathology of murine MS 
Cdk4R24C/R24C::Tyr-NRASQ61K/+ (NRAS-Cdk4) mice develop angiotropic MSs similar to 
human congenital nevi (Figure 4.2a) by postnatal day 10 (P10), from melanocytes 
escaping the confines of the hair follicles and by P60 they occupy majority of hypodermis 
(Figure 4.2b and 4.2c). The dorsal skin of NRAS-Cdk4 was immunostaied with a panel of 
melanocyte markers (Sox10 and Mitf), mast cell marker (Tryptase), and macrophage 
marker (F4/80). The majority of MSs are composed of Sox10 and Mitf positive cells. These 
melanocytes are interspersed with macrophages and mast cells which create a specific 
niche in the hypodermis of mouse with high MS counts (Figure 4.3). 
NRAS-Cdk4 mice frequently have melanocytic cells in lymph nodes (Hacker et al, 2007), 
but almost never develop observable visceral metastasis. This may be partially because 
the animals must be euthanized when a melanoma reaches 100 mm in diameter, or 
because micrometastasis are not easily visible.  It is possible that the melanocytic cells in 
lymph nodes could have migrated from MSs in the hypodermis.  
Where possible we examined lymph nodes from mice with melanocytoma with high MS 
counts, and stage 3 malignant melanoma and found that metastasis is present in them as 
early as P60 (Figure 4.4a and 4.4b). Regional and distant lymph nodes are mainly 
populated by balloon like melanocytes in mice with melanocytoma (Figure 4.4 b lower left), 
while in mice with malignant melanoma these lymph nodes have high populations of 
melanophages (Figure 4.4b lower right). These colonies are histopathologically 
reminiscent of human pigmented balloon cell nevus (Figure 4.4c).  
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We also, investigated the development of nevi and MSs in a conditional transgenic mouse 
model of melanoma, Tyr::CreERT2;BrafCA;Ptenlox/lox (TBP). In this case the mutations are 
induced in adult mice. The mice develop nevi very quickly at day 10 post-mutation 
induction (D10), and stage 3 melanoma by D20. By D30 Melanomas that rapidly emanate 
from the pigmented nevi become non-pigmented (white melanoma), suggesting that they 
have switched phenotype to different differentation status, possibly to a Schwann cell-like 
phenotype (Handoko 2013) (Figure 4.4).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 ǀ MSs creates a special niche in the hypodermis. The immunoperoxidase 
staining of dorsal skin of NRAS-Cdk4 mice shows that MSs are comprised of Sox10 and 
Mitf positive cells (melanocyte lineage markers top panels). The non-melanocytic cells that 
infiltrate the MSs are mainly composed of mast cells (Tryptase positive) and macrophages 
(F4/80 positive). Scale bars = 50 μm 
 
Mice need to be euthanized by D35 due to size of tumors. However despite using a large 
cohort we were not able to capture the time points required to study the formation of 
dermal nevi and MSs. Understanding the spatio-temporal migratory patterns of 
melanocytes from epidermis to dermis was a crucial first step in the study in terms of trying 
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MS MS
MS MS
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to validate mechanisms of nevus development using topical drug treatments. This is 
something that would be difficult or impossible to follow in humans since the formation of 
congenital nevi is only possible by studying samples obtained from spontaneous abortions 
or fetal deaths in utero, which would only facilitate a single time point (Cramer 2012) study 
of nevogenesis. 
 
 
 
 
 
 
 
 
 
Figure 4.4 ǀ nevogenesis and melanomagenesis inTyr::CreERT2; BrafCA; Ptenlox/lox (TBP) 
mice. BN: Blue Nevus, MM: Malignant Melanoma, and WMM: White Malignant Melanoma. 
At Day 10 (D10) post induction mice develop BN and by D20 majority of the lesions 
progress to form MM. At D30 the enclosed area in blue is composed of BN, MM, and 
WMM. Scale bars: 0.5 cm. 
 
Genetic background affects MS count 
Male NRAS-Cdk4 were bred with females from many CC strains to generate progeny 
heterozygous for both the Cdk4 and NRAS mutant transgenes. Dorsal skin was collected 
from at least 3 mice of each CC cross, and the number of angiotropic MSs was scored for 
each sample from 1 (least dense/resistant) to 10 (most dense/susceptible). Linkage 
analysis was carried out based on the phenotypic score for hypodermal microsatellite 
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density in the dorsal skin of transgenic X CC strain progeny (Figure 4.6). We mapped a 
QTL to chromosome 10 which contains 20 genes (53-70 Mb) (Figure 4.6a). Analysis of the 
segregation of genomic segments from the 8 founder strains (129S1/SvImJ, A/J, 
C57BL/6J, CAST/EiJ, NOD/LtJ, NZO/HlLtJ, PWK/PhJ, and WSB/EiJ) through the linked 
interval showed that the NZO/HlLtJ (NZO) founder had contributed the causal allele. Allele 
segregation analysis and SNP cataloguing (Figure 4.7b and 4.7c) delimited the (-1-
Log10(P) interval to a region (56-66 Mb) containing 11 genes (Dcbld1, Man1a, Gja1, Hsf2, 
Serinc1, Ascc1, Cdh23, Sgpl1, Hk1, Ccar1 and Tet1). Dcbld1 encodes a plasma 
membrane protein with unknown function which is strongly expressed in melanocytes, 
Man1a encodes Mannosidase alpha protein, Gja1 which encodes Cx43 the most 
ubiquitous connexin in mammals and previously suggested to be involved in melanoma 
progression (Villares 2009, Stoletov 2013, Sargen 2013, Zuker 2013). Hsf2 encodes a 
transcription factor for hsp70 which is considered to be a metastasis suppressor in 
prostate cancer (Björk 2016), Serinc1 encodes an enzyme that incorporates amino acid 
Serine into membrane (Inuzuka 2005), Ascc1 encodes activating signal co-integrator 1 
complex subunit 1 which is known to be involved in development of esophageal 
adenocarcinoma (Orloff 2011), Cdh23 encodes cadherin-related 23 protein which is 
involved in breast cancer metastasis and development of familial and sporadic pituitary 
adenomas (Apostolopoulou  2012, Zhang 2017). Sgpl1 encodes Sphingosine-1-phosphate 
lyase 1 which acts as tumor suppressor in colon cancer (Oskouian 2006), Hk1 encodes 
Hexokinase-1which is an important enzyme in glucose metabolism and its upregulated in 
lymphatic metastasis and adverse prognosis in Chinese gastric cancer (Gao 2015), Ccar1 
encodes a transcription factor which controls β-Catenin expression and controls the 
migration and invasion of gastric cells (Chang 2017). Finally, Tet1 encodes an epigenetic 
factor Ten-Eleven Translocation 1 which converts 5-methylcytosine (5-mC) to 5-
hydroxymethylcytosine (5-hmC). It is usually absent in many cancers, and its expression 
induces the PTEN expression via demethylation of the PTEN promoter and impedes the 
invasion and metastasis of gastric cancer (Pei 2016). 
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Figure 4.5 ǀ Nodal metastasis appear early in mice with melanocytoma. a, 
Representative images of H&E staining of melanocyoma (left) and malignant melanoma 
(right) from susceptible NRAS-Cdk4  mice. b, H&E images of distal lymph nodes from 2 
months old mouse with melanocytoma (left) and 21 months old mouse with malignant 
melanoma (right). High power image of H&E stained lymph nodes (lower right) show high 
number of melanophages (yellow arrows) and melanocytes (blue arrows) in mice with 
malignant melanoma (right).  Scale bars = 300 μm. c, H&E images of  human melanoma 
metastasis (right), bleached murine lymph node metastasis (middle) and human balloon 
cell nevus (left).  
60 days old 480 days old
Melanocytoma MM
Lymph node Lymph node
a
b
H&E - Mouse 
lymph node
H&E - Human 
balloon cell nevus
Bleached
c
H&E – Human
Melanoma metastasis 
136 
 
Gene expression analysis of candidate genes 
NRAS-Cdk4 mice develop MSs during anagen phase of each hair cycle (Damsky 2015, 
Chitsazan 2016). Hence, significant up/down-regulation of the mapped genes on 
chromosome 10 could help us to narrow the number of candidate genes. 20 susceptible 
adult CC strain mice (n=20) euthanized during anagen phase of hair cycle and another 
cohort of 20 susceptible adult CC strain mice (n=20) were euthanized during telogen 
phase of hair cycle. Dorsal skin from all mice collected and gene expression study using 
RNA extracted from these samples revealed that only Dcbld1 and Gja1 expression are 
under control of hair cycle. The expression of Dcbld1 and Gja1 was upregulated 3 and 7 
folds respectively during anagen vs. telogen phase. Hence, we picked Gja1 which is highly 
differentially expressed between anagen and telogen as the main candidate for further 
analysis. Correlation gene expression study revealed that Gja1 expression is positively 
linked to activation of Wnt signaling and pigmentation genes (Figure 4.7a).The strongest 
positively correlated genes are Fzd5 (r = 0.95), Tyr (r = 0.93) and Mlana (r = 0.90). Fzd5 
encodes a receptor for Wnt ligand which is involved in metastasis in many cancers 
(Weeraratna  2002, Thiele 2011, Steinhart  2017). Tyr and Mlana are important melanocyte 
linage markers (Boyle  2002, Du  2003). 
Gja1 expression is also positively correlated with other gap junctional subunit such as Gjb2 
(r = 0.86) and Gjb6 (r = 0.78). Gjb2 and Gjb6 express Cx26 and Cx30, two important 
connexins in the skin that have been previously linked to melanomagenesis and 
metastasis (Saito-Katsuragi 2007, Riker 2008). Diversity in type of connexins could explain 
the intricate interactome of different cells in the skin during the anagen.Gja1 expression is 
also negatively correlated with expression of Bves (r = -0.71) and Hspb7 (r = -0.68). Bves 
encodes an important metastasis suppressor, blood vessel epicardial substance which is 
an integral protein which is involved in the formation of tight junctions. BVES loss is 
required for epithelial-mesenchymal transition (EMT) in human colorectal carcinoma 
(Williams 2011). HSPB is a also tumor suppressor which works in tandem with P53 (Lin 
2014).  
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Figure 4.6 ǀ Genetic background dictates MS count of NRAS::Cdk4 mice. 
Representative images of H&E staining of MS at each score (1-10) across 45 CC strain 
backgrounds. Only MSs in the hypodermis have been counted. Scale bars = 500 μm. 
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In sum, Gja1 expression is positively correlated with expression of genes involved in 
metastasis and negatively correlated with metastasis inhibitor Bves and tumor suppressor 
Hspb7. Further analysis of the Cancer Genome Atlas (TCGA) data set also revealed that 
GJA1 is significantly differentially expressed between human metastatic melanoma (368 
samples) and primary melanoma (103 samples). Other candidate genes in chromosome 
10 region such as CCAR1, CDH23, MAN1A, SERINC1, and TET1 are also overexpressed 
in human metastatic melanoma vs. primary melanoma (Figure 4.8b). 
 
In vivo study of Connexin 43 expression 
To confirm that Gja1 is expressed in the mouse model, I performed multiplexed 
immunofluorescence staining with Tyramide-based amplification (IF-TSA). Dorsal skin 
from NRAS-Cdk4 mice was stained with Sox10 and Cx43 antibodies, to examine protein 
expression in baby and adult mice. Baby mice carrying the putative Gja1 causal allele 
showed high levels of Cx43 expression mainly in deep dermis and hypodermis where MSs 
are formed. Surprisingly, Cx43 is absent in epidermis and superficial dermis where dermal 
nevi are formed (Fig 4.9a). Dermal and hypodermal nevi do not express Cx43 and 
expression is limited to melanocytes residing in hair follicle bulb or bulge (Fig 4.9b and 
4.9c).  
Further, I stained 4 small and 4 medium human congenital nevi, and 4 human normal skin 
to study the expression pattern of CX43 in human melanocytic lesions. The CX43 
expression in small human congenital nevi was similar to our mouse model. Only 
melanocytes residing in the hair bulb or bulge express CX43 (Figure 4.9c and 4.10a).  
This is not the case in medium size human congenital nevi (Figure 4.10b). In these 
samples, CX43 expression is also detected in nevocytes.  Superficial nevocytes do not 
express CX43 but deeper (more mature) nevocytes residing in the deep dermis express 
CX43. Also, deep nevocytes rarely show mislocalized expression of CX43 (Figure 4.7a) 
which is suggestive of functional gap junctions.  
Melanocytes in normal skin do not express CX43 while keratinocytes express high levels 
of CX43 (Fig 4.10c). It is possible that change in CX43 expression in melanocytes be the 
result of nevus maturation (Pawlikowski 2013) since superficial and less mature nevocytes 
are CX43 negative. 
  
139 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
a
b
140 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 ǀ Mapping the modifier gene for development of MS. a, Genome-wide scan 
based on M density score in 45 CC strains. MS density score was treated as a multinomial 
analysis with values ranging from one to ten. The x-axis shows the chromosomal position, 
and the y-axis shows the 2log10(p) values; the p-values were derived from the linkage 
haplotype data. b, SNP cataloguing of the interval on murine chromosome 10 reveals only 
11 genes that have NZO specific regulatory changes. c, List of candidate genes with NZO 
specific regulatory changes. Gja1, Hsf2, Cdh23, Hk1, Ccar1 and Tet1 have been 
previously linked to metastasis in literature. Gja1 has 8 regulatory SNPs in its promoter 
regions, Hsf2 and Ascc1 have 2 regulatory SNPs and the remaining genes each have only 
one regulatory SNP which could potentially change their expression. Analysis of gene 
expression of 20 CC strains revealed that only Dcbld1 and Gja1 expression is under 
influence of hair cycle. 
 
  
c
Genes
NZO
Regulatory 
changes
Linked to 
metastasis
Hair cycle 
dependent
Dcbld1 1 NO YES
Man1a 1 NO NO
Gja1 8 YES YES
Hsf2 2 YES NO
Serinc1 1 NO NO
Ascc1 2 NO NO
Cdh23 1 YES NO
sgpl1 1 NO NO
Hk1 1 YES NO
Ccar1 1 YES NO
Tet1 1 YES NO
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4.5 Discussion 
 
In this chapter we have conducted an unbiased genetic screen to map the modifier 
gene(s) for development of MSs. These melanocytic lesions that appear in the hypodermis 
layer of skin were previously described as dermal nevi (Viros 2014, Damsky 2015). We did 
not use this terminology to describe these lesions since they appear in the hypodermis. 
Also, we have categorized dermal lesions that appear in the deep dermis and superficial 
hypodermis as deep penetrating nevus (chapter 3). In this study we have only counted the 
number of MSs that are present in deep hypodermis and show angiotropic features. Based 
on our QTL study, allele segregation, SNP cataloguing, gene expression and gene 
correlation studies during anagen and telogen phases of hair cycle we picked Gja1 
(encodes Cx43) as our candidate for further study. High expression of CX43 correlates to 
poor prognosis in many cancers (Sargen 2013, Stoletov 2013, Brockmeyer 2014, Poyet 
2015, Tanaka 2016).  
The high MS count CC strains are pigmented and majority of these cells have balloon cell 
structure both in the hypodermis and lymph nodes while albino CC strains develop lower 
number of MSs in the hypodermis and do not become balloon like, hence they can only be 
monitored using Sox10 or other melanocyte markers using IHC.  
Each MS in high (pigmented) and low (albino) MS count mouse strains is comprised of a 
population of melanocytes, mast cells, and macrophages. Others have also shown that 
chronic UV exposure exacerbates the formation and number of MSs and angiotropic MSs 
(Viros 2014, Bald 2014). This positive effect in the formation of MSs has been attributed to 
the release of high mobility group box 1 (HMGB1) from epidermal keratinocytes exposed 
to damaging effects of UV (Bald 2014).  
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Figure 4.8 ǀ Gja1 expression is highly correlated with known metastatic genes. List of 
genes which their expression is positively (a) and negatively (b) correlated with Gja1 
expression (r>0.65) in dorsal skin of 20 susceptible CC strains. Genes are sorted based 
on Gja1 expression using gene expression correlation matrix (top to bottom). Genes 
involved in metastasis are highlighted in green, melanocyte genes highlighted in yellow, 
Shh pathway genes highlighted in pink, and Wnt signaling genes highlighted in orange. 
View appendix 1 for complete list of genes highly correlated with Gja1 expression. c, 
Analysis of TCGA data set revealed that 6 out of 10 genes which mapped to murine 
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chromosome 10 are also differentially expressed in highly motile human metastatic 
melanomas (368 samples) versus primary melanomas (103 samples). GJA1 is 
significantly upregulated in primary melanoma VS metastatic melanoma while CCAR1, 
CDH23, MAN1A1, SERNC1 and TET1 are significantly upregulated in the metastatic 
melanoma VS primary melanoma. See appendix 2 for list of genes highly correlated with 
candidate genes from TCGA data set. 
The expression of Cx43 in the melanocytes that are based in the hair follicle (Figure 4.8 
and 4.9) is probably necessary for their cell-cell communications with other keratinocytes 
and hair follicle stem cells (HFSCs) that reside in the hair bulb. Intriguingly the expression 
of Gja1 in susceptible strains  is  positively  correlated  with  many  genes  that  have  been  
previously  linked  to metastasis  and  negatively  correlated  with  genes  that  block tumor  
progression  and metastasis (Weeraratna  2002, Thiele 2011, Sargen 2013, Stoletov 2013, 
Brockmeyer 2014, Poyet 2015, Tanaka 2016, Steinhart  2017). 
Cell-cell communications occur largely at gap junctions, where plasma membrane of 
neighbouring cells form 2-3 nm gaps that are bridged by channel-forming proteins called 
connexins. There are 21 human connexion genes. Connexins can also form hemi-
channels which enable the cell to communicate with extracellular matrix (ECM) and 
microenvironment. They enable cell-cell, cell-ECM, and cell-microenvironment 
communications by allowing exchange of myriad of signals e.g. secondary messengers, 
electrical signals, microRNAs and small metabolites (Goodenough 2009, Naus 2010). 
Most cells express number of different connexins. Connexins can form hexameric 
assemblies (connexons) of homomeric or hetermeric connexins (Goodenough 1996, Falk 
1997, Segretain 2004). Connexons can form gap junctions with identical (homotypic) or 
different (heterotypic) connexins (Dedek 2006).  
Despite the limitation of assembly combinations, there are a large number of possible gap 
junction combinations since they can be composed of 21 family members (White 1994). 
CX43 is mainly expressed in hair follicles and nevocytes residing in deep dermis (mature 
nevocytes). Melanocytes residing in the hair follicle also express Cx43 both in NRAS-Cdk4 
mice and in human hair follicles near the nevus. MSs in baby mice also show weak Cx43 
expression.  
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Figure 4.9 ǀ Connexin 43 is expressed in the murine deep dermis and hypodermis. a, 
Immunofluoresence with tyramide signal amplification (IF-TSA) staining of dorsal skin from 
susceptible baby mice at P10 with Cx43 and Sox10. Cx43 expression is absent in the 
epidermis and superficial dermis (dotted lines depict this area). The majority of the deep 
dermis and hypodermis express high levels of Cx43. Higher power image of this staining 
with bright field presentation (b) shows the formation of an early MS (enclosed with dotted 
lines). Melanocytes with Cx43 expression are depicted with red arrow head and Cx43 
negative melanocytes are depicted with black arrowhead. c, IF-TSA staining of human and 
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murine hair follicles in anagen (growth phase of hair cycle) shows similar pattern of 
expression of connexin 43 with most of expression present in the hair bulb. Note that 
dermal papilla (DP) in human hair follicle is weakly CX43 positive while mouse DP is Cx43 
negative. Melanocytes residing in the hair bulb are connexin 43 positive both in mouse and 
human (dotted arrows) while escaped melanocytes in the dermis do not express connexin 
43 (white arrow). Scale bars = 100 μm. 
 
 
Although many studies support the notion that connexins are tumour suppressors, recent 
evidence suggests that, in some tumour types, they may facilitate specific stages of 
tumour progression.  Sargen et al. studied the expression of CX43 in 34 nevi and 
melanoma samples. CX43 immunoreactivity was much higher in the malignant melanoma 
samples (Sargen 2013). Both melanoma and breast cancer cells can metastasize to brain. 
The homing mechanism appeared to be controlled by upregulation of Cx43 via Twist 
(Stoletov 2013). Knocking down Cx43 or blocking intercellular communication using 
carbenoxolone inhibits tumor cell extravasation, and brain colonization. Primary melanoma 
and breast cancer tumors in patients also verified the correlation between CX43 
upregulation and increased recurrence and metastasis (Stoletov 2013).   
The Cx43 expression pattern in NRAS-Cdk4 mice with high microsatellite counts is 
concordant with the location of microsatellites in the deep dermis and hypodermis with 
most of Cx43 being expressed in hair follicles. A similar pattern is evident in human dermal 
nevi and considering the positivity of proximal and distal lymph nodes in strains with high 
MS counts, we set out to study the gene expression of all candidate genes (on the murine 
chr10 mapped area) in highly migratory melanoma cells. CCAR1, CDH23, MAN1A, 
SERINC1 and TET1 are upregulated in human metastatic melanoma while GJA1 has 
higher expression in primary melanoma.  
Melanoblasts and melanocytes are highly migratory during the early development and it is 
possible that two types of melanocytic lesions that appear in superficial dermis and deep 
dermis (MSs) have different molecular machinery which would confer different migratory 
potential to them. We have used laser capture microdissection (LCM) to capture MSs and 
superficial dermal nevi and isolated high quality RNA (RIN>7) from them which will be 
discussed in chapter 5.  
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Cells with high CX43 expression are known to secrete factors that are positive regulators 
of metastasis e.g. IL-6, IL-10, MCP-1 and TGFB (McLachlan 2006 Linnskog 2014 Dai 
2009 Yoshimura 2013 Terai 2012). Understanding how these early MSs form is a first step 
towards understanding how their development could be clinically monitored in the future. 
This study will help to better understand the behaviour of melanocytes that become mobile 
and form MSs in the hypodermis. 
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Figure 4.10 ǀ CX43 expression in human melanocytic lesions. a and b IF-TSA staining 
of human small (a) and medium congenital nevi (b) with CX43 primary antibody. Small 
congenital nevocytes do not express CX43 while the adjacent keratinocytes are positive 
for CX43. Medium congenital nevi show more complex pattern of CX43 expression in both 
epidermis adjacent to the lesion and in less mature nevocytes of superficial dermis and 
mature nevocytes of deep dermis. CX43 expression in keratinocytes has an intermittent 
pattern compared to normal skin and small congenital nevi. Mature nevocytes (lower right) 
of medium congenital nevi show high expression of CX43 while less mature nevocytes 
(lower left) do not express CX43. Scale bars = 800 μm. c, IF-TSA staining of human 
normal skin (n=4) with CX43 and SOX10 primary antibodies. Keratinocytes in epidermis 
and hair follicle show strong positivity for CX43 while melanocytes (red arrows) do not 
express CX43.Scale bars = 300 μm.  
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Chapter 5 
5.1 Introduction 
This chapter focuses on detecting gene expression changes during progression from 
nevus to dermal melanoma (melanocytoma) and malignant melanoma (MM) in the 
Cdk4R24C/R24C::Tyr-NRASQ61K (NRAS-Cdk4) mouse model (Ferguson 2010, Wurm 2012). 
They develop MM characterized by downward invasion into the dermis and hypodermis, 
cellular atypia, and other histological signs of malignancy. These mice carry an NRASQ61K 
mutation common in malignant melanoma, and a germline Cdk4R24C mutation, mimicking 
families who carry such mutations, or alterations in the gene encoding its binding partner, 
p16 (Zuo 1996). In genome-wide association study (GWAS) of melanoma susceptibility 
one of the strongest associated regions is at MTAP/CDKN2A (Law 2012). The best 
associated SNP maps near CDKN2A, in the 5’ UTR of the adjacent gene MTAP (Falchi 
2009).  
It is speculated that MTAP/CDKN2A-associated SNPs mark regulatory elements that 
influence the expression of CDKN2A. Further, in terms of gene expression signature our 
murine MMs are not dissimilar to many human lesions. Previous comparison of gene 
expression in NRAS-Cdk4 MMs with human MM revealed a significant overlapping gene 
signature with a group of well-differentiated human MMs that express MITF and 
melanocyte antigens (Sensi 2011). In earlier chapters we studied the non-cell autonomous 
effect of microenvironment (mainly keratinocytes) on development of melanocytoma 
(chapter 2 and 3), and melanocytic microsatellites that reside in the hypodermis of skin 
(chapter 4).  
In this chapter we report our study on cell-autonomous changes that drive the 
transformation and progression of melanocytic lesions from stage 1 (S1/early 
melanocytoma) to stage 3 (S3) MM (Ferguson 2010; Wurm 2012) in the NRAS-Cdk4 
mouse model. Considering the possibly skewing effect of RNA from keratinocyte 
populations in S1, we decided to first assess gene expression of normal skin vs. stage 3 to 
obtain the keratinocyte and MM-specific gene expression signatures. On using genome-
wide gene expression arrays using whole tissue we found significant differences in 
surprisingly few genes between the respective murine MM stages. One of these genes 
was Dusp6, a negative regulator of MAPK pathway (Figure 5.1). Role of Dusp6 is 
controversial. While many studies support a tumor suppressor role for Dusp6 (Furukawa 
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2003, Xu 2005, Furukawa 2005, Okudela 2009, wong 2011), others suggest that it can act 
as an oncogene (Nunes-Xavier 2010, Messina 2011, Degl’Innocenti 2013, Shojaee 2015).  
In our gene expression study the expression of Dusp6 increases with transformation and 
progression of MM. It was interesting for us to pursuit this further on protein level using 
mouse and human nevi and melanoma. To help put Dusp6 expression in some kind of 
biological context, I have correlated its expression with that of other proteins marking 
various aspects of melanoma cell behaviour and/or differentiation status. I have also 
studied the protein expression of ETS1 a transcription factor for DUSP6 (Ekerot 2008, 
Zhang 2010) and BRN2 a marker for melanoma invasiveness (Boyle 2011, Fane 2017, 
Simmons 2017) using immunohistochemistry (IHC) and IF with Tyramide signal 
amplification (IF-TSA). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 ǀ Regulation of MAPK pathway via ERK dephosphorylation. Activated p-
ERK can be inactivated by dephosphorylation via cytoplasmic DUSP6 or nuclear DUSP5 
(from Caunt 2012). 
 
 
5.2 Hypothesis 
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That during the transformation of benign moles to melanocytoma, and malignant 
melanoma there is a gradual accumulation of molecular changes that individually are 
insufficient, but when combined are responsible for transformation to melanoma and 
progression to more aggressive behaviour.  
 
 
5.3 Methods 
Mouse melanoma model  
The Cdk4R24C/R24C::Tyr-NRASQ61K mouse model has been previously described (Ferguson 
2010; Wurm 2012). Tyr-NRAS mice carry a melanocyte-specific activating mutation 
(Q61K) in human NRAS cDNA. They occasionally develop MM at an advanced age, but 
they do so earlier when crossed onto the Cdk4R24C/R24C background. The average age of 
onset is 150 days. In our hands, Tyr-NRASQ61K mice on an FVB background rarely 
develop nevi or MM until crossed on to the mutant Cdk4R24C background. Most studies on 
murine MM are conducted using pigmented backgrounds (e.g. BL6). Use of such strains 
with the various ‘onco-transgenic’ melanoma models (e.g. carrying oncogenic Nras, Braf, 
Hgf, Ret, Grm1) results in extreme hyperpigmentation, particularly within the lesions, that 
obscures the histopathology. Bleaching to remove excess melanin has rarely been 
reported, although it is simple to do. Unfortunately, bleaching destroys many antigens, 
hence normally prevents immunohistochemistry staining of the lesions. Thus the 
Cdk4R24C/R24C::Tyr-NRASQ61K were bred onto an albino FVB background.  
 
Histopathological classification of melanocytic lesions 
Benign nevus classification has provided in length in chapter 3. Stage 1 (S1) is reminiscent 
of thin melanocytoma in humans. Although the vast majority of these lesions never 
progress to melanoma, some do, and thus they can be thought of as a transitional stage 
between benign nevus early melanoma. They are made up of dense proliferations of 
nevoid cells residing in the superficial dermis and extend to mid dermis. These cells are 
somehow polymorphic and have low mitotic rate and few apoptotic cells.  
Stage 2 (S2) or late melanocytoma is reminiscent of thick human melnocytoma. S2 
melanocytoma is comprised of less densely-packed sheets of cells with atypia, still nevoid-
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like in appearance, polymorphic, and with higher mitotic rate compared to S1. They tend to 
populate the whole dermis.  
Stage 3 (S3) is considered MM. They occupy the majority of hypodermis and reach the 
muscle layer or panniculus carnosus (fascia in humans). S3 MM cells are no longer nevoid 
in appearance and show higher mitotic rates than S2. Some clusters of nevocytes can be 
only detected at the edges of dermal-hypodermal boundary.  
NRAS-Cdk4 mice also develop hypodermal malignant melanoma metastasis which are 
reminiscent of human subcutaneous metastasis and are not in continuum with previous 
stages.  These lesions are comprised of a well-circumscribed nodule which is only located 
in the hypodermis which is covered by normal nevocytes in deep and superficial dermis. 
These cells are highly polymorphic, show high mitotic rates and are engulfed by high 
number of blood vessels (Wurm 2012). All experiments were carried out with institute 
animal ethics approval. A98004M. Mice were euthanized before tumors exceeded 10 mm 
in diameter. 
 
Non contact laser capture microdissection  
With PALM MicroBeam a verity of biological material can be microdissected and lifted 
directly from glass slides using the “AutoLPC” function of PALM RoboSoftware. 
 
Preparation of slides  
Samples on nuclease free Membrane Slide: Membrane slides NF are glass slides covered 
with a membrane on one side which is certiﬁed to be free of DNase, RNase and human 
DNA. These slides are covered with polyethylene naphthalate (PEN)-membrane. This 
PEN-membrane is highly absorptive in the UV-A range, which facilitates laser cutting. This 
membrane is easily cut together with the sample and acts as a stabilizing backbone during 
lifting. Therefore even large areas can be lifted by a single laser pulse without affecting the 
morphological integrity (Zhang 2010). 
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Sample collection 
An adhesive Cap is used as a collection device for all RNA experiments. Adhesive Caps 
are produced with cleanroom technology and can therefore be considered as RNase-free. 
The intention of these Adhesive Caps is to allow LCM without applying any capturing liquid 
into the caps prior to LCM. This minimizes possible RNase activities. Beside the quick 
relocation of the lifted samples in the cap due to instant immobilization means that there is 
no risk of evaporation and crystal formation during extended specimen harvesting.  
 
Formalin Fixed Parafﬁn Embedded (FFPE) and PAXgene Fixed Paraffin Embedded 
(PFPE) Sections 
Sections are mounted onto Membrane Slides the same way as routinely done using glass 
slides. After mounting slides are dried overnight in a drying oven at 56°C. Parafﬁn will 
reduce the efﬁciency of the laser, sometimes strongly inhibiting cutting and lifting. 
Deparaffination is carried out using standard protocols for normal glass slides. Most 
standard staining procedures can be used for FFPE and PFPE sections. We usually 
perform Hematoxylin or Cresyl Violet staining. Skipping the Eosin staining of the HE-
procedure helps additionally against RNA degradation. 
 
Flash frozen sections 
Sections are mounted onto Membrane Slides similarly as when using glass slides. As ﬁrst 
step the dehydration in ice-cold 70% ethanol for 2-3 minutes is performed in order to 
reduce RNase activity. It is important to remove tissue freezing medium before laser 
cutting because such media will interfere with laser efﬁciency. Removing this medium is 
done by dipping the slide 5-6 times into ice-cold RNase-free water. Using frozen sections 
endogenous RNases may still be active after the short ﬁxation step. Therefore we keep all 
incubation steps as short as possible and use ice-cold RNase free water and solutions for 
all steps. We usually perform Hematoxylin or Cresyl Violet staining. Skipping the Eosin 
staining of the HE-procedure helps additionally against RNA degradation. 
 
Assessment of RNA quantity and quality from FFPE and PFPE sections 
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We apply the QIAGEN RNeasy® FFPE Kit and PAXgene® Tissue RNA Kit with some 
LCM-speciﬁc modiﬁcations. These procedures are very effective and allow a high ﬁnal 
concentration of RNA due to a small elution volume (12 μl). Genomic DNA contamination 
is minimized by a DNase I digest on the puriﬁcation column. RNA from FFPE and PFPE 
material will frequently not show clear proﬁles and only rough estimations of the size 
distribution and quality of the RNA are possible. 
Assessment of RNA quantity and quality from frozen sections 
The QIAGEN RNeasy® Micro Kit combined with Adhesive Cap in our hands results in very 
good yield and quality of RNA. Quality control by direct analysis using Qsep100 analyzer is 
possible with quite large microdissected samples (often some 4 mm2 collected area from 
tissue sections of 8 μm thickness) and is limited to concentrations ≥5 ng/μl. Total RNA 
extracted from nevi and melanoma samples, with ribosomal RNA peaks ratio of ≥1.7 
(28S:18S) are selected for downstream studies. 
 
cRNA Synthesis 
We usually use 500 ng of total RNA for cRNA syntehsis using Illumina® TotalPrepTM RNA 
Amplification Kit. The yield and quality check is performed using Nanodrop Lite and 
Qsep100 analyzer respectively.  
 
Analysis of cRNA size 
The size distribution of cRNA is evaluated using Qsep 100 analyzer. The Qsep 100 can 
provide a fast and accurate size. The expected cRNA profile is a distribution of sizes from 
250 to 5500 nucleotide (nt) with most of the cRNA at 1000 to 1500 nt. 
 
Expression array analysis  
RNA was subjected to one round of amplification/labeling with a MessageAmp kit 
(Ambion), then 1.5 μg labeled cRNA will be hybridized to MouseWG-6 v2.0 Expression 
BeadChips. Labelling with 100 ng of total RNA gives high reproducibility (r2>0.99 across 
independent experiments). Data was extracted using GenomeStudio (Illumina) and 
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imported into GeneSpring (Agilent) for normalisation, visualisation, and unsupervised 
hierarchical clustering. Analysis of variance (p-value ≤0.05 using Benjamini and Hochberg 
correction for multiple testing) was applied to identify genes whose expression differs 
between groups. 
 
Immunohistochemistry and multiplexed fluorescent immunohistochemistry with 
Tyramide signal amplification 
Sections from paraffin-embedded lesions will be dewaxed, and treated with Dako low pH 
antigen retrieval solution at 1000C for 15 minutes. Endogenous peroxidase activity will be 
quenched in 3% H2O2, and sections blocked with 5% bovine serum albumin. Primary 
SOX10 (sc-17342), BRN2 (ab151796), ETS1 (sc-55581) and DUSP6 (sc-134837) 
antibodies will be applied, followed by appropriate secondary antibodies. After washing, 
the signal was amplified using FITC, CY3, CY3.5 and CY5. Finally slides were washed, 
counterstained with DAPI and coverslipped using DAKO mounting medium. Entire slides 
scanned using Vectra spectral imaging system (PerkinElmer) to accurately identify all 
regions at 4X magnification. Multispectral image (MSI) captured using phenochart software 
and imaged from 420 nm to 720 nm using Vectra 3.1 Automated quantitative pathology 
imaging system. Three MSI per sample was analysed using InForm analysis software for a 
fluorescent 4-plex IHC panel of SOX10, BRN2, ETS1 and DUSP6. Positive cells were 
segmented and counted per 20 magnification field.   
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Figure 5.2 ǀ Whole-genome gene expression study of stage 3 MM vs. normal skin. a, 
H&E staining of murine normal tail skin and stage 3 (S3) MM that were used for gene 
expression study of normal skin versus MM using Cdk4::NRAS mouse model. b and c, 
gene expression of normal skin versus S3 MM using Illumina® Mouse WG-6 v2.0 
Expression BeadChips. Selective list of genes expressed differentially in S3 MM versus 
normal skin. Metrn, Vim, and Sox10 are highly expressed in S3 MM while Krt84, Expi, and 
Krt15 are not expressed in S3 MM. 
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5.4 Results 
Whole-genome gene expression study of murine melanoma progression 
As mentioned previously the use of the NRAS-Cdk4 mouse model allows access to 
melanocytic lesions over the spectrum of stages of progression from benign nevus to MM 
(Ferguson 2010). First, since the samples we used were not microdissected (only 
trimmed), meaning that there could be keratinocyte contamination in the early lesions, we 
set out to clarify exactly which genes are likely to be differentially expressed in the mouse 
skin keratinocytes and melanocytic lesions. Figure 5.2a shows the H&E staining of normal 
tail skin (n=3, left panel) versus the S3 MM (n=3, right panel) that was used in this study. 
About 3,000 genes were significantly differentially expressed between skin and melanoma 
(p<0.05). A selection of genes expressed higher in normal skin vs. MM are shown in figure 
5.2b (Krt84, Expi, Krt15, Sox21, Fgfr2, Krt33a, Col17a1, Irf6, and Sox7) (appendix 3). All 
of the keratinocyte genes can be disregarded from future analyses in this chapter. Figure 
5.1c shows a selection of genes expressed higher in the MM vs. normal skin (Metrn, Vim, 
Sox10, Mc1r, Dusp4, Dkk3, Dusp6, Cd44, Dct, S100a1, Tgfbr2, Ednrb, Ets1, Gna11, 
Mapk9, Tgfb1, and Tgfbr1).  
Functional enrichments of gene expression of genes highly expressed in S3 MM vs. 
normal skin reveals that these genes are involved in extracellular exosome and vesicle 
formation, amino acid and sugar metabolism, and development of pancreatic cancer and 
regulation of pigmentation (while genes that have been downregulated in S3 melanoma 
vs. normal skin are involved in single organism process, fatty acid degradation, and 
peroxisome formation (https://string-db.org). 
This allows us to infer which candidates genes would be likely to be expressed in the 
melanocyte/melanoma cells with highest population in malignant melanoma versus normal 
skin tissue mostly comprised of keratinocytes.   
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Figure 5.3 ǀ Whole-genome gene expression study of melanoma progression. a, 
Immunoperoxidase staining of stage 1 (S1), stage 2 (S2), and stage 3 (S3) MM with the 
melanocyte marker Trp1. Arrows point to the advancement of tumor edge in dermis, 
hypodermis and muscle. Scale bars = 300 μm. b and c, Selective list of genes that are 
highly expressed in S3 (b) and S1 melanoma (c).Gene expression study of S1 versus S2 
and S3 determined using Illumina® MouseWG-6 v2.0 expression Bead Chips. 
Keratinocyte signature (KCS) was deducted from all stages prior to analysis.  
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Next we used genes expression comparison between S1 early melanocytoma, S2 late 
melanocytoma, and S3 MM and deducted the keratinocyte specific (KCS) gene expression 
signature in order to negate the masking effect of keratinocyte RNA. In Figure 5.3a, Trp1, 
a melanocyte marker has been used to highlight the melanocytic cells, to better visualise 
the progression of melanoma. Unsupervised hierarchical clustering revealed 300 genes 
significantly differentially expressed (p<0.05) in S3 MM (n=4) versus S1 early 
melanocytoma (n=3), and S2 late melanocytoma (n=3). Figure 5.2b shows a selective list 
of genes highly expressed in S3 MM (Car2, Qpct, Sema6d, Ednrb, Dusp6, H2-Ab1, 
Vcam1, Usp18, Dusp23, Hist1h2be, Hist1h2bf and Hist1h2bh). A selective list of genes 
highly expressed in S1 vs. S3 melanoma has been presented in Figure 5.2c (Krt16, 
Chi3l1, Stfa1, Lamb3, S100a9, Junb, Rab25, Anxa11, Lypd3, Mmp9, Gjb6 (which are all 
keratinocyte genes except Anxa11 and Mmp9) (appendix 4). Genes that are highly 
expressed in S3 melanoma after deduction of KCS are involved in nucleosome structure, 
developmental pigmentation, and immune responses (Figure 5.3c) while genes that are 
highly expressed in S1 after deduction of KCS are involved in skin and epidermal cell 
differentiation, and membrane bound vesicle formation (https://string-db.org). Despite our 
effort to nullify the masking effect of keratinocyte, the majority of genes differentially 
expressed between S1 and S2 were keratinocyte genes. One way to avoid much of the 
influence of stromal contamination in tumours is to use laser capture microdissection. 
Hence, we moved on to collect melanocytes, nevocytes, early and late melanocytoma, and 
MM cells from normal skin, nevi, early and late melanocytomas, and MM samples using 
laser capture microdissection.   
 
Laser capture microdissection  
Gene expression studies performed using nevus and melanocytoma were highly masked 
with KCS. In order to get a better understanding of cell autonomous genes whose 
expression changes during MM progression we devised a new gene expression study 
using laser capture microdissected samples (Figure 5.4). Laser capture microdissection 
was performed using formalin fixed paraffin embedded (FFPE), Paxgene-fixed paraffin-
embedded (PFPE) and flash frozen samples. RNA yield and RNA purity was higher in 
flash frozen samples. RNA extracted from laser-captured materials from FFPE and PFPE 
did not show 18s and 28s peaks. Only RNAs extracted from flash frozen samples revealed 
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high RNA integrity number (RIN>7, Figure 5.5). So very pure high quality RNA was 
isolated from lesions at different stages of progression, but we were unable to continue 
this part of project since Illumina ceased the manufacturing of murine chips. All high quality 
RNAs have been stored in -80 freezer.  
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Figure 5.5 ǀ Qsep 100 analysis of total RNA extracted from flash frozen blocks (a), RNA 
isolated post-LCM (b), and RNA ladder (c) versus negative control (d). 
 
In vivo validation of Dusp6 expression changes during melanocytic lesion 
progression 
Dusp6 was the only gene consistently up-regulated during transformation and progression 
of melanoma (Figure 5.2 and 5.3), therefore we selected Dusp6 (an inhibitor of MAPK 
pathway) as the best candidate for further study. The expression level of Dusp6 increases 
with progression which is intriguing considering its known effect as a negative regulator of 
MAPK pathway. It was interesting for us to study this finding further and validate the result 
on protein level. In order to validate the gene expression result on protein level, we stained 
murine nevi and melanoma with Dusp6 antibody and quantitated its expression using 
Aperio software. Dusp6 is highly expressed in melanoma compared to nevus confirming its 
overexpression in malignant stage (Figure 5.6a and b). Further, we found that Dusp6 
expression is up-regulated with progression and formation of cutaneous metastasis. The 
highest expression was observed in cutaneous metastasis (Figure 5.6c and d). This result 
confirms our gene expression array results (figure 5.2 and 5.3) suggesting that Dusp6 
expression is correlated with melanoma progression and metastasis. 
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DUSP6, ETS1, and BRN2, expression in human nevi and thin melanoma 
To confirm the role DUSP6 in melanoma progression in human, we used multiplexed 
immunofluorescence staining with Tyramide-based amplification (IF-TSA) and quantitated 
the protein expression using InForm software 2.2. To help put changes in DUSP6 staining 
in the context of the behaviour of the melanocytic cells, we used 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 ǀ Dusp6 is up-regulated with melanoma progression. a, Immunoperoxidase 
staining of Dusp6 expression of S3 melanoma and its adjacent nevus of NRAS-Cdk4 
transgenic mouse on FVB background. b, Aperio analysis of intensity of strong positive 
cells in murine congenital nevi (n=4) versus S3 melanoma (n=4). c and d, 
Immunoperoxidase staining and quantitative protein expression analysis of Dusp6 in S1 
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(n=4), S2 (n=3) and S3 (n=3) using Aperio software. This result confirms our gene 
expression  array  results (Figure 5.2 and 5.3)  suggesting  that  Dusp6  expression  is  
correlated  with  melanoma progression and metastasis. Analysis was performed on 20X 
magnification using Aperio IHC nuclear staining with Sox10 (500 cells counted per field) in 
S1, S2, S3, fast and slow samples. Dusp6 expression is upregulated with progression of 
melanoma (p=value calculated using the two-tailed T test (* = p<0.01, ** = p<0.001 and 
****= p<0.0001). Scale bars = 300 μm. 
 
ETS1 a transcription factor for DUSP6 and SOX10, and BRN2 a marker of invasiveness. 
Next, we analysed the expression of ETS1 in our panel of human melanocytic lesions and 
normal skin. Ets1 is an activator of Sox10 enhancer in mouse and chick and it loss or 
misssense mutations result in development of white belly patches in pigmented mice 
(Saldana-Caboverde 2015). It is known that Sox10 is crucial for maintance of congenital 
nevi and melanoma (Shakhova 2012) so it was intriguing to compare the protein 
expression of its upstream activator in human normal skin (n=4) to congenital nevi (n=5), 
benign nevi (n=5) and superficial spreading melanoma (n=8). We also stained t our panel 
with BRN2 which has been linked to an invasive phenotype in population of melanoma 
cells (Boyle 2013, Fane 2017, Simmons 2017). DUSP6 expression in human congenital 
nevi (n=5) is very heterogenous. There are populations of nevocytes that moderately 
express DUSP6 while other nevocytes are negative for DUSP6 expression. Benign nevi 
(n=5) express high levels of DUSP6 in almost all neovcytes. Both congenital nevi and 
benign nevi highly express SOX10 and ETS1 but only congenital nevi express BRN2 
(Figure 5.7 and 5.9). Superficial spreading melanomas (SSMs) highly express DUSP6 
which is homogenous through the lesion both in melanoma cells and in keratinocytes. 
Infiltrates express lower level of DUSP6 while expressing high levels of ETS1. Similar to 
benign nevi only few melanoma cells are BRN2 positive (Figure 5.8). Normal human skin 
epidermis is barely positive for DUSP6 and normal melanocytes with SOX10 positivity do 
not express ETS1 or BRN2 (Figure 5.7c). Much to our surprise, the human congenital nevi 
(n=5) have the highest expression of BRN2 vs. benign nevi (n=5) and SSMs (n=8) (Figure 
5.9).  Majority of BRN2 positive nevocytes also do not express DUSP6 which based on our 
murine and human study is a marker for transformation and progression. These BRN2 
positive nevocytes are also ETS1 positive and entirely SOX10 positive (Figure 5.7a lower 
right panel). While all nevi (congenital and benign) express ETS1, SSMs do not express 
this transcription factor but in the infiltrates (Figure 5.8). 
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Figure 5.7 ǀ Immunofluoresence with tyramide signal amplification (IF-TSA) of human 
congenital nevi (a, n=5) and benign nevus (b, n=5) with a panel of DUSP6, SOX10, ETS1 
and BRN2 antibodies. (a) Lower right panel shows the expression of a band of nevocytes 
near a hair follicle. Majority of nevocytes express ETS1 and BRN2 while only few express 
DUSP6. Note that hair follicles and adjacent epidermis do not express DUSP6, ETS1, and 
BRN2. (b) Lower right panel shows the expression of nevocytes near a hair follicle. All 
nevocytes express DUSP6 and ETS1 while only few are BRN2 positive. Scale bars = 500 
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μm. c, IF-TSA of human normal skin with a panel of DUSP6, SOX10, ETS1 and BRN2 
antibodies. SOX10 positive melanocytes do not express DUSP6, ETS1 or BRN2. Scale 
bars = 100 μm. 
 
Further the analysis of gene expression of DUSP6 and ETS1 in TCGA dataset (368 
metastasis vs. 103 primary melanoma) revealed significant 8 and 7.8-fold increase in 
metastatic melanoma versus primary melanoma. However, POU3F2 (encodes BRN2) is 
not significantly differentially expressed between human metastatic melanoma and primary 
melanoma (appendix 5). We were not able to validate this result on protein level due to 
lack of thick and metastatic melanomas. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 ǀ Immunofluoresence with tyramide signal amplification (IF-TSA) of thin 
melanoma with a panel of DUSP6, SOX10, ETS1 and BRN2 antibodies.Melanoma cells 
and keratinocytes express high levels of DUSP6. Only few melanoma cells express BRN2 
which are also ETS1 positive. Scale bars = 200 μm. 
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Figure 5.9 ǀ Quantitation of DUSP6, BRN2, and ETS1 in human melanocytic lesions. 
Relative protein expression of DUSP6, BRN2 and ETS1 in congenital nevi (CMN, n=5), 
benign nevus (BN, n=5) and superficial spreading melanoma (SSM, n=8) per 20X field. 
DUSP6 expression is higher in SSMs than BN (p<0.01) and CMN (p<0.0001). BN also 
show higher DUSP6 expression than CMN (p<0.0001). On the other hand CMN have 
higher BRN2 expression than BN and SSMs (p<0.00001). BRN2 is not significantly 
differentially expressed beteen BN and SSMs (p=0.2). ETS1 is also not differentially 
expressed between CMN and BN (p=0.1) while SSM has less ETS1 expression compare 
to CMN (p<0.0001) and BN (p<0.0001). 
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5.6 Discussion 
Different cellular activities e.g. proliferation, differentiation, survival and cellular death is 
controlled by a family of Ser-Thr protein kinases known as Mitogen-activated protein 
kinases (MAPKs) (Kim 2010). Extracellular signal-regulated kinase (ERK) which is 
activated via binding of extracellular ligand to the receptor tyrosine kinase (RTK) has 
several isoforms i.e. ERK1-8 (Dhillon 2007). The phosphorylated ERK then activates a 
variety of signalling cascades and transcription factors via phosphorylation. Controlling 
MAPK pathway involves the closely regulated interaction of stimulating and inhibiting 
kinases and phosphatases such as DUSP6, a dual specificity phosphatase. Melanocytes 
harbouring NRASQ61K are in constant hyperactivated state with respect to the MAPK 
pathway, leading to the propensity to form benign and eventually malignant melanocytic 
lesions. DUSPs (dual specificity phosphatases) comprise of a superfamily of protein 
phosphatases (Denua 1995, Denub 1998) of 61 members. One of the best-known 
subgroups of DUSPs that can target mitogen-activated protein kinases (MAPKs) is 
classified as MAPK phosphatases (MKPs). This subgroup has 11 members which can 
simultaneously dephosphorylate Ser-P/Thr-P and Tyr-P in the activation motifs of MAPK 
(The-X-Tyr) and subsequently deactivate the MAPK pathway (Kamata 2005). The activity 
of DUSPs is also under the control of cellular oxidative state since oxidation of active sites 
of these phosphatases lead to their inactivation (Tonks 2005, Lambeth 2004, Chiarugi 
2003). DUSP1, DUSP2, DUSP4 and DUSP5 are specifically located in nucleous, DUSP6, 
DUSP7 and DUSP16 are located in cytosole, while DUSP8, DUSP9 and DUSP10 can 
reside both in cytosol and nucleus (Patterson 2009).  
In this chapter we use NRAS-Cdk4 mouse model to study the gene and protein expression 
changes that occur during progression. After identification of melanocytic and keratinocytic 
specific gene expression signatures we were able to some extent search for cell 
autonomous changes in S1, S2 and S3 melanomas. Dusp6 is the only gene that its 
expression is constantly upregulated during transformation and progression.  
Analysis of TCGA MM dataset revealed only two somatic DUSP6 mutations in 153 
patients with malignant melanoma. Also, analysis of gene expression of human metastatic 
melanoma versus primary melanoma revealed a significant increase in DUSP6 expression 
in metastatic stage (Figure 5.3e). Neural crest derived tumors such as glioblastomas also 
show DUSP6 upregulation. High DUSP6 expression in human glioblastomas has been 
linked to the malignant phenotype and inhibition of DUSP6 expression both in vivo and in 
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vitro suppresses Cisplatin resistance (Messina 2011). In other cancers such as colorectal 
cancer DUSP6 expression opposes the effect of anti-apoptotic factor BCL-2. 
Overexpression of DUSP6 in human colorectal HCT116 sensitizes these cells to apoptotic 
factors such as 5-Fluorouracil (Piya 2012). These studies suggest a dual role for DUSP6 
during transformation and progression which is cancer type dependent.  
The exact role of Dusp6 in carcinogenesis and metastasis is controversial in many cancer 
types. It is possible that role of Dusp6 be tissue dependent and even controlled by tissue 
microenvironment. In vitro study on digestive tract cancer cells such as esophageal 
squamous cell carcinoma (11 cell lines) and nasopharyngeal carcinoma (7 cell lines) 
revealed complete and 71% loss respectively of DUSP6 expression in these cancer cell 
lines. DUSP6 expression was also downregulated in esophageal squamous cell carcinoma 
(40%) and nasopharyngeal carcinoma tumors (75%). Upregulation of DUSP6 reduces the 
cell migration ability of these cells in vitro (Wong 2011). In pancreatic cancer cell lines 
DUSP6 acts as tumor suppressor gene and its expression is downregulated compared to 
immortalised normal pancreatic ductal cells. However in vivo studies reveal a more 
complex dual role for DUSP6 since its expression is upregulated during proliferation phase 
of tumorogenesis and downregulated with invasion and metastasis (Furukawa 2003, Xu 
2005, Furukawa 2005). In contradiction, upregulation of DUSP6 in papillary thyroid 
carcinoma cell lines increases the invasion and metastatic ability of these cells. Silencing 
DUSP6 expression resulted in less malignant phenotype (Degl’Innocenti 2013). In lung 
tumors only 17.7% of studied samples have shown low expression or loss of 
heterozygosity (Okudela 2009). Epigenetic changes such as methylation of CpG islands in 
intron 1 of DUSP6 has been linked to downregulation of DUSP6 expression (Xu 2005). 
Chemoresistance is a devastating factor in treatment of glioblastoma. Human primary and 
long term cell cultures of glioblastoma exhibit high DUSP6 expression both on RNA and 
protein levels. Similar to melanoma cell lines, DUSP6 upregulation in glioblastoma cells 
increased tumorogenesis in vivo (Messina 2011, Li 2012). A study on MCF-7 breast 
cancer cell line revealed that silencing of DUSP6 and/or DUSP5 result in hyperactivation 
of MAPK pathway which inhibit proliferation and migration of these cells while upregulation 
of DUSP6 and/or DUSP5 keeps MAPK pathway in transient activation state which is pro-
growth and pro-migration (Nunes-Xavier 2010) which is in contrast to the pro-growth and 
anti-migration role of DUSP6 in pancreatic cancer cell lines (Wong 2011). A recent 
comprehensive study by Shojaee et al. depicts a more complex role for DUSP6 in 
tumorogenesis (Shojaee 2015). In human NRASG12D pre-B cells malignant transformation 
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is met with oncogene-induced apoptosis of majority of these cells while surviving cells that 
were not affected and transformed had high DUSP6 expression. Colony formation ability of 
DUSP6-/- B cell lineage leukemia was significantly reduced compared to the DUSP6+/+ 
cohorts (Shojaee 2015). 
The role of ETS1 in transformation and progression is still illusive and controversial. Keehn 
et al. reported that expression of ETS1 in human invasive is significantly higher than 
benign nevi (Keehn 2003) while a larger study reported that ETS1 is widely expressed in 
benign and malignant melanocytic lesions such as dermal nevi, metastatic melanoma and 
primary melanomas (Torlakovic 2004). Expression of ETS1 is only nuclear in these two 
studies.  
More recent functional studies reveal an oncogenic role for ETS1 but the expression 
patterns are only cytoplasmic which reveals mislocalization of ETS1. A functional study on 
the role of ETS1 revealed that it exacerbates melanomagenesis through the activation of 
ETS1-MET axis in combination with or without PAX3. Majority of ETS1 was expressed in 
cytoplasm while PAX3 is only expressed in nucleus (Kubic 2015). In concordat with this 
study, Potu et al. reported that Ets1 upregulation amplifies NRAS activity via its 
overexpression which leads to a malignant phenotype. ETS1 and NRAS were highly 
expressed in metastatic and primary melanoma vs. benign nevi. While benign nevi show 
clear nuclear staining of ETS1, primary and metastatic melanomas show only cytoplasmic 
staining (Potu 2017). In our study the expression of ETS1 is only limited to nucleus and no 
mislocalization was detected. ETS1 is a transcription factor for DUSP6 in fibroblasts, lung 
cancer cells and leukemia cells (Ekerot 2008, Zhang 2010, Shojaee 2015). 
In our study the expression of BRN2 and ETS1 is positively correlated while there is no 
link between ETS1 and DUSP6 expression. It is possible that epigenetic changes that 
block the expression of DUSP6 be responsible for this in subset of nevi and melanomas.   
Some studies point to the role of BRN2 as a developmental transcription factor which is 
mainly expressed in undifferentiated melanoblasts or dedifferentiated malignant melanoma 
cells (13, 38-43). Hence, differentiated melanocytes and nevocytes are negative for BRN2 
and metastatic melanoma cells have the highest BRN2 expression. This is in direct 
contrast with findings of Richmond-Sinclair et al. that reported BRN2 is not expressed in 
70% of 129 cutaneous melanomas that they studied. Also, this study revealed that BRN2 
is expressed in melanomas that bear BRAFV600E mutation and originate from non sun 
exposed area of skin while majority of melanomas from sun exposed areas of skin do not 
170 
 
express BRN2. BRN2 positive group of tumors also show high pMAPK and P16 
expression while the BRN2 negative group highly express P53 and pRB (Richmond-
Sinclair 2008). While all SSMs that were used in our study are from sun exposed area of 
skin their mutation is unknown.  
 
5.7 Future aims 
 
1. High quality RNA from microdissected mouse nevi (n=6), stage 1(n=6), stage 2 (n=6) 
and metastasis (n=6) purified to be compared with isolated RNA from mouse nevi, stage 
1(n=6), stage 2 (n=6) and metastasis (n=6). We were unable to complete this due to lack 
of funding. High cost of RNAseq or agilent chips vs original illumina chips. The isolated 
RNA materials will be kept in -80°C pending future funding. 
2. Establishing melanoma cell lines from fast growing and slow growing melanoma strains, 
monitoring the growth of these melanoma cell lines in vitro, ablation of Dusp6 expression 
in fast growing cell lines and comparison of growth rate versus slow growing cell lines. 
3. In vivo functional study of Dusp6 in melanoma progression using Tyr-Cre::Dusp6fl/fl 
mice. These mice will be crossed with NRAS-Cdk4 mice that develop fast growing 
melanomas to see if this will impede the formation of melanoma. 
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Chapter 6 
The overarching aim of this thesis was to examine how differences in genetic background 
influence dermal nevus development. This can be done in human populations using 
genetic association studies using the phenotype of nevus free and nevus prone, or the 
number of nevi per person. Genome wide association studies (GWAS) of nevus and 
melanoma have revealed many loci (Udayakumar 2009,  eh  2009, Duffy 2010, Barrett 
 2011, Law 2015). However, these represent common variants that individually have a very 
small impact on risk, and in nearly all cases the true causal genes/variants are not yet 
identified. Hence no potential drug targets have resulted from such studies. Many of the 
single nucleotide polymorphisms (SNPs) found by GWAS are near pigmentation genes 
e.g. TYR, TRP1, MC1R, suggesting some degree of population stratification. In addition 
many of the implicated genes are of unknown function. Even when their function is known, 
how and where they act or interact during nevogenesis or melanoma progression has yet 
to be determined. It is difficult to confirm nevus or melanoma susceptibility genes and to 
understand their mode of action. These studies can be skewed by the effects of genetic 
ethnicity, diversity of lesion subtype, even within an indivdual patient with multiple nevi, let 
alone between patients, and it is very difficult to test gene-environment interactions. 
,Further, it is very difficult to functionaly validate even a strong GWAS hit, not the least in 
the case where the gene has a cell extrinsic actions that may be able to be properly 
modelled in 2D/3D cell culture studies. Forward genetic strategies can be successful in 
understanding disease. An example of this is the Collaborative Cross (CC), a powerful and 
revolutionary approach for mapping genes for complex conditions (CC Consortium, 2012; 
Churchill, 2004). The CC can bring to light new genes and gene interactions involved in 
these complex diseases. For example it was recently found that one of the CC strains 
develops ulcerative colitis (Rogala, 2014). This disease is not present in any of the 
founders, i.e. the CC has uncovered genetic interactions that confer this phenotype. 
Genes which do not predispose to a disease, but which can influence its course or 
severity, are “modifier genes”. They are very difficult to identify, especially in humans 
(Nadeau, 2001). An excellent example of the power of the transgene modifier approach 
comes from the work of Hunter et al. (Lifsted, 1998). To find modifier genes of breast 
cancer metastasis, they crossed a relevant transgenic mouse with each of 27 strains. 
Recombinant inbred mouse lines are generally derived from just two parental strains. 
Despite the smaller size and lower heterogeneity of their strain panel compared to the CC, 
they discovered a set of interacting genes in a pathway that regulates metastasis; the 
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“Diaspora” pathway, alleles of which predict survival outcomes for patient genotype groups 
(Crawford, 2008). A similar strategy has been used to identify a modulator of breast cancer 
metastasis in mouse and humans by a non-cell-autonomous mechanism (Faraji, 2012). 
These studies used a small number of closely related common inbred strains. Instead, we 
can use the CC to harness most of the available genetic repertoire of the mouse. The 
mapping power of the CC has recently been demonstrated using coat colour as a known 
Mendelian trait (Ram, 2012).  
The primary focus of this project was to use transgene modifier approach along with CC to 
discover modifier genes that exacerbate nevogenesis and melanocytic microsatellite 
formation in many CC strains.  This project was stemmed from five overarching questions: 
1. How melanocytes with NRAS-Cdk4 mutations reach the dermis and form dermal 
melanocytic lesions? 
2. Does strain background modifies histopathology of melanocytic lesions with 
NRAS-Cdk4 mutations? 
3. Does genetic background affects nevogenesis and is responsible for formation of 
large or giant dermal lesions? 
4. Does genetic background affects the formation of angiotropic microsatellites in 
the hypodermis? 
5.  What cell intrinsic molecular changes drive the progression, and metastasis of 
melanocytic lesions? 
These questions have been answered fully or partially in different chapters of this 
dissertation. In this chapter we provide the key findings, shortcomings, and limitations that 
hampered us to fully answer all five questions.  
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6.1 Summary of key findings and discussion 
Melanocytes reach the dermis by breaking hair follicles 
When we first asked the question “How do melanocytes with NRAS-Cdk4 mutations 
reach the dermis and form dermal melanocytic lesions?”. Normally melanocytes 
mainly reside in the hair follicles or epidermis of NRAS-Cdk4 mouse model would form 
dermal melanocytic lesions. We answered this question in chapter 2 by taking dorsal skin 
from NRAS-Cdk4 and wild type mice at different time points (at postnatal day 1, 3, 5, 10, 
15, 21, 42, and 60) and subsequently staining these samples with Sox10 (a melanocyte 
marker) to track the transport of these lesions. We found that melanocytes escape hair 
bulb or hair bulge (Chitsazan 2016) and migrate to superficial or deep dermis where they 
congregate to form melanocytic lesions. Also, melanocytes breaking out of long hair 
follicles that are located in the hypdermis during anagen probably explain the derivation of 
melanocytic microsatellites in the hypodermis. These microsatellites usually form near 
blood vessels (angiotropism). The temporal development of dermal nevi begins at about 
post-natal day 5 (P5) and an early “band” of nevi appeared by P10. These tend to become 
fully-developed nevi by P42, hence the mouse model provides a unique teleological 
window into formation of these lesions. Understanding the spatio-temporal migratory 
patterns of melanocytes from epidermis to dermis was a crucial first step in the study in 
terms of trying to validate mechanisms of nevus development. 
 
Somatic NRAS mutation is not the sole driver of nevogenesis, microenvironment 
can also play a role 
Despite the evolutionary differences in the pigmentary system between species (mouse 
melanocytes are usually limited to hair follicles whereas in humans they are also located in 
the epidermis), virtually all genes involved in regulating mouse melanocyte behaviour (i.e. 
pigmentation) are relevant in humans (Walker et al., 2012). NRAS-Cdk4 mice represent a 
useful animal to model nevogenesis. One must ask “Does strain background modify the 
histopathology of melanocytic lesions in NRAS-Cdk4 mice?”. By crossing 70 different 
collaborative cross strains with NRAS-Cdk4 transgenic mice we observe tremendous 
diversity in histopathological architecture of melanocytic lesions. This was surprising since 
all progeny shared a similar NRAS-Cdk4 mutation. The histopathological classification of 
murine melanocytic lesions presented in Chapter 3. 
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Here we discovered that these lesions range from small superficial and deep blue nevi to 
giant lesions covering the whole dorsal skin of mice. These giant nevi were shown to be 
composed of interconnected units, each of which is histopathologically defined as 
pigmented epithelioid melanocytoma (melanocytoma), or giant congenital nevus.  
In sum, this is the first methodical study of histopathological classification of NRAS-Cdk4 
mouse model using 70 collaborative cross strains. Here we show that innate genetic 
background dictates the histopathology of NRAS-Cdk4 driven melanocytic lesions. This is 
also possible in human since a wide range of melanocytic lesions from small to large and 
giant nevi. Understanding the innate genetic diversity is also important in the case of 
melanomas that develop from these nevi or develop de novo in different patients with 
diverse genetic background which makes the treatment of melanoma so complicated. 
 
The Cdon-Shh-Edn1 axis activation exacerbates nevogenesis 
NRAS-Cdk4-CdonNOD/+ mice have activated Shh-Edn1 axis which result in exacerbation of 
nevogenesis. In these mice instead of many blue nevi developing on the dorsal area of 
skin, they exhibit large melanocytomas that cover the dorsal area of the mice which are in 
essence giant congenital nevi. Patients with giant congenital nevi have higher than normal 
risk for the development of malignant melanoma (85%) and neurocutaneous 
melanocytoma (60%) (Kinsler 2013, Martins de Silva 2017). Almost half of patients with 
neurocutaneous melanocytoma die from central/peripheral nervous system malignant 
melanoma (Kinsler 2013, Martins de Silva 2017).  
The development of large and contiguous melanocytic lesions is linked to the activation of 
Shh-Edn1 axis in NRAS-Cdk4 susceptible and Cdon+/- mice while resistant NRAS-Cdk4 
mice develop small and discontinuous melanocytic lesions. Also, the pattern of distribution 
of giant congenital nevi in susceptible mice strains is similar to bathing trunk pattern in 
human. These patients have the highest risk for development of MM and neurocutaneous 
melanocytoma (Martins de Silva 2017). Perhaps SHH-EDN1 signalling acts as a rheostat, 
via melanocyte EDN1-GNAQ-MAPK, in exacerbating blue nevi to form very large or giant 
nevi. 
We propose that our strategy, using mouse models could be helpful also in gaining 
insights into genetic background influences in other rare diseases. In the case of giant 
congenital nevi, they are only seen in about 1/20,000 births, hence no large genetic 
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association studies have yet been performed on large cohorts of cases and controls. But 
giant congenital nevi can be very disfiguring, by definition covering significant parts of the 
body surface, and with a high propensity to convert to melanoma. Studying human lesions 
post-natally does not tell us how they are formed. In years to come DNA from large 
enough cohorts may become available for appropriate GWAS studies, which may shine 
some light onto genetic susceptibility, but not being a common disease it will be very 
difficult to attract traditional research funding. To confirm our hypothesis that keratinocyte 
cytokines may be involved in the formation of giant nevi would entail sensitive gene 
expression and or immunohistochemical studies of representative skin samples from 
perhaps hundreds of patients and ethnic matched controls, again a difficult study to 
realize. Thus we speculate that targeting keratinocyte cytokines might be a target for 
further investigation as a therapy for these nevi.  
One would hope to have a drug therapy by which giant nevi could be controlled, or even 
reversed, since they can spontaneously regress (Arpaia et al., 2005; Nath et al., 2011; 
Cusak et al., 2009). Surgical excision is the gold standard for treatment of most cutaneous 
tumours. But topical treatments are now available for solar keratosis and in situ squamous 
and basal cell carcinomas (e.g. fluorouracil, imiquimod, Picato gels), lesions previously 
only removed by excision.  
The same may eventually be true for large/giant nevi. We note that topical treatment of 
pigmented BCCs with the SMO antagonist LDE225, and Bosentan an inhibitor of Edn 
signalling, which we used in our study to suppress the development of dermal nevi, results 
in the disappearance of the melanocytosis associated with the lesions and could be a 
potential non-invasive treatment for removal of disfiguring large and giant nevi or patients 
with large number of nevi. It is not known whether germline CDON variants influence the 
development of human congenital nevi, but our findings enable us to postulate that 
variants in any gene that result in up-regulation of the SHH pathway, or any other pathway 
that increases expression of secreted keratinocyte cytokines with mitogenic effect on 
melanocytes, could also be candidates. The Shh-Edn1 axis is normally active only in 
anagen, when it most likely functions in the programmed activation of melanocyte stem 
cells, which supply daughter cells that migrate to the hair bulb (Rabbani et al., 2011). 
Hence in conditions of stress caused by environmental or genetic factors (such as Cdon or 
deregulation of other Shh pathway components) it is not surprising that melanocytes can 
escape their normal follicular niches and congregate in the dermis as nevi. Edn1 binds to 
the melanocyte Ednrb receptor and stimulates signalling through Gnaq/Gna11 and 
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subsequently the MAPK pathway. GNAQ is somatically mutated in ~80% of human blue 
nevi, suggesting that signalling through it is important in dermal nevus development, and 
mice expressing an activated Gnaq mutant in their melanocytes exhibit essentially the 
same phenotype in terms of dermal melanocytic nevi that we observe in our model with 
activated keratinocyte Shh (Huang et al., 2015).  
Murine models with keratinocyte-specific deregulation of Shh pathway components e.g. 
Shh (Ellis 2003), Ptch1 (Peterson 2015), Smo (Grachtchouk 2003; Eberl 2012), and Gli2 
(Grachtchouk 2000), also exhibit melanocyte hyperplasia. With regard to the role of Cdon 
gene variation in exacerbation of nevogenesis, another important aspect of our strategy is 
the notion that different genes act at different stages of tumor progression (Ferguson 
2014). For instance we have shown before (Ferguson 2014) and confirmed now that the 
QTL at the Cdon gene is only detected for the phenotype of giant congenital nevus, not 
whether they proceed to melanoma.  
Hence the strains carrying the CdonNOD allele are not necessarily more prone to the 
development of melanoma. In these mice it is fitting that keratinocyte-produced mitogens 
increase total nevocyte count per strain, whereas the transformation of an individual nevus 
(of which there are >10,000 per mouse on an FVB strain background) is extremely low (a 
0.04% probability that a nevus will convert to melanoma; Chi 2014), but modified by other 
epigenetic or cell extrinsic effects that have not yet been elucidated.  
 
 
A region on murine chromosome 10 is linked to the development of melanocytic 
microsatellite 
The appearance of angiotropic melanocytic microsatellites (MSs) is an important 
prognostic marker for loco-regional nodal metastasis and distant metastasis in patients 
with a melanoma (Van 2008, Lugassy 2011). Patients with primary melanoma and 
matched loco-regional and distal metastasis did not show vascular or lymphatic invasion. 
Metastasis was only linked to the presence of angiotropism in these patients while 
angiotropism was absent in similar group of patients with primary melanoma and no loco-
regional or distal metastasis (Lugassy 2011).  
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It should be noted that presence of MS or angiotropism is usually not reported in the 
pathological report hence there are limited information available in majority of pathological 
studies. However the presence of angiotropic MS is nearly ubiquitous in congenital 
melanocytc nevi both in newborn and adults (97%) (Barnhill 2010, Lugassy 2011), atypical 
spitzoid melanocytic nevi and atypical spitzoid dysplastic nevi (Barnhill 2011, Wilsher 
2013). In this chapter we asked the following question “Does innate genetic background 
affect the formation of angiotropic microsatellites in the hypodermis?”.  
Here we performed an unbiased genetic screen based on the microsatellite count and 
selected Gja1 (expressing Cx43) as the best candidate based on allele segregation, SNP 
cataloguing, and previous association with nevogenesis. Our gene and protein expression 
studies revealed that Gja1 and Cx43 expression, respectively, is much higher during 
anagen. Also, Cx43 is not expressed in the mouse epidermis, but in hair bulb and hair 
bulge areas where melanocytes interact with keratinocytes. However it is not yet clear how 
this interaction might affect the development of MSs and why early and fully develop MSs 
do not express Cx43.  
An interesting result on the interaction of cells expressing connexion 43 comes from the 
work of Chen et al. on brain metastasis (Figure 6.1). Murine and human breast and lung 
cancer cells express high levels of protocadherin 7 (PCDH7) which facilitates their binding 
to normal astrocytes in the brain tissue. The formation of GAP junctions between Cx43 of 
cancer cells and astrocytes initiates an intercellular signiling between these cells. Cancer 
cells then transfer high levels of cGMP to astrocytes via the establish GAP junctions and 
promote the astrocytes to synthesise and release of mitogenic cytokines such as IFNα and 
TNF. 
These cytokines activate STAT1 and NF-κB signiling in cancer cells which leads to their 
proliferation (Chen 2016 In our NRAS-Cdk4 mouse model only melanocytes that reside in 
the hair follicle bulge and bulb express Cx43, while Cx43 expression in telogen is limited to 
bulge melanocytes. Melanocyte stem cells could possibly use similar strategy to exploit 
metabolic machinery of keratinocytes and produce high population of differentiated cells 
which could escape hair follicle bulb and form MSs. Previous study by Chang et al. reveal 
a sophisticated interaction between melanocyte stem cells, differentiated melanocytes and 
hair bulb stem cells which activation of melanocyte stem cells could lead to apoptosis of 
hair bulb stem cells (Chang 2013).  
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Figure 6.1 ǀ Cx43 mediates brain metastasis (from Chen 2016). 
 
Very little is known about the relative expression of various connexins in skin, nevi and 
melanoma or how different connexins combine to form the connexon, the makeup of which 
have a large effect on cell behaviour. Dissecting the connexin interactome in mouse and 
human nevi and melanoma are important for understanding nevo/melanoma-genesis and 
also development of angiotropic microsatellites that promote metastasis. In terms of 
histopathology, murine MSs from NRAS-Cdk4 mice have balloon cell structures which are 
reminiscent of pigmented balloon cell nevi and metastatic balloon cell melanomas. While 
they lack the nuclear atypia of tumour and metastatic cells, they are enclosed by less 
collagen unlike the balloon cell nevi. It is not clear why these balloon cells with high 
melanin content are more mobile than the dendritic melanocytes. The appearance of 
balloon like melanocytes in the lymph node metastasis of has been recently been reported 
in BRAFCA/+PTEN-deficient mice (Young 2017). The appearance of these bulky cells in the 
lymph node metastasis of both NRAS-Cdk4 and BRAFCA/+PTEN suggest that these cells 
might go through epithelial-to-mesenchymal transition (EMT) before initiation of 
dissemination via extra/intra-vascular routes. 
(Chen 2016)
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The in vivo imaging has shown that angiotropic melanoma cells follow the vessels and 
invade brain (Bentolila 2016). These mobile melanoma cells have gone through EMT and 
are mesenchymal in appearance during transition but look balloon like after arrival in the 
brain. These results in combination with our study reveal a more complex dissemination 
pattern in metastasis arising from benign nevus, melanocytoma and melanoma. 
 
The dual role of Dusp6 in development of melanocytic lesions 
Understanding early transformative changes that drive melanomagenesis is crucial for 
developing better diagnosis and treatment procedures for melanoma patients. Here we 
asked a very basic question: “What cell intrinsic molecular changes drive the 
transformation, progression, and metastasis of melanocytic lesions??”. By studying 
gene expression of melanocytes, nevocytes and different stages of melanoma (S1, S2 and 
S3) we found out that a gene that encodes Dusp6 is highly upregulated with 
transformation, progression, and metastasis.  
Our mouse results is in line with previous study by Li et al. that show Dusp6 
overexpression in a melanoma mouse model will increase tumorigenicity, enhance 
anchorage independent proliferation and metastasis (Li 2011). Interestingly 
overexpression of MEK reduced the ability of these melanoma cells to metastasize to 
distant organs. However, the increased DUSP6 expression was only studied on one 
human melanoma cell line (A375) which failed to validate the mouse results. A previous 
study on human thick melanoma revealed two types of melanomas with high and low 
expression of DUSP6. Both DUSP6 negative and positive melanomas have poor 
prognosis (Li 2011). However the expression of DUSP6 was not studied on normal skin 
and benign nevi which can’t help us to put the expression of DUSP6 in context. A 
challenge that is shared by many studies conducted on human samples including ours is 
the lack of comprehensive information on the samples e.g. mutation and lack of different 
time points during transformation of nevus to melanoma. 
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6.2 Challenges and shortcomings - Chapter 2 
Scoring nevus density of pigmented CC strains 
It is difficult to quantitate melanocytic cell number in pigmented strains because of the 
dense melanin deposits mask most nuclei. This is not helped even with Sox10 staining of 
melanocytes in pigmented lesions since fluorescence is also masked by heavy pigment 
deposits. For lightly pigmented low nevus count strains we assessed the number of lightly 
pigmented (brown) dendritic nevus cells. For heavily pigmented strains (i.e. dark 
pigmentation covering a large portion of the dermis), we also try to assess dendritic “nevus 
cells”, but essentially we scored based on the area covered by dense pigmentation as a 
marker for the density score. Using Aperio software to score the pigmentation levels on 
different background produced similar results to manual scoring.  
 
6.3 Challenges and shortcomings - Chapter 3 
Orthogonal approaches measuring gene and protein expression in skin 
Orthogonal approaches such as qPCR and western blotting are very useful in quantitating 
gene and protein expression. However the result is highly dependent on the hair cycle 
phase and could simply be varied between strains not only by age but by the stage of hair 
cycle. Hence the gene expression and protein expression needs to be closely monitored 
and interpreted based on the aforementioned factor.  Another factor that influences the 
result of gene and protein expression is the differences in hair follicle density between 
susceptible and resistant, and WT and Cdon KO mice. We were unable to use western 
blot or qPCR due to such limitations. We have focused on IF staining in which we could as 
best as possible select areas of skin with similar numbers of hair follicles for the 
quantitative expression comparisons. Western blotting and/or qPCR would not allow us to 
take into account the differences in hair follicle density or stage at all. The levels of 
expression of Glis is generally quite low adult mouse skin unless in anagen. Hence we 
thought best to quantitate our results using the very sensitive Perkin Elmer InForm 
software after tyramide signal amplification.   
Lack of GWAS study on human large and giant congenital nevi 
In terms of germline gene variation there are no GWAS or genetic associated studies 
conducted on human large or giant congenital nevi patients, nor familial studies that might 
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reveal rare mutations. In terms of somatic mutations, CDON missense mutations must be 
uncommon since NRAS is the only recurrently mutated gene in large and giant congenital 
nevi. Hence, we were unable to validate the occurrence of germ line or somatic mutations 
of CDON. But in essence, since the SHH-EDN1 effect is non cell autonomous, whether 
somatic mutations of CDON are present in the human nevi is irrelevant. Human congenital 
nevi do however carry mutations that affect the pathways in melanocytes downstream of 
the EDN1 receptor, EDNRB (e.g. GNAQ, GNA11, NRAS, BRAF etc).  Also, it is not just 
EDN1 that could stimulate these melanocyte pathways, but also other secretory cytokines 
with mitogenic effect on melanocytes can activate MAPK pathway (e.g. KITL, EDN2, 
EDN3. HGF etc).  
Hence any modifier gene that could increase the expression of one of these keratinocyte 
cytokines could potentially also exacerbate nevogenesis (Figure 6.2).  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 ǀ Convergence of signaling pathways under the activity of MAPK could 
exacerbates the effect of somatic NRAS or BRAF mutations (from Etchevers 2014). 
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6.4 Challenges and shortcomings - Chapter 4 
In chapter 4 we mapped an interval on murine chromosome 10, which, after fine mapping 
and SNP cataloguing, was narrowed to an area containing 11 genes. Surprisingly 6 of 
these genes have been previously linked to metastasis in different cancers including 
melanoma. The major shortcoming of this chapter is that while initial protein expression 
studies and comparisons were performed, Gja1 was not validated as the candidate in this 
genetic interval. This would require a large amount of extra work, such as testing more CC 
strains with recombinations within the interval to further fine map the region, and in vivo 
studies using knock out mouse model of our candidate gene Gja1. The latter work has 
commenced but it is not possible to complete within the timeframe of this PhD project, due 
to the large amount of back crossing, crossing with tissue specific Cre, and finally crossing 
with NRAS-Cdk4 mice. 
6.5 Challenges and shortcomings - Chapter 5 
Again, this chapter was based only upon initial follow-up of a large amount of work that my 
PhD panel thought was worth reporting. As discussed in Chapter 5 the gene expression 
comparisons of lesions at different stages of progression was so mplcated by keratinocyte 
contamination of the very early lesions. I put a large amount of effort in to working up and 
optimisation of microdissection methodologies to circumvent this contamination effect, but 
was not able to continue with global gene expression on the microdissected RNA.  In 
addition, validation of changes in DUSP6 staining during human melanoma progression 
was hindered by the extreme difficulty in obtaining a clear progression series of human 
melanomas of the same subtype.  
 
6.6 Future research direction 
Future studies stem from chapter 3 
In chapter 3, we used two FDA-cleared to inhibit the effect of Smo and EdnrB during 
nevogenesis. We will also use these drugs on mice with fully developed blue nevi, deep 
penetrating nevi, epithelioid blue nevi, melanocytoma and melanoma to observe the 
possible inhibitory effect. This study will provide more information about the possibility of 
set up a clinical trial. I have commenced initial studies on the nevus susceptible mouse 
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model to determine whether topical treatment with Shh or Edn1 pathway inhibitors can 
induce regression of nevi.   
 
 
 
Future studies stem from chapter 4 
In chapter 4, we mapped Gja1 as a modifier gene for development of angiotropic 
microsatellites. We have received the Cx43fl/fl mice and will cross them with K14-Cre and 
Tyr-Cre to design keratinocyte and melanocyte specific Cx43 deficient mouse models. 
This will help us to gain a better understanding of the role of Cx43 in development of 
microsatellites and metastasis on NRAS-Cdk4 background. Also, we will try to map the 
epidermis and hair follicular distribution of connexin monomers, and the makeup of 
connexons, by performing 6-plex immunofluorescence staining with tyramide signal 
amplification of mouse and human skin, nevus, melanoma, and metastasis sections with a 
panel of connexin (Cx26, Cx30, Cx43, Cx46), melanocyte (Sox10), keratinocyte (Krt14), 
and stem cell marker (Sox9). We will try to establish a better link between melanocytic 
microsatellite count per stain and the density of melanocytic or melanoma cells in the 
lymph nodes. Finally, we will use sixty paraffin-embedded blocks containing human 
melanocytic lesions including congenital naevi, benign nevi, dysplastic nevi, melanoma in 
situ, thin melanoma, and metastases to study the CX43 expression in human samples. 
 
Future studies stem from chapter 5 
In chapter 5, we have identified Dusp6 as a marker of fast cycling cells. We will continue to 
study this by establishing fast and slow growing nevi and melanoma. Next, we will inhibit 
Dusp6 expression in fast growing melanoma to impede their growth and increase Dusp6 
expression in slow growing melanoma to potentially expedite their growth. We will apply 
the opposite strategy in the case of nevi cell lines and observe the potential changes. 
We also will conduct a new gene expression study using RNA isolated from 
microdissected melanocytes, nevocytes and melanoma cells and compare their gene 
expression with RNA isolated from whole tissue samples.  
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6.7 Conclusions 
In this study we used a multidisciplinary approach to study nevogenesis, development of 
angiotropic microsatellites, melanoma progression and metastasis. Our findings suggest 
that Cdon-Shh-Edn1 is a novel therapeutic target for patients with giant congenital nevi 
and melanocytoma. In addition, this work provides evidence that connexions modify the 
development of melanocytic microsatellites within the skin. The major lesson from this 
work is that the development of nevi is to a large degree controlled by the 
microenvironment surrounding the melanocytic lesion.  
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Appendix 1: List of genes positively (red) and negatively (yellow) correlated with 
Gja1 expression 
  Gja1 
 
  Gja1 
Gja1 1 
 
Gjb2 0.86 
Fzd5 0.95 
 
Dbf4 0.86 
Dsg4 0.94 
 
Tgm6 0.86 
Proser2 0.93 
 
Zdhhc13 0.85 
Cryba4 0.93 
 
Krt35 0.85 
Prr9 0.93 
 
Shcbp1 0.85 
Elf5 0.93 
 
Gadl1 0.84 
Tyr 0.93 
 
Krt32 0.84 
Krt82 0.93 
 
Msx2 0.84 
Lap3 0.92 
 
Knstrn 0.84 
Krtap26-
1 0.91 
 
Krt34 0.84 
Ggt1 0.91 
 
Nek2 0.84 
Fam26d 0.91 
 
Etv4 0.84 
Stra6 0.91 
 
Rnf149 0.83 
S100a7a 0.91 
 
Dok4 0.83 
Cpm 0.9 
 
Cenpe 0.83 
Sptssb 0.9 
 
Dct 0.83 
Golga7b 0.9 
 
Krtap3-3 0.83 
Mlana 0.9 
 
Kcnh1 0.83 
Slc7a5 0.89 
 
Clspn 0.83 
Vsig8 0.89 
 
Chn2 0.83 
Gprc5d 0.89 
 
Cdk1 0.82 
Slc7a8 0.89 
 
Marcksl1 0.82 
Ppp1r3b 0.89 
 
Krtap11-1 0.82 
Lrrc75b 0.89 
 
Specc1 0.82 
Fbp1 0.88 
 
Krt31 0.82 
Krt27 0.88 
 
Spag5 0.82 
Bdh1 0.88 
 
Slc39a14 0.82 
Slc16a7 0.88 
 
Bub1 0.82 
Unc5b 0.88 
 
Ret 0.82 
Slc39a8 0.87 
 
Dcbld1 0.81 
Krtap13-
1 0.87 
 
Gpx2 0.81 
Foxe1 0.87 
 
Krt73 0.81 
Krt83 0.87 
 
Lig1 0.81 
Ero1l 0.87 
 
Krtap22-2 0.81 
Fam49a 0.87 
 
Cep55 0.81 
Foxn1 0.86 
 
Tmem229b 0.81 
Dusp2 0.86 
 
Tyrp1 0.81 
  Gja1 
 
  Gja1 
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Dtnb 0.81 
 
Slc7a1 0.77 
Gabrp 0.8 
 
Kit 0.77 
Bora 0.8 
 
Fblim1 0.77 
Nfe2l3 0.8 
 
Aurka 0.76 
Rasl11b 0.8 
 
Arg2 0.76 
Tspan6 0.8 
 
Edn1 0.76 
Krt28 0.8 
 
Zdhhc21 0.76 
Ckap2l 0.8 
 
Mcm2 0.76 
Tpx2 0.8 
 
Sprr1a 0.76 
Gnmt 0.8 
 
Lurap1l 0.76 
Hells 0.8 
 
Arid3a 0.76 
Rab3ip 0.8 
 
Krtap4-7 0.76 
Cdc25c 0.8 
 
Crot 0.76 
Col12a1 0.8 
 
Ercc6l 0.76 
Dera 0.79 
 
Tnc 0.76 
Ctse 0.79 
 
Arl15 0.76 
Spc25 0.79 
 
Pitrm1 0.76 
Cdca2 0.79 
 
Rnf222 0.75 
Krtap9-3 0.79 
 
Nup210 0.75 
Gclc 0.79 
 
Pbk 0.75 
Krt33b 0.79 
 
Ror2 0.75 
Bub1b 0.79 
 
Slc45a2 0.75 
Wif1 0.79 
 
Kif20b 0.75 
Gjb6 0.78 
 
E2f8 0.75 
Otub2 0.78 
 
Mdga1 0.75 
Birc5 0.78 
 
Slc35g1 0.74 
Cdc20 0.78 
 
Spint1 0.74 
Msx1 0.78 
 
Mthfd2 0.74 
Syce2 0.78 
 
Rcc2 0.74 
Shh 0.78 
 
Smox 0.74 
Krtap7-1 0.78 
 
Kremen2 0.74 
Gm10036 0.78 
 
Gtse1 0.74 
Rad51 0.78 
 
Tgfa 0.74 
Smc2 0.78 
 
Ccser1 0.74 
Mxd3 0.78 
 
Rfc4 0.74 
Wnt5a 0.78 
 
Tom1l1 0.74 
Gpnmb 0.78 
 
Diaph3 0.74 
Irx4 0.78 
 
Kif20a 0.74 
Fam46b 0.77 
 
Alx4 0.74 
Mis18bp1 0.77 
 
Krt81 0.74 
Neo1 0.77 
 
Krt86 0.74 
 
  Gja1 
 
  Gja1 
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Tgm3 0.74 
 
Espl1 0.68 
Kif26a 0.74 
 
Plk2 0.68 
Prss53 0.73 
 
Sox13 0.68 
Krt72 0.73 
 
Evl 0.68 
Nop56 0.73 
 
Traf4 0.68 
Mtbp 0.73 
 
Cep164 0.68 
Basp1 0.73 
 
Erc1 0.67 
Bnc2 0.73 
 
Tle3 0.67 
Rad18 0.73 
 
Ephb3 0.67 
Hspa14 0.72 
 
Gsdma 0.67 
Nusap1 0.72 
 
Dusp6 0.67 
Nkd2 0.72 
 
Dhfr 0.67 
Cdk4 0.72 
 
Pitpnm3 0.67 
E2f2 0.72 
 
Dnmt1 0.67 
Cdc45 0.72 
 
Rbp1 0.67 
Psrc1 0.72 
 
Cntfr 0.67 
Igsf3 0.72 
 
Lbr 0.67 
Kif7 0.72 
 
Ptch1 0.67 
Slc6a19 0.71 
 
Zfp553 0.67 
Nfil3 0.71 
 
Chaf1a 0.67 
Kif23 0.71 
 
Atad5 0.67 
Epha2 0.7 
 
Isyna1 0.67 
H2afx 0.7 
 
Rhpn2 0.66 
Mcm4 0.7 
 
Zfat 0.66 
Cyp2s1 0.7 
 
Shb 0.66 
Prr11 0.7 
 
Asf1b 0.66 
Sema6a 0.7 
 
Nkrf 0.66 
Vdr 0.7 
 
Cdca7 0.66 
Ctns 0.69 
 
Ppp2r1b 0.66 
Tdp1 0.69 
 
Mark1 0.66 
Gli3 0.69 
 
Hmmr 0.66 
Plekhg1 0.69 
 
Esco2 0.66 
Pxylp1 0.69 
 
Polr1e 0.65 
Pola2 0.69 
 
Pprc1 0.65 
Mtap 0.69 
 
Lyar 0.65 
Serinc5 0.69 
 
Mms22l 0.65 
Dut 0.68 
 
Trpv3 0.65 
Mcm3 0.68 
 
Kifc1 0.65 
Spdl1 0.68 
 
Atad2 0.65 
Plxna1 0.68 
 
Myo10 0.65 
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  Gja1 
 
  Gja1 
Cep97 0.65 
 
Celsr2 0.62 
Enc1 0.65 
 
Ccnb2 0.62 
Ccnd1 0.65 
 
St6gal1 0.62 
Pappa 0.65 
 
Anp32b 0.61 
Nedd9 0.65 
 
Rnaseh2b 0.61 
Pop1 0.64 
 
Cenpi 0.61 
Tmeff1 0.64 
 
L3mbtl2 0.61 
Ranbp1 0.64 
 
Nup43 0.61 
Noc2l 0.64 
 
Eaf1 0.61 
Ift74 0.64 
 
Thoc6 0.61 
Map3k5 0.64 
 
Nmral1 0.61 
Mad2l1 0.64 
 
Plxnb1 0.61 
Rab15 0.64 
 
Hirip3 0.61 
Car12 0.64 
 
Ccnd2 0.61 
Whsc1 0.64 
 
Rab34 0.61 
Lrp12 0.64 
 
S1pr3 0.61 
Adamts9 0.64 
 
Smtn 0.61 
Lin9 0.63 
 
Gdf10 0.61 
Ifitm10 0.63 
 
Bach2 0.61 
Gmnn 0.63 
 
Tril 0.61 
Klrg2 0.63 
 
Ppp2r3a -0.61 
Ndc1 0.63 
 
Scin -0.61 
Cdca4 0.63 
 
Fgf11 -0.61 
Slc44a1 0.63 
 
Dusp13 -0.62 
Tcf19 0.63 
 
Ahr -0.64 
Pdcd4 0.63 
 
Wdr41 -0.65 
Tjp2 0.63 
 
Setd3 -0.68 
Mcm5 0.63 
 
Hspb7 -0.68 
Braf 0.63 
 
Bves -0.71 
Slc16a11 0.63 
   Lhx2 0.63 
   Smarca4 0.62 
   Smn1 0.62 
   Mettl8 0.62 
   Ddx39 0.62 
   Rab44 0.62 
   Tipin 0.62 
   Ammecr1 0.62 
   Rhno1 0.62 
   Dctpp1 0.62 
   Mocos 0.62 
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Appendix 2: Top 10 genes correlated with candidate genes from angiotropism 
linkage 
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Appendix 3: List of gene differentaly expressed between S3 and normal tail skin 
  Symbol p Regulation FC Symbol p Regulation FC
Metrn 7.58E-06 up 53.40093 Gbp3 0.002109 up 14.57312
Syt4 3.39E-06 up 39.45795 Hexa 2.36E-04 up 14.5372
C4a 0.004386 up 39.44178 LOC380706 4.29E-04 up 14.45502
Plp1 4.23E-08 up 36.38424 St6gal1 4.92E-08 up 14.27336
ctsz 6.96E-05 up 36.24376 Rhoc 5.12E-04 up 13.96646
Vim 1.38E-06 up 34.12374 Lyz2 1.76E-04 up 13.92605
Tmem14c 6.50E-06 up 32.8507 Syngr1 1.03E-04 up 13.79572
Nppb 6.59E-04 up 31.94804 Igf2bp2 5.26E-04 up 13.17086
C4a 0.003114 up 29.59298 2310040A07Rik0.006514 up 13.15387
Sox10 1.23E-07 up 29.13505 Cd63 1.03E-04 up 13.08937
Slc45a2 7.57E-04 up 28.8962 Sri 4.31E-05 up 12.95427
Trf 1.42E-06 up 28.82491 Ets1 4.31E-04 up 12.71202
E330034G19Rik1.59E-04 up 26.55375 Anxa6 2.37E-04 up 12.60618
Slc45a2 8.20E-04 up 25.54596 Gpr137b 1.49E-07 up 12.55539
Phlda1 1.45E-05 up 25.35037 Lgals3bp 0.002816 up 12.45218
Lhfpl2 2.81E-05 up 24.14974 Tspan4 5.08E-05 up 12.41375
Gstp1 2.57E-06 up 23.66661 Tyr 2.98E-04 up 12.31767
Fez1 7.08E-05 up 23.54545 LOC1000468831.86E-04 up 12.19021
Insc 8.99E-06 up 23.41725 Tmod1 3.58E-06 up 12.1823
Megf10 8.56E-08 up 22.91981 Gpnmb 9.37E-06 up 12.04973
LOC1000485544.08E-04 up 21.97288 Nrcam 3.76E-04 up 11.73007
Ifit3 0.007715 up 20.95441 Dpysl2 8.53E-08 up 11.66019
C2 3.14E-05 up 20.91254 Lbh 8.91E-04 up 11.60907
Megf10 1.15E-07 up 20.64805 Ube1l 0.007644 up 11.49753
Fez1 6.37E-05 up 20.50714 Dkk3 6.07E-04 up 11.45916
Mc1r 0.005062 up 19.93181 Cyba 0.003939 up 11.35533
Timp1 0.001701 up 19.36412 LOC1000469533.59E-05 up 11.14357
C1qb 7.82E-06 up 19.33357 Eng 1.62E-04 up 11.14255
Emp3 1.13E-04 up 18.3658 Mcam 0.002023 up 11.04342
Timp1 0.001415 up 18.24675 Tmem176b 6.76E-05 up 11.0222
Aadacl1 5.62E-07 up 17.91425 Armcx2 6.92E-04 up 10.91515
Emp3 2.44E-07 up 17.7067 Olfm1 0.002229 up 10.86113
Dusp4 4.81E-04 up 16.93547 2210010N04Rik8.32E-05 up 10.81521
Aebp1 1.86E-06 up 16.70963 Cugbp2 4.58E-07 up 10.65763
Man2b1 2.79E-05 up 16.45113 Plekhb1 0.001178 up 10.64552
LOC383981 5.21E-09 up 16.39825 Cd97 7.15E-05 up 10.64257
Gbp2 0.003085 up 16.07947 Bst2 0.003714 up 10.62123
Syngr1 1.25E-05 up 15.84899 Ctsz 3.99E-04 up 10.57499
Gbp3 9.37E-04 up 15.77024 Dctn4 2.27E-05 up 10.50772
Lgals1 7.28E-07 up 15.68164 C1qc 6.93E-05 up 10.50147
Ela1 8.11E-04 up 15.53233 LOC385699 7.97E-05 up 10.43302
Gstp1 6.04E-06 up 15.24677 Kcnn4 0.001312 up 10.42506
2310040A07Rik0.007065 up 15.17902 Iigp2 0.005218 up 10.37634
Cep170 2.98E-05 up 14.91736 2310014H01Rik1.38E-07 up 10.34196
Mgat4b 3.41E-08 up 14.85566 Lass2 9.92E-07 up 10.29307
Cd97 4.99E-05 up 10.26537
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  Symbol p Regulation FC Symbol p Regulation FC
Fermt2 9.77E-05 up 10.23331 Dusp4 4.20E-05 up 8.04391
Dennd5a 3.21E-05 up 10.19302 5031436O03Rik3.89E-05 up 8.006043
Grb10 3.12E-04 up 9.98502 Sdpr 0.003495 up 7.982078
Tuba1a 2.73E-04 up 9.981905 LOC100045343.96E-04 up 7.916644
Bace2 0.001839 up 9.958223 Calu 0.004825 up 7.881936
Mgp 0.001067 up 9.906899 Syde1 6.80E-05 up 7.854989
Sepp1 0.001443 up 9.870643 Vegfb 1.13E-05 up 7.69777
Gpnmb 0.00281 up 9.762015 Dusp6 1.98E-04 up 7.622442
Mcoln3 1.03E-05 up 9.749008 H2-D1 8.40E-04 up 7.558251
Renbp 1.68E-05 up 9.67749 Snx10 4.52E-04 up 7.547583
Ccnd1 8.68E-04 up 9.6745 2310047A01Rik7.58E-04 up 7.449744
Dkk3 3.97E-04 up 9.642129 Calu 0.002463 up 7.438108
Specc1 0.005331 up 9.615511 Ifitm1 0.004263 up 7.401457
St3gal6 8.89E-05 up 9.54871 2610200O14Rik3.84E-04 up 7.381403
Ctsz 9.18E-04 up 9.539115 Olfm1 4.11E-06 up 7.337728
Fxyd5 6.02E-04 up 9.441154 Gpx7 4.32E-06 up 7.317973
Epdr1 1.50E-04 up 9.40813 Tmsb10 2.76E-04 up 7.265918
Lyz 1.08E-06 up 9.387224 Plekho2 5.76E-04 up 7.217587
Hbb-b1 0.001878 up 9.385243 H2-D1 0.001116 up 7.142329
LOC674135 0.002787 up 9.329122 Galk1 5.65E-05 up 7.07013
Fxc1 0.001973 up 9.247446 Dusp6 0.001215 up 7.054006
Lbh 2.56E-05 up 9.163786 Trem2 0.002631 up 7.052371
Sytl2 9.68E-04 up 9.119543 Mcam 0.007053 up 6.892709
6720469N11Rik0.00112 up 9.104646 Hbb-b2 0.00624 up 6.85074
Scly 9.85E-05 up 9.087372 Ppm1f 0.004445 up 6.811772
Ms4a7 0.001334 up 8.954047 Acot7 0.002605 up 6.806245
Slc45a2 0.001873 up 8.94855 Ddit3 0.00334 up 6.729267
LOC383099 3.55E-07 up 8.888801 Cotl1 0.001805 up 6.70259
Ifi27 0.005205 up 8.790092 Gpnmb 7.59E-06 up 6.665006
Gusb 3.02E-04 up 8.789815 H2-K1 0.002552 up 6.63826
Samd9l 7.30E-04 up 8.760407 2610027C15Rik0.001087 up 6.626056
Eno2 1.21E-06 up 8.618735 Fscn1 0.006608 up 6.612679
Sdcbp 4.54E-06 up 8.533064 Cdk2 6.90E-04 up 6.560614
Tspan10 0.005127 up 8.531222 Fxyd5 0.002948 up 6.546064
EG630499 0.002406 up 8.435089 Csrp2 0.008061 up 6.515853
Uap1l1 3.18E-04 up 8.419153 Tmem176a 8.09E-04 up 6.442013
Enpp5 1.38E-04 up 8.326103 Cryab 2.45E-05 up 6.414673
G0s2 3.95E-04 up 8.267694 Ttc7b 0.001646 up 6.40431
St3gal5 0.003042 up 8.264798 Bin1 1.83E-04 up 6.39506
Sema3b 3.77E-04 up 8.256878 Cd44 1.44E-04 up 6.372951
Cpe 1.18E-04 up 8.242963 Lass2 1.42E-06 up 6.370818
Ftl1 1.18E-04 up 8.186755 Prdx4 4.35E-06 up 6.370151
Adm 0.001609 up 8.171984 Gsta1 0.001553 up 6.324022
Tacc1 2.02E-04 up 8.155523 Smpdl3a 6.30E-06 up 6.312695
Psen2 1.82E-04 up 8.067988 D12Ertd647e9.43E-07 up 6.303988
Sdcbp 1.16E-05 up 8.061649 BC046404 5.50E-04 up 6.30118
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Symbol p Regulation FC Symbol p Regulation FC
Krt84 1.63E-10 down -228.719 Nuak2 7.11E-05 down -14.834
2310034C09Rik1.24E-09 down -186.567 Grhl1 0.002845 down -14.8157
Serpinb12 6.94E-05 down -69.1538 Krt33a 5.95E-04 down -14.4985
Expi 0.005073 down -52.0704 Col17a1 0.003957 down -14.4962
Dapl1 9.58E-06 down -45.6938 Tgm1 4.49E-04 down -14.3092
Sbsn 0.005906 down -38.4977 LOC1000467411.91E-04 down -14.0985
2310040C09Rik0.002216 down -37.773 LOC547380 0.001369 down -13.9101
Pkp1 0.004556 down -35.8935 Hal 0.001486 down -13.6513
Aqp3 0.005976 down -35.3096 Pdzk1ip1 0.003724 down -13.5987
Krt15 0.005073 down -33.4912 Hoxd10 2.50E-07 down -13.5077
Krtap16-3 7.08E-04 down -33.0938 Hspb1 0.001889 down -13.5039
Rarres1 0.00508 down -32.6279 Hoxd9 7.34E-08 down -13.3973
A030004J04Rik0.006753 down -32.3703 Lrrc15 0.006802 down -13.3619
Serpinb6c 1.64E-05 down -30.3599 4632417N05Rik3.79E-05 down -13.2702
Mt4 8.90E-05 down -29.6621 Pnpla5 4.47E-05 down -13.0036
Pp11r 5.71E-05 down -29.4936 Prss8 2.03E-05 down -12.9927
Ckmt1 0.003563 down -28.8227 OTTMUSG000000009714.79E- 5 down -12.9824
Tcfap2c 0.001268 down -28.819 Ugt1a10 9.26E-04 down -12.8874
Nupr1 0.00103 down -28.619 Rdh9 3.35E-05 down -12.8567
Rdh12 9.41E-04 down -27.8775 Fxyd4 2.40E-06 down -12.818
2310005G13Rik5.23E-07 down -27.7382 Selenbp2 2.59E-06 down -12.4815
Barx2 3.93E-04 down -25.8593 Irf6 0.001298 down -12.4227
Hopx 0.003689 down -25.7787 Arhgef4 1.50E-04 down -12.4075
Cds1 7.68E-04 down -25.5323 Ctnnbip1 1.45E-04 down -12.1766
Sox21 1.50E-04 down -21.6202 Ugt1a10 6.37E-04 down -12.1404
Scgb1a1 9.37E-07 down -20.5111 Ank 0.005316 down -12.0932
Krtap13-1 7.43E-05 down -20.4657 Rnf208 5.42E-05 down -12.0112
Dgat2 0.005094 down -20.1006 Tuba8 1.64E-04 down -11.9838
LOC1000442047.36E-07 down -19.2325 Elovl6 0.003225 down -11.8895
Tmem45a 0.003363 down -18.6771 Mapk13 4.79E-04 down -11.7023
Tns4 0.00431 down -18.5138 Rbp7 1.15E-05 down -11.5594
Mycl1 2.57E-04 down -18.4657 Sema4a 3.94E-04 down -11.4354
LOC1000442043.73E-06 down -17.142 Slc40a1 1.23E-05 down -11.4305
Acox2 1.49E-04 down -16.8326 3300005D01Rik3.16E-04 down -11.3648
Bglap-rs1 0.004246 down -16.7992 Limk2 3.51E-06 down -11.0818
Cldn4 0.007573 down -16.6309 BC054059 3.71E-04 down -10.9351
Fgfr2 0.006327 down -16.5578 Igsf9 4.57E-05 down -10.9066
Hoxd8 5.68E-07 down -16.5505 Gldc 1.72E-04 down -10.7724
Calml3 3.48E-04 down -16.5091 Rasgrp1 4.59E-05 down -10.7434
Tmem79 9.83E-04 down -16.4106 Pdlim4 0.001233 down -10.5443
Krt86 3.66E-05 down -16.308 Atp12a 6.25E-04 down -10.4979
Clip4 7.08E-04 down -16.1237 Spon2 4.04E-04 down -10.4038
Cyb561 2.66E-04 down -15.4291 Tlcd1 3.64E-05 down -10.392
S100a14 0.001867 down -15.3824 Sult2b1 2.85E-04 down -10.234
Trim29 0.001012 down -15.3792 Tuba8 7.23E-05 down -10.1383
Ripk4 5.70E-04 down -10.1304
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Symbol p Regulation FC Symbol p Regulation FC
LOC1000461200. 07642 down -10.1299 Cpa4 5.51E-04 down -8.18543
2310033E01Rik4.33E-04 down -10.1226 Hebp2 4.99E-04 down -8.1665
Lrrc28 3.63E-05 down -10.1074 Rab3d 3.55E-04 down -8.12701
Tcfap2c 3.75E-07 down -10.0668 Pla2g4f 7.26E-04 down -8.12449
Nrarp 9.45E-04 down -10.0064 Abpb 3.07E-07 down -8.09764
Cmtm8 6.51E-07 down -9.84392 Cib2 5.85E-04 down -8.07548
Atg9b 0.002294 down -9.8106 Btbd11 1.04E-05 down -8.04566
Hal 0.001888 down -9.79336 Krtap16-4 6.02E-04 down -8.03861
Alox12b 3.08E-04 down -9.71492 A030007L17Rik0.005842 down -8.00316
Crabp2 2.18E-04 down -9.68989 Actb 0.001121 down -7.85892
OTTMUSG000000049664.94E-05 down -9.65565 Agpat4 3.71E-06 down -7.83517
Pank1 3.06E-05 down -9.63629 Dusp14 5.08E-06 down -7.81435
C79267 7.00E-06 down -9.35731 5830404H04Rik4.80E-05 down -7.7967
OTTMUSG000000107472.67E- 6 down -9.28194 Ltb4r1 3.83E-04 down -7.7945
AA409316 3.82E-05 down -9.26138 Nfix 0.002034 down -7.76038
Klf4 0.003724 down -9.24234 Klf4 0.003576 down -7.64601
4930438A08Rik2.38E-04 down -9.23095 Tm4sf4 2.28E-06 down -7.62528
Itgb4 0.001041 down -9.2186 1110036O03Rik3.36E-05 down -7.57553
Bcl11b 0.001074 down -9.15926 Mtap7 0.001475 down -7.57262
Stard5 2.62E-06 down -9.12026 Gcat 1.82E-04 down -7.55018
BC039632 5.73E-04 down -9.11339 Hoxb7 3.14E-04 down -7.5157
Palmd 7.73E-04 down -9.11119 Acacb 1.07E-04 down -7.51152
Emp2 0.002682 down -9.08896 Rdh11 9.06E-05 down -7.49488
Atp6v1c2 0.001717 down -9.0337 Fabp5 0.001051 down -7.45233
Psca 1.29E-05 down -8.98341 Tuft1 1.47E-04 down -7.44765
Gjb4 3.57E-04 down -8.89423 Mansc1 2.56E-05 down -7.30295
Ccdc120 2.47E-04 down -8.88478 Actb 5.83E-04 down -7.19582
Egfr 2.59E-04 down -8.83902 5430433G21Rik9.36E-04 down -7.11196
Dm15 8.22E-06 down -8.83318 Pcdh1 1.68E-04 down -7.07048
Ovol1 4.04E-05 down -8.76665 Osbpl3 1.82E-04 down -7.04257
Ugt1a10 9.52E-05 down -8.76326 Cmtm8 1.45E-06 down -7.01137
Naprt1 1.88E-05 down -8.74061 Ppif 1.64E-05 down -6.98744
Sox7 3.74E-05 down -8.73445 Sgpp1 3.93E-05 down -6.98584
Mtap2 9.28E-04 down -8.71187 D9Ertd280e 2.71E-04 down -6.98491
Gpr109a 0.002622 down -8.6821 BC021614 1.95E-06 down -6.95961
Egr2 0.00146 down -8.6335 Klk10 8.83E-04 down -6.9586
Hsd17b7 0.005807 down -8.60018 Slco3a1 1.28E-04 down -6.95773
Gltp 0.004638 down -8.55485 Ell3 2.11E-06 down -6.90729
Dhcr24 7.32E-04 down -8.53531 2310047D13Rik0.002681 down -6.8834
Dlx3 0.006677 down -8.45682 Il13ra1 8.79E-04 down -6.88299
Sdc1 3.41E-04 down -8.35417 Pdcd4 1.21E-05 down -6.84901
AI661453 9.55E-05 down -8.32911 Itpkc 3.75E-06 down -6.82474
Id1 5.78E-06 down -8.31411 Klf5 0.004171 down -6.76364
D16Ertd472e0.001226 down -8.28168 4833409F13Rik1.18E-06 down -6.72272
4632427C23Rik8.39E-04 down -8.27199 Luzp1 0.002243 down -6.64781
Tiam1 1.70E-04 down -8.24444 Itgb4 0.001025 down -6.6416
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Appendix 4: Gene expression profiling S3 vs. S1 melanoma 
Gene LogFC (S3 vs. S1) P.Value 
Car2 10.247 0.000353215 
Qpct 8.3566 7.64E-05 
Ednrb 7.53 0.007328914 
Sema6d 7.8965 0.019791965 
Dusp6 7.6575 3.81529E-05 
H2-Ab1 5.7851 0.010086523 
Vcam1 4.51 0.007223759 
Usp18 4.4758 0.006065279 
Dusp23 3.2498 0.00351508 
Hist1h2be 2.7485 0.007450028 
Cyp7a1 2.58584 0.03041699 
Sp5 2.534623 0.001737648 
Oas1g 2.49453 0.013883523 
Slc45a2 2.366916 0.011066997 
Ifit3 2.357629 0.002992523 
Lmo2 2.315036 0.009409501 
Oas1g 2.232349 0.002482399 
Hpse 2.18447 0.014862797 
Fcgr4 2.164948 0.005662231 
Oasl2 2.163185 0.003378932 
EG667977 2.003416 0.021180351 
Hist1h2bf 2.0001 0.000964453 
Hist1h2bh 2 0.001057836 
Usp18 1.986873 0.027110676 
Tpd52l1 1.986593 0.024551409 
Aif1 1.964149 0.004114213 
Psmb8 1.963154 0.004913133 
Cdkn2a 1.953197 0.035106226 
Tpd52l1 1.922451 0.032441971 
Pi4k2b 1.898004 0.001972563 
Irgm1 1.885813 0.00036888 
Sfrs5 1.881634 0.023778617 
Bmp15 1.832675 0.015822738 
Plac8 1.798208 0.007164127 
Sbk 1.787414 0.024128764 
Ly6c1 1.763215 0.011566003 
Gimap8 1.742587 0.018168938 
Maob 1.729111 0.00539632 
Abp1 1.6336 0.014022096 
Atp6ap2 1.613991 0.006714994 
Kit 1.602053 0.037206167 
Hist1h2bn 1.594874 0.001780597 
LOC638301 1.579727 0.000673733 
237 
 
Lama1 1.576606 0.028928626 
Klk1 1.568355 0.008681186 
AI607873 1.566455 0.01274632 
Shf 1.559632 0.010742157 
Hist1h4a 1.552415 0.016700717 
Calm2 1.532909 0.015538266 
Eif2ak2 1.532724 0.017266002 
Nckap1 1.528891 0.057627606 
Dcn 1.511798 0.003014611 
Hist1h2bj 1.510719 2.65E-05 
Ube2l6 1.498342 0.007501191 
Hist1h2bk 1.49794 0.01247838 
Asphd2 1.492979 0.002770187 
EG433865 1.491414 0.00233863 
Clk1 1.482343 8.07E-05 
Ube2l6 1.478832 0.004022044 
Mgl2 1.477008 0.003264857 
Ifit2 1.476846 0.02921549 
Igh-6 1.476671 0.015091298 
Atp6ap2 1.473051 0.007835933 
Dock1 1.470035 0.012932706 
Eif4a2 1.455725 0.008073212 
mtDNA_ND4L 1.450778 0.075706147 
1700021K14Rik 1.446563 0.00461036 
Sec11c 1.44053 0.001842936 
Atp6ap2 1.440167 0.006361434 
Ly86 1.435562 0.006602544 
Clec4b1 1.423205 0.002422402 
Dyrk3 1.422951 0.020113521 
Reg1 1.420714 0.014530664 
Pi4k2b 1.418528 0.000325606 
Rnf213 1.417633 0.007533679 
Nudt4 1.413777 0.0051538 
Ifi47 1.396672 0.037207365 
Mpeg1 1.379831 0.00298173 
Slfn1 1.351826 0.007291272 
Igh-6 1.34264 0.004106978 
Id4 1.332305 0.002928703 
Cd59b 1.327686 0.00758957 
Vat1l 1.321144 0.128484482 
Nt5c3l 1.320889 0.003513603 
Glrb 1.314218 0.016112275 
Slc3a2 1.313625 0.02234367 
EG434858 1.311997 0.001152834 
Ifit2 1.301085 0.001714144 
LOC381649 1.294801 0.001361739 
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Jam2 1.28893 0.021628236 
Rab38 1.273039 0.009124414 
Art3 1.272077 0.004697433 
LOC100045617 1.271006 0.193432706 
Hist1h4f 1.269084 0.016650414 
Gvin1 1.26771 0.007288613 
Clec4b1 1.262325 0.001171732 
Ms4a6d 1.258328 0.014275581 
Hnrnpk 1.257673 0.000659738 
Tnfrsf19 1.254525 0.023316256 
Cd72 1.245332 0.019639912 
Ccr5 1.24297 0.03469485 
Ddah1 1.23503 0.088172932 
C130078N17Rik 1.23297 0.01680274 
Siat9 1.230391 0.000102015 
D14Ertd668e 1.225743 0.00057162 
A630077B13Rik 1.216404 0.005821002 
Gadd45a 1.216299 0.003285285 
Laptm5 1.207136 0.005776025 
Lin7a 1.19468 0.006024679 
Rbm11 1.19391 0.018068267 
3830408P04Rik 1.189474 0.01000013 
Abi3 1.184213 0.007683282 
Gch1 1.176219 0.005487877 
Nt5c3l 1.175824 0.015200051 
Mgl1 1.171912 0.013261118 
Sla 1.169845 0.011983694 
Tmf1 1.167106 0.029918238 
Hist1h2bm 1.166768 0.001488257 
Phf11 1.165267 0.074029956 
Adk 1.164365 0.001608453 
Hnrpa1 1.15676 0.005974908 
Oca2 1.155388 0.004024013 
Fam120a 1.152119 0.001266192 
Cd84 1.150816 0.024072425 
Phf11 1.145742 0.004646133 
Rbbp7 1.145433 0.016310764 
Dnajb6 1.142882 0.000245755 
Ms4a7 1.138679 0.007167994 
Sepx1 1.137757 0.004808616 
Dnajb6 1.137513 0.009355766 
scl0004175.1_57 1.136108 0.00389321 
Hddc2 1.133477 0.063196518 
Pgp 1.132096 0.034049134 
Etv1 1.129342 0.006430401 
Enpp2 1.126856 0.003746878 
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Sh3kbp1 1.124759 0.023248566 
P2ry14 1.124599 0.00655613 
Ccr5 1.123964 0.00011854 
Gdi1 1.123754 0.009532062 
Etv4 1.121907 0.019832061 
Sccpdh 1.120859 0.043347648 
Gsdmdc1 1.120308 0.01100383 
Fgd6 1.116672 0.005362519 
D11Lgp2e 1.109123 0.007266692 
Pik3ap1 1.105506 0.079017504 
Hnrnph1 1.102299 0.018528795 
Gcnt1 1.101578 0.01018405 
Agfg1 1.099212 0.002796846 
Fbln1 1.098963 0.00066565 
Mitd1 1.098594 0.014057595 
LOC385825 1.097732 0.001543794 
Tm7sf3 1.096383 0.000158332 
Mdk 1.095958 0.006231457 
Cxcl9 1.08961 0.030743242 
Spry4 1.089157 0.006318275 
Hist1h2bc 1.084501 0.037736917 
Gdpd3 1.081506 0.01503541 
Scye1 1.080613 0.001754112 
Tlr13 1.076773 0.009109145 
Tef 1.076283 0.001504315 
Fbxo3 1.073393 0.041162751 
LOC669053 1.072278 0.002750908 
Hrb 1.065025 0.037906722 
Psmd10 1.064372 0.032299909 
Ss18 1.058281 0.001731957 
Gyg 1.058203 0.001585124 
Notum 1.052936 0.056048386 
Flnb 1.050833 0.0044665 
Stat1 1.049984 0.019290918 
Ypel5 1.049162 0.000185608 
Nhsl1 1.044471 0.022972712 
Cyfip2 1.043102 0.023179811 
Sh3kbp1 1.041412 0.000156788 
Rbbp7 1.041234 0.016110986 
D14Ertd668e 1.036076 0.000167968 
Sdcbp 1.035544 0.029380369 
Tlr7 1.034986 0.023856618 
BC018465 1.031833 0.010882638 
Rps3 1.030818 0.006443435 
Adnp 1.030696 0.024306827 
LOC232606 1.023441 0.000544238 
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Hist2h2aa2 1.021537 0.01247992 
A730054J21Rik 1.017896 0.015947287 
Mylc2b 1.013441 0.029476983 
Enc1 1.012139 0.002174496 
Bxdc2 1.009719 0.000736489 
Mafg 1.009512 0.004143515 
H28 1.006783 0.007166107 
Tcf12 1.003864 0.019055107 
Ptgds2 1.003636 0.016763922 
EG240327 1.003346 0.033379819 
LOC100048480 1.002382 0.004226916 
Fgd6 1.000174 0.060523906 
Lyplal1 0.995399 0.007804339 
Hist1h4j 0.995047 0.002508784 
Rnf135 0.99477 0.026079332 
P2ry13 0.993931 0.003158486 
Hps3 0.993036 0.001668311 
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Gene LogFC (S1 vs. S3) P.Value 
Krt16 12.7532 0.005032 
Chi3l1 9.7847 0.0201 
Stfa1 9.2 0.00017 
Lamb3 10.841 0.017139 
S100a9 8.575 0.028232 
Junb 5.1112 0.0182 
Rab25 4.32 0.004987 
Anxa11 3.5 0.021359 
Lypd3 3.2143 0.049677 
Mmp9 3.3 0.005166 
Gjb6 2.8 0.003205 
Krt6b -3.17013 0.01171 
Sprr1b -2.93938 0.02813 
Stfa1 -2.65245 0.003259 
Prss18 -2.54905 0.035152 
Klk6 -2.46898 0.022445 
BC100530 -2.44743 0.028968 
EG408196 -2.40697 0.01071 
Krt5 -2.27918 0.001914 
Krt79 -2.27214 0.02608 
Ly6d -2.17697 0.004217 
Klk8 -2.1613 0.028412 
Cnfn -2.15895 0.020735 
Sprr2d -2.0804 0.000477 
Sult2b1 -2.06972 0.037683 
Clic3 -2.056 1.24E-05 
Ly6d -1.93576 0.045648 
Fxyd3 -1.9309 0.026425 
Evpl -1.92449 0.034718 
Serinc2 -1.87926 0.039488 
Cebpb -1.78454 0.015301 
Lad1 -1.7795 0.019416 
Prom2 -1.76744 0.006043 
Ercc2 -1.75682 0.021261 
Ngfr -1.74093 0.02916 
Spnb3 -1.73206 0.02452 
Sprr1a -1.72597 0.00385 
Gjb3 -1.6321 0.012552 
S100a14 -1.62178 0.030312 
Sphk1 -1.6091 0.030884 
Slc6a8 -1.58628 0.007716 
Casp14 -1.57157 0.022335 
Cnfn -1.5672 0.019018 
Fbxl11 -1.5631 0.04904 
Car12 -1.54942 0.026437 
242 
 
9530027K23Rik -1.54744 0.019197 
Defb14 -1.51712 3.97E-05 
Sfn -1.51507 0.044272 
Cd109 -1.51008 0.004003 
Tmem54 -1.50269 0.003643 
Hr -1.49388 0.049944 
4631405K08Rik -1.4843 0.034602 
Capg -1.47081 0.032695 
Bcat2 -1.47059 0.019992 
LOC245892 -1.47051 0.032731 
Anpep -1.46201 0.024952 
Psme3 -1.46144 0.030402 
2610009E16Rik -1.45385 0.01887 
Homer2 -1.44104 0.008905 
Epgn -1.43645 0.005449 
Abhd9 -1.43558 0.034177 
Serpina3n -1.42414 0.001619 
Foxq1 -1.41915 0.005145 
H2-M2 -1.4044 0.005896 
Aqp9 -1.40432 0.007537 
Tmprss13 -1.40115 0.017771 
Egln3 -1.39407 0.01542 
Tmprss13 -1.39338 0.024388 
Ubl7 -1.38641 0.028073 
BC004728 -1.36887 0.031511 
Klf13 -1.35979 0.02038 
Cav1 -1.35944 0.039989 
Tagln2 -1.35897 0.017697 
Smox -1.35827 0.034553 
BC004728 -1.35742 0.000783 
Serpinb3b -1.35708 0.008947 
Smox -1.35649 0.01596 
LOC381860 -1.34376 0.006303 
Cyp4f39 -1.34046 0.002042 
Arg1 -1.32995 0.007977 
Mllt4 -1.32861 0.025318 
Ap2a1 -1.32516 0.042419 
BC065085 -1.31516 0.010506 
Scaf1 -1.30844 0.056213 
Il17rc -1.30423 0.01671 
1700025G04Rik -1.28732 0.00154 
LOC100046483 -1.28085 0.006004 
Flrt3 -1.28062 0.014602 
Gcnt2 -1.27808 0.01672 
Ltbp4 -1.27663 0.003267 
Chit1 -1.27653 0.00083 
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Palm -1.27109 0.008527 
Bok -1.26791 0.001168 
Josd2 -1.26739 0.028931 
Map3k6 -1.25575 0.023837 
Ppard -1.25204 0.023833 
Npm3-ps1 -1.24999 0.039548 
Hdac5 -1.24789 0.000159 
Furin -1.22823 0.036547 
Ndrg1 -1.22771 0.002733 
Cdc42ep5 -1.22738 0.009265 
Npm3 -1.22599 0.000228 
Itpr3 -1.22085 0.008321 
Cdh13 -1.2201 0.0026 
Prkcdbp -1.21356 2.00E-06 
Blmh -1.21088 0.000835 
2310007G05Rik -1.209 0.009909 
Rnase4 -1.20857 0.007532 
Bnipl -1.20735 0.001624 
Plek2 -1.20719 0.018984 
Synpo -1.20517 0.000266 
Erdr1 -1.19684 0.008896 
Endod1 -1.19455 0.000621 
Lmna -1.19363 0.023602 
A430096B05Rik -1.1926 0.038457 
Angptl4 -1.1916 0.012158 
Hdc -1.18914 0.001404 
Il33 -1.17996 9.79E-05 
Areg -1.17704 0.038027 
Fkbp8 -1.17607 0.000899 
Plec1 -1.17446 0.035376 
Ndrl -1.17325 0.008997 
Actb -1.17312 0.025676 
Lmna -1.17276 0.010051 
Fam129b -1.16896 0.037642 
Eif6 -1.1688 0.000584 
Mark2 -1.16786 0.000438 
Thy1 -1.16779 0.000938 
Cyb5r3 -1.16272 0.000543 
Fam132a -1.15715 0.000593 
Slc2a1 -1.15699 0.030428 
Hgs -1.15474 0.000126 
Tcfap2c -1.15087 0.003282 
Ltbp4 -1.14974 0.008801 
C130090K23Rik -1.14942 1.76E-06 
Klk11 -1.14026 0.000876 
Pde1b -1.13623 0.010734 
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Rapgefl1 -1.13572 0.000925 
Bcl7c -1.13477 0.037969 
C77080 -1.13439 0.012754 
Dgka -1.13068 0.0359 
Pde1b -1.12958 0.012987 
Slco2a1 -1.12631 0.00123 
Eps8l2 -1.12507 0.046682 
Uck2 -1.12464 0.00095 
Cyp2b10 -1.12133 0.000832 
Sdc4 -1.12113 2.01E-05 
LOC100048721 -1.12089 0.001251 
Wnt10a -1.11213 4.60E-05 
Fam115c -1.09434 0.040172 
Aldh18a1 -1.09151 0.00209 
4933407C03Rik -1.09011 0.02374 
S100a16 -1.08709 0.018985 
Vat1 -1.08153 0.045565 
Ino80b -1.0783 0.030992 
Fermt1 -1.06861 0.005408 
AI481316 -1.06421 1.45E-06 
Itpkb -1.05919 0.000385 
Lce3c -1.05897 0.008794 
Usp2 -1.03985 0.00945 
Lcn2 -1.03849 0.009448 
Ankrd22 -1.03786 0.025558 
Lmna -1.03528 0.042832 
Sf3b4 -1.03375 0.001096 
Ccnt1 -1.03368 0.037171 
Serpinb6a -1.02803 0.010004 
Hdac5 -1.02284 0.002844 
Uck2 -1.01231 0.024131 
Slc25a1 -1.00375 0.000279 
Akr1b8 -0.99937 0.005313 
Aprt -0.99367 0.015485 
1190002H23Rik -0.99173 0.006219 
Ndufa3 -0.99169 0.00363 
Trp53 -0.98761 0.031997 
Ext1 -0.98596 0.003293 
LOC100046483 -0.98595 0.033829 
Orai1 -0.97984 0.004321 
Ass1 -0.97975 0.000222 
Aldoa -0.979 0.002665 
Mall -0.97743 0.004942 
Il1r2 -0.97522 4.90E-05 
Tmem45b -0.97375 0.021281 
Sh3bgrl3 -0.9732 0.002011 
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Pdgfa -0.97213 0.056719 
Dnmt3l -0.97212 0.000814 
Wnt3a -0.96547 0.009386 
Ahnak2 -0.96348 0.029777 
Atf3 -0.96109 0.033458 
Tpm1 -0.95782 5.52E-05 
Nbl1 -0.9533 0.031262 
2610035D17Rik -0.95282 0.020442 
2300004C15Rik -0.94888 0.016835 
Myo1e -0.94656 0.034667 
Cdc42ep4 -0.94588 0.040632 
Gna13 -0.94522 0.018837 
Ahnak -0.94399 0.013364 
Purb -0.94331 0.02118 
Npm3-ps1 -0.93862 0.004218 
Cdca7 -0.93614 0.000833 
LOC100047419 -0.93535 0.002864 
Obfc2b -0.93222 0.010785 
Pcdh7 -0.92937 0.019505 
Wnt4 -0.92758 0.004564 
Pkm2 -0.92314 0.002144 
Stat3 -0.92224 0.011649 
Arhgef1 -0.90764 0.039955 
2210023G05Rik -0.90749 0.007757 
Tomm6 -0.90412 0.031433 
Uba1 -0.90399 0.001927 
Entpd2 -0.90109 0.010215 
Ndufa3 -0.89481 0.000996 
Lss -0.89285 0.006301 
Elovl1 -0.88925 0.011894 
Polr2a -0.88819 0.001228 
Lmna -0.88578 0.020845 
9030619K07Rik -0.88564 0.005778 
Styx -0.8837 0.004978 
Rnu6 -0.87789 0.010314 
Car13 -0.87629 0.026674 
Fam162a -0.87559 0.019944 
Klf6 -0.87045 0.012348 
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Appendix 5: List of genes differentially expressed between human metastasis and 
primary melanoma 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Gene logCPM PValue
DUSP6 8.111519103 0.000745292
EDN1 1.717414898 0.061659637
EDN3 6.178411092 2.91066E-09
EDNRA 3.254382162 1.96185E-06
POU3F2 3.390107634 0.264229636
GLI1 1.770661459 1.37062E-05
SHH 1.508576135 0.000202695
NTM 3.386307292 0.004575069
OPCML 1.485709919 4.08523E-05
ZEB1 4.654526018 4.11465E-13
ETS1 7.726328109 0.003022034
TGFB2 3.557590955 0.173681835
TGFBR1 6.673329074 0.346489974
TGFB3 4.287321324 9.68551E-09
TGFB1 6.135397725 0.000647391
TGFBI 8.192451729 0.002056265
TGFBR2 7.023262033 0.003217058
TGFBR3 5.116016274 0.014784709
DCBLD1 3.429120248 0.542622947
MAN1A1 4.513929597 5.29716E-14
GJA1 5.691504606 7.1852E-20
HSF2 3.874996846 0.264840689
SERINC1 7.535637571 0.008244481
ASCC1 4.420274513 0.303873625
CDH23 1.839840342 0.000108607
SGPL1 5.77268312 0.984316286
HK1 7.388268527 0.775551788
CCAR1 5.548297122 0.000420877
TET1 2.527577612 1.40877E-06
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